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Organophosphorous compounds (OPs) form the basis of many biocides and 
nerve agents, affecting millions of people each year. Current treatments for acute OP 
poisoning use atropine to prevent neurotransmitter overaccumulation, and oximes for 
rescuing phosphorylated acetylcholinesterase (AChE) prior to an irreversible ageing 
event, but medical care may be required for weeks. Hydrolysis of the OP 
phosphoester bond prevents the inhibitive phosphorylation of AchE, thus enzymes 
are an obvious candidate for novel treatments. Enzyme-based therapies for OP 
poisoning have been shown to delay mortality, but leaching of lipophilic OPs from fat 
deposits leads to prolonged toxicity, superseding the detoxifying effects of the 
enzyme due to systemic clearance. Furthermore, these same enzymes may be used 
for the bioremediation of waterways affected by OP pesticide runoff from crops. Here, 
an artificial membrane-binding protein from the OP-degrading enzyme OpdA is 
produced that spontaneously partitions into membranes to enhance enzyme-based 
therapies for OP poisoning. OpdA was expressed in Escherichia coli with high yields, 
and cationised with high efficiency to homogenise the surface charge for subsequent 
anionic surfactant engraftment, giving a supercationic enzyme, cOpdA, which 
maintained structure and activity, but rapidly penetrated cells, resulting in 
cytotoxicity. Electrostatic engraftment of an anionic polymer surfactant to the surface 
of the cOpdA mitigated the cytotoxicity, and the constructs were shown to remain 
active at the cell surface for 5 days. Crucially, the surfactant conjugation has no 
deleterious effects on the enzyme, and surprisingly causes a significant increase in 
its turnover rate and substrate affinity. Small angle X-ray scattering and molecular 
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dynamics simulations show that the surfactant forms a highly-dynamic compact 
corona surrounding the enzyme. Finally, the high-yield expression system for OpdA 
by Escherichia coli is used in conjunction with a new bioprinting methodology to 
produce a 3D bacterial microreactor for OP degradation. The novel cell-laden bioink 
is printable at high resolutions, is not cytotoxic, and maintains its structure over 
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[cOpdA][S] Cationised and conjugated OpdA using oxidised IGEPAL CO-890 








BCA Bicinchoninic acid  
BChE Butyrylcholinesterase 
BSA Bovine serum albumin 
BUDE Bristol University Docking Engine 
cAMP Cyclic adenosine monophosphate 
CAP Catabolite activator protein 
CD Circular dichroism 
cEGFP Cationised enhanced green fluorescent protein 
cf 5-(6)-Carboxyfluorescein-tagged 
CMC Critical micelle concentration 
cOpdA Cationised OpdA 





DECP Diethyl chlorophosphate 
DEUP Diethylumbelliferyl phosphate 
DFPase Difluorophosphatase from Loligo vulgaris 
DLS Dynamic light scattering 
DMEM Dulbecco’s Modified Eagle’s Medium 
DMPA N,N’-dimethyl-1,3-propanediamine 
DNA Deoxyribonucleic acid 
DTNB 5,5'-dithiobis-(2-nitrobenzoic acid) 
E3 Esterase from Lucilia cuprina 
EDC N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
EDTA Ethylenediaminetetraacetic acid 
FBS Foetal bovine serum 
FDR False discovery rate 
FTIR Fourier transform infrared spectroscopy 
GFP Green fluorescent protein 
GPI Glycosylphosphatidylinositol 
GST Glutathione-S-transferase 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HLB Hydrophile–lipophile balance 
hMSC Human mesenchymal stem cell 
IEF Isoelectric focusing 
IMS Intermediate syndrome 
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LB Lysogeny broth 
LD50 Lethal dose for 50% of the population 
MALDI–TOF MS Matrix-assisted laser-desorption ionisation time-of-flight mass 
spectrometry 
MD Molecular dynamics simulations 
MES 2-(N-morpholino)ethanesulfonic acid 
MPH Methyl-parathion hydrolase from Plesiomonas sp. 
NA 1-Naphthyl acetate 
NHS N-hydroxysuccinimide 
NR Neutron reflectometry 
OP Organophosphorous compound 
OPAA Organophosphorous-compound anhydrolase from Alteromonas sp. 
OpdA Organophosphorous-compound degrading enzyme from Agrobacterium 
tumefaciens 
OPH Organophosphorous-compound hydrolase from Sphingobium fuliginis 
OPIDP Organophosphorous compound induced delayed polyneuropathy 
PBMPF Pyrenebutylmethylphosphonofluoridate 
PBS Phosphate buffered saline 
PEG Polyethylene glycol 
pI Isoelectric point 





PTE Phosphotriesterase from Pseudomonas diminuata 
RA Retinoic acid 
ROSIE Rosetta online server that includes everyone 
S Oxidised IGEPAL CO-890 surfactant 
SASA Solvent-accessible surface area 
SAXS Small angle X-ray scattering 
scGFP Supercharged superfolder green fluorescent protein 
scOpdA Supercharged OpdA 
SDS Sodium dodecylsulphate 
SDS–PAGE Sodium dodecylsulphate–polyacrylamide gel electrophoresis 
SEM Scanning electron microscopy 
sfGFP Superfolder green fluorescent protein 
SiRNA Silencing ribonucleic acid 
SRCD Synchrotron-radiation circular dichroism 
SsoPox Sulfolobus solfataricus paraoxonase 
TEMPO 2,2,6,6-tetramethyl-1-piperidinyloxyl 










1.1 Organophosphorous compounds 
Organophosphorous compounds (OPs) are a versatile class of substances used 
in agriculture, industry, and military settings. OPs are typically neurotoxic, due to 
inhibition of acetylcholinesterase (AChE); an enzyme required to terminate nerve 
signals by hydrolysing acetylcholine (ACh). Furthermore, OPs are generally lipophilic 
and sequester into fatty tissues, leaching out over time and prolonging toxicity. 
Current treatments for OP poisoning address the symptoms of AChE inhibition, 
known as cholinergic crises, but do not detoxify the persistent systemic OPs. 
Enzymes isolated from bacteria have been shown to hydrolyse OPs, detoxifying them 
under physiological conditions.1 These enzymes are being investigated for their 
potential to treat OP-poisoned patients, but currently enzyme-based treatments 
suffer from short systemic half-lives.2  
The first OP identified was monoethyl phosphate in 1820 by Lassaigne, which 
was later synthesised by Pelouze in 1833.3,4 Subsequently, di- and triethyl 
organophosphates were synthesised by Voegeli in 1834.4,5 These simple molecules 
are used as precursors for the synthesis of other compounds. The first synthesised 
OP with anticholinesterase properties was tetraethyl pyrophosphate, discovered by 
Clermont in 1854, and was used as an insecticide.4,6 OPs are currently used 
worldwide as pesticides. OP-pesticide use in the UK is decreasing (Figure 1-1A), but 
worldwide OPs are still used prolifically (Figure 1-1B). In 2004, the use of persistent 
organic pesticides (generally organochlorines) were banned by the Stockholm 
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Convention,7 which corresponds to a relative increase in the use of OP-based 
pesticides. 
 
Figure 1-1 OP-pesticide use. A) OP-pesticide use in the UK (solid line), compared to total 
pesticide use (dashed line); data from Fera Science, LTD, 
https://secure.fera.defra.gov.uk/pusstats/. The Stockholm Convention in 2004 banned the 
use of persistent organic pesticides,7 which prevented the use of organochlorine pesticides. 
B) Worldwide OP-pesticide use in 2014; data from the Food and Agricultural Organisation of 
the United Nations, http://www.fao.org. 
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Between 1936 and 1949 Gerhard Shrader discovered several highly-toxic OPs: 
tabun, sarin, soman, and cyclosarin. These form the G-series of militarised nerve 
agents. The V-series nerve agents were developed in the 1950s, the most famous 
being VX as discovered by scientists at Porton Down, Salisbury.8 In the late 1980s, a 
new class of agents were developed, known as ‘Novichok’ agents, meaning 
‘newcomer’ in Russian; very little is known about these agents.9 A timeline of the 
discoveries and uses of anticholinesterases is presented in Figure 1-2. In response 
to the recent high-profile nerve-agent use, the UK government is investing £48 M in 
a new Chemical Weapons Defence Centre.10 
 
Figure 1-2 Timeline of the discoveries and uses of anticholinesterases. 
Anticholinesterases may also be used as therapeutics, although OPs are not 
widely clinically used. Metrifonate has been used as an antihelmenthic in the 
treatment of schistosomiasis,11 and has been studied as a potential prophylactic 
treatment,12 but it is no longer commercially available.13 More recently, metrifonate 
was shown to have some clinical benefit for treatment of Alzheimer’s disease, but 



























































exposure to OPs has been linked to increased risks of developing Alzheimer’s 
disease.15 Malathion is used in the treatment of head lice, and may also be used in 
treatment of scabies.16 Diisopropyl fluorophosphates and echothiophate are used in 
the treatment of chronic glaucoma, under brand names Fluostigmine or Dyflos, and 
phospholine, respectively.17  
Organophosphorous compounds are also used as plasticisers and lubricants,18 
and flame retardants.19 Generally, halogenated OPs are used as flame retardants, 
whereas non-halogenated, i.e., alkylated, OPs are used as plasticisers and 
lubricants.20 Aromatic and aliphatic OPs were initially developed for lubrication of 
aircraft engines, but also found use in the automobile industry, and have been in use 
for over 50 years.21 OP-based flame retardants became widespread after the ban of 
brominated flame-retardants, accounting for 20% of flame retardants in Europe in 
2006.19 
1.1.1 Structures and properties 
Broadly, OPs are chemicals comprising a phosphorus atom forming a double 
bond with either an oxygen (oxon) or a sulphur (thion) atom, and single bonds with 
three other chemical groups, of which at least one must be organic. The class can be 
further divided into groups comprising varying numbers of P–C, P–O, and P–N bonds 
(Figure 1-3–5). These compounds may also be modified via halogenation to produce 




Figure 1-3 Nomenclature of organophosphorous compounds (left) with examples (right); 














































































Figure 1-5 Nomenclature of organophosphorous compounds (continued). 
Many OPs are enantiomeric, and some have more than one chiral centre, e.g., 
soman has two chiral atoms: the central phosphorous, and the α-carbon of the 
pinocolyl sidechain (Figure 1-6). The enantiomers of OPs have different 
anticholinesterase activities, with the Sp enantiomers being significantly more toxic in 
all the weaponised OPs.22 Moreover, oxons are directly toxic to humans, whereas 






















































detoxified by hepatic carboxylesterase prior to oxidation in humans, reducing toxicity, 
although impurities and OP-coexposure can inhibit this mechanism.24 
 
Figure 1-6 Enantiomers of soman. 
1.1.2 Mechanism of action 
The therapeutic and biocidal properties of OPs are primarily due to the inhibition 
of AChE, which is a homodimeric protein with an α/β-hydrolase fold (Figure 1-7A),25 
found primarily in cholinergic synaptic clefts.26 AChE hydrolyses acetylcholine (Figure 
1-7B) in synaptic clefts to terminate the propagation of nerve signals and subsequent 
overstimulation of acetylcholine receptors (AChRs; Figure 1-8). The toxicity of an OP 
correlates well with its anticholinesterase activity.27 OPs also inhibit the plasma 






















understood; it is thought not to affect cholinergic functions, instead regulating ghrelin, 
a hormone that regulates hunger.28 
 
Figure 1-7 A) Crystal structure of AChE (PDB ID: 3LII).25AChE is a homodimeric protein with 
α/β-hydrolase folds. The two monomers are coloured blue and red, with the active site 
coloured yellow in each. B) A close-up view of the active-site residues, with distances 
between the nitrogen (blue) and oxygen (red) atoms indicated. C) Acetylcholine is hydrolysed 
by a serine in the active site of AChE. A histidine and a glutamate are required to active the 



































































Figure 1-8 The action of OPs at the synaptic junction. Nerve impulses trigger the release of 
acetylcholine from vesicles into the synaptic junction. Acetylcholine crosses the cleft, and 
binds with acetylcholine receptors (AChRs), continuing the impulse. Acetylcholinesterases 
(AChEs) normally hydrolyse the acetylcholine and thus cease AChR activation, however OPs 
inhibit AChE activity, prolonging the impulse and overstimulating the AChRs. 
OPs phosphorylate the active site serine of AChE and BChE via a nucleophilic 
substitution reaction, thereby inhibiting it (Figure 1-9). The cholinesterase may 
spontaneously reactivate if the OP–serine bond hydrolyses, or irreversible inhibition 
may follow if a second group on the OP leaves, a process known as ageing. The 
ageing rates of OPs varies greatly: soman has an ageing rate of 6.6 h-1, whereas VR 
has an ageing rate of 0.005 h-1.29 Some OPs will also spontaneously reactivate.29 The 
















Figure 1-9 Schematic of inhibition of AChE by phosphorylation of the active-site serine by an 
OP, catalysed by an active-site histidine and glutamate.. 
1.1.3 Symptoms of OP poisoning  
The initial inhibition of AChE leads to an overaccumulation of ACh, causing a 
cholinergic crisis resulting from overstimulation of the parasympathetic nervous 
system. The primary symptoms are salivation, lacrimation, urination, defaecation, 
gastrointestinal distress, emesis, miosis, and muscle fasciculation, which is 
commonly remembered with the pneumonic ‘SLUDGEMM’. In the brain, 
overstimulation by acetylcholine and subsequent enhancement of glutamatergic 
transmission may lead to seizures and status epilepticus: a state of continuous 
seizing.31 After initial muscle fasciculations from overstimulation, desensitisation of 
































typically associated with seizures are suppressed, therefore damaging seizing may 
go unnoticed.33 The convulsing also leads to oxidative stress, which may progress to 
radical-mediated DNA damage and therefore genotoxicity.34,35 
In approximately 20% of patients 2–4 days after exposure, muscle weakness 
develops, particularly in muscles of the respiratory system but also in proximal limb 
muscles, and may persist for up to 21 days.36 This is known as intermediate syndrome 
(IMS). Muscle damage from convulsions was investigated as a potential cause,37 
although the typical measures of muscle damage, increased expression of creatine 
kinase and aspartate aminotransferase, are not good predictors of IMS 
development.38 Repetitive nerve stimulation may be used to identify patients at risk 
of developing IMS, however.39,40 
1–4 weeks post-exposure, a further syndrome, known as OP-induced delayed 
polyneuropathy (OPIDP) may present.41 OPIDP only occurs after exposure to a subset 
of OPs: non-ageing compounds will not lead to OPIDP, and will protect against 
OPIDP-inducing agents.42 Triaryl phosphates, typically used as plasticisers, 
lubricants, and flame retardants, are not anticholinesterases, but do cause OPIDP.43 
OPIDP is thought to be primarily caused by phosphorylation of neuropathy target 
esterase,42 however other targets, such as transient receptor potential cation channel, 
member A1 have been identified.44 
1.1.4 Treatments 
Inhibitors of AChRs can relieve the symptoms of OP poisoning by preventing 
the transmission of the impulse to the distal neuron. Atropine is the most commonly 
used AChR inhibitor, although it only acts on muscarinic AChRs. AChR inhibitors are 
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inherently toxic, and so dosages must be carefully controlled. Generally, atropine is 
administered until atropinisation is observed: the point at which parasympathetic 
pathways become inhibited. Other AChR inhibitors have been investigated for OP 
poisoning, such as anisodamine,45,46 and scopolamine.47 
Cholinesterases may be reactivated prior to the ageing event by a strongly 
nucleophilic dephosphorylating agent, typically oximes. There is no single universally 
effective oxime, and different OPs are affected differently,29 e.g., diethyl pesticides 
are reported to be more-readily reactivated than dimethyl pesticides.48 Obidoxime is 
regarded as the best oxime in terms of versatility, toxicity, and its ability to cross the 
blood–brain barrier, but its use is hampered by commercial availability.49 The 
effectiveness of oximes in improving clinical outcomes is debated.48,50,51 Moreover, 
exposure to oximes may increase the need for ventilation and increase chances of 
IMS development.52 Non-oxime reactivators are also being developed, which show 
improved efficacy in vitro, although have shown no in vivo benefit thus far.53 
Benzodiazepine anticonvulsants are also commonly administered after OP 
poisoning. Diazepam is the most widely used, however Avizafone, a pro-Diazepam, 
is adopted by some countries.49 Midazolam is also being considered as a 
replacement.54 
In the event of likely OP exposure, non-organophosphorous anticholinesterases 
may be used to reversibly inhibit a portion of AChE, such that when OP exposure 
leads to inhibition of the remaining AChE, the reversibly-inhibited AChE may be 
reactivated. Pyridostigmine is currently the only FDA-approved drug for prophylaxis 
for soman exposure, although research into other prophylactic drugs is being 
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performed.55 The major drawback of the stigmine-based prophylactic strategies is the 
inherent toxicity risk. 
Atropine and oximes make up the standard treatment for OP poisoning, with 
benzodiazepines also commonly used. Different countries adopt different oximes and 
benzodiazepines in their standard treatments, although pyridostigmine and atropine 
are universally used as prophylactic and anticholinergic treatments, respectively 
(Table 1-1).49 In addition to the drugs regime, supportive care is also necessary to 
treat patients suffering from paralysis, apnoea, and coma.  
Country Prophylaxis Anticholinergic Reactivator Anticonvulsant 
UK Pyridostigmine Atropine Pralidoxime 
mesylate 
Avizafone 
US Pyridostigmine Atropine Pralidoxime 
chloride 
Diazepam 
Germany Pyridostigmine Atropine Obidoxime — 
Finland Pyridostigmine Atropine Obidoxime — 
Norway Pyridostigmine Atropine Obidoxime Diazepam 
Netherlands Pyridostigmine Atropine Obidoxime Avizafone 
Sweden Pyridostigmine Atropine HI–6 — 
Canada Pyridostigmine Atropine HI-6 Diazepam 
Table 1-1 Standard drugs used in the treatment of OP poisoning in different countries. 
Adapted from Jokanović (2006).49 
Supplemental drugs have also been explored as adjunctive therapies. N-acetyl-
L-cysteine, an antioxidant thought to reduce the effect of the oxidative stress, was 
found to reduce the need for atropine,56,57 but did not improve survival rates,56 and 
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was even deleterious when combined with pralidoxime in rats.58 High-dose sodium 
carbonate has shown some benefit in reducing the acidosis resulting from 
convulsions, reducing hospitalisation time.59 
In acute OP poisoning cases, the typical treatments require hospitalisation for 
several weeks. This is in part due to the slow leaching of lipophilic OPs from fatty 
deposits over time, which can cause recurrence of symptoms.60 Therefore, there is a 
need to develop new strategies to treat OP poisoning that address the ongoing 
cause, i.e. residual systemic OP, as well as the symptoms. Development of novel 
strategies for OP poisoning is difficult in clinical settings, though, as randomised 
control trials deviating from the standard treatments in acutely poisoned patients are 
unethical.61  
Enzyme-based treatment strategies are now being investigated. BChE has been 
studied for use as a bioscavenger, and has shown some efficacy in increasing the 
survival of OP poisoned animal models.62-67 BChE has completed phase-1 clinical 
trials (ClinicalTrials.gov identifier: NCT00333528), although the results are yet to be 
reported. BChE-treatment suffers from its ability to only scavenge a single OP 
molecule, therefore relatively large doses are required. Human BChE is approximately 
85 kDa,68 therefore 600 mg is required per mg of sarin to reach stoichiometric 
scavenging, for example. However, scavenging strategies are effective treatments for 
rapidly-ageing OPs such as soman. Moreover, pseudocatalysis can be achieved by 
combining AChE69 or BChE70 with oximes to continuously regenerate active BChE. 




1.2 Organophosphorous compound hydrolases 
OP hydrolases are promising candidates for OP-poisoning treatment. Whereas 
current small-compound treatments address the cholinergic crisis, they do not 
actively degrade the OP itself. OP hydrolases, however, rapidly degrade OPs under 
physiologic conditions. Therefore, these enzymes are being explored as adjunctive 
therapies for OP-poisoning. 
1.2.1 Sources 
OP-degrading enzymes are present in both prokaryotes and eukaryotes. In 
prokaryotes, OP-hydrolysing enzymes have been identified in many species, 
including Brevundimonas diminuta (PTE [Phosphotriesterase]),75 Sphingobium 
fuliginis (OPH [Organophosphorous-compound hydrolase]),76 Sulfolobus solfataricus 
(SsoPox [Sulfolobus solfataricus paraoxonase]),77 Plesiomonas sp. (MPH [Methyl-
parathion hydrolase]),78 Alteromonas sp. (OPAA [Organophosphorous-compound 
acid anhydrolase),79 and Agrobacterium tumefaciens (OpdA [Organophosphorous-
compund degrading enzyme type A]).80 It is thought that the OP-hydrolysing abilities 
evolved in soil bacteria due to the extensive use of OP-pesticides in fields.81 The 
enzymes share similarities with amidohydrolases, β-lactamases, and prolidases.82 
Members of the amidohydrolase superfamily (PTE, OPH, SsoPox, OpdA) have been 
shown to have lactonase activity,83 and some lactonases have demonstrable OP-
degrading activity.84 
Examples of eukaryotic OP-hydrolysing enzymes include DFPase from the 
squid Loligo vulgaris,85 E3 from the blowfly Lucilia cuprina86 with homologues in the 
fruitfly Drosophila melanogaster,87 and PON1 found in most mammalian species.88 In 
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humans, polymorphisms in the pon1 gene affect susceptibility to OP-poisoning.89 E3 
has been shown to be involved in the metabolism of lipids.90 As with the prokaryotic 
amidohydrolase-family enzymes, PON1 has been shown to have lactonase activity.91 
The native activity of DFPase is unknown.92 
1.2.2 Hydrolytic mechanisms 
OP-degrading enzymes can be categorised into 5 characteristic folds: triose 
isomerase α/β barrels (PTE, OPH, SsoPox,77 OpdA), β-lactamase αβ/βα sandwiches 
(MPH), pita-bread folds (OPAA), α/β hydrolase fold (E3),90 and β-propellers (DFPase, 
PON1).92 With the exception of E3, the enzymes are all metallohydrolases. The triose 
isomerase barrel, β-lactamase αβ/βα sandwich, and pita-bread fold enzymes all have 
binuclear divalent metal ion active sites. DFPase and PON1, β-propeller enzymes, are 
binuclear, although only one ion is thought to contribute to their catalytic activity, with 
the other required for maintaining their structure.92-94 The active site of E3 comprises 
a catalytic triad of serine, histidine, and glutamate, similar to that of AChE.90 A 








Figure 1-10 A) OpdA (dimer) representing triose isomerase α/β barrels (PDB ID:2D2J).95 B) 
The active site of OpdA. C) OP-hydrolysis mechanism of OpdA.96 The reaction proceeds 
through a SN2 reaction by nucleophilic attack of the phosphorus centre by a hydroxide 














































































Figure 1-11 A) MPH (dimer) representing β-lactamase αβ/αβ sandwiches (PDB ID: 1P9E).97 B) 
The active site of MPH. C) OP-hydrolysis mechanism of MPH.98 The reaction proceeds via an 
SN2 reaction through the nucleophilic attack of the phosphorus centre by a hydroxide 




























































































Figure 1-12 A) OPAA (trimer) representing pita-bread folds (PDB ID: 3L7G).99 B) The active 
site of OPAA. C) OP-hydrolysis mechanism of OPAA.92 The reaction proceeds via an SN2 
reaction through the nucleophilic attack of the phosphorus centre by a hydroxide coordinated 















































































Figure 1-13 A) E3 (monomer) representing α/β hydrolase folds (PDB ID: 5CH3).100 B) The 
active site of E3. C) OP-hydrolysis mechanism of E3.90 Firstly, an active-site serine residue 
attacks the central phosphorus, forming a phosphorylated-serine intermediate and releasing 
the OP leaving group. Secondly, an H2O molecule deprotonated by an active-site histidine 






























































































Figure 1-14 A) DFPase (monomer) representing β-propellers (PDB ID: 1E1A).85 B) The active 
site of DFPase. C) OP-hydrolysis mechanism of DFPase.92 An active-site aspartic acid attacks 
the central phosphorus of the OP, forming an aspartic acid–OP intermediate. The OP is then 

































































































The metal-ion preference varies between the enzymes. Both OpdA and PTE will 
function with several divalent ions, e.g. Zn2+, Mn2+, Co2+, and Cd2+.95 OpdA has a 
natural preference for a Fe–Zn active site, but will also bind Co to form a more active 
Fe–Co active site,95 whereas the similarly folded PTE is primarily Zn–Zn, although Cd–
Cd and Co–Co substituted enzymes are more active.101,102 MPH is active with Zn2+, 
Mn2+, Co2+, Ni2+, and Fe2+.98 Conversely, PON1 is specific for Ca2+, and is inhibited by 
Mn2+, Co2+, and Cu2+.103 DFPase is unaffected by addition of Sr2+, Mn2+, Ni2+ and Co2+, 
but is denatured by addition of Zn2+ and Cd2+.93 
1.2.3 OP-degrading enzymes in animal studies 
Many of the early animal studies focused on prophylactic strategies. Ashani et 
al. reported in 1991 that pretreatment with 15 and 26 μg·mouse-1 MPH injected 
intravenously conferred a 7.3 and 2.9-fold increase in the LD50 for mice challenged 
with paraoxon and diethylfluorophosphate, respectively.104 They also noted the short 
circulation time of the enzyme: complete clearance was observed in 3 hours, with an 
approximate half-life of 40 minutes. Raveh et al. reported in 1992 that 22 μg·mouse-1 
MPH intravenously increased the LD50 of tabun 5.65-fold.105 Subsequently, Kaliste–
Korhonen et al. demonstrated that intravenous administration of PTE protects the 
cholinesterase activity of mice when challenged with paraoxon,106,107 and DFP, sarin, 
and soman.108 They also reported the elimination half-life of PTE to be between 4–5 
hours. Intravenous administration of PON1 was shown to protect cholinesterase 
activity in rats poisoned with paraoxon and chlorpyrifos oxon by Costa et al. in 
1990.109 In 2000, Li et al. demonstrated that intraperitoneal injection of human PON1 
into mice protected against diazoxon and chlorpyrifos oxon, but not paraoxon.110 
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They also reported that in vivo enzymatic activity against the OPs peaks 4 hours after 
injection.  
More recent work has investigated the possibility of post-exposure enzyme 
treatments. Gresham et al. showed that 0.15 mg·kg-1 intravenous OpdA delayed 
mortality in rats challenged with 3×LD50 of methyl-parathion from 12% survival at 3 
hours to 100% survival at 16 hours, although none survived to 24 hours.2 It was also 
shown that the in vivo half-life of OpdA was between 45–60 minutes, with further 
studies in African green monkeys confirming this.111 In a separate African green 
monkey study, 1.2 mg·kg-1 intravenous OpdA delivered immediately after 3×LD50 
dichlorvos prevented lethality up to the experiment’s endpoint of 240 minutes, 
although AChE activity had decreased to approximately 20% by this time.71 
Wille et al. predicted that doses of 3 g, 5 g, and 432 g of OpdA would be required 
to detoxify 3 μM of soman, cyclosarin, and VX, respectively, in a 70 kg man in 3.9 
minutes due to the poor catalytic activity of OpdA against these agents.112 Gupta et 
al. posit that a useful enzyme must have a kcat/Km>107 M-1·min-1 for a given substrate, 
and also present the poor catalytic rate of PON1 against a cyclosarin analogue: 
approximately 2×102 M-1·min-1.113 Using their calculations for estimating the dose 
required to reduce the concentration of an OP 100-fold in 1 minute for a 70 kg man, 
3 kg of PON1 would be required to detoxify 2 μM of cyclosarin. Therefore, it is 
apparent that injecting the required dose of wild-type enzymes alone for post-
exposure treatment of OP-poisoning is unfeasible. 
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1.2.4 State of the art 
With data showing some efficacy of OP-hydrolases in treating OP poisoning, 
new strategies are being investigated to improve the in vivo efficiency of these 
enzymes. This commonly involves rational engineering of enzymes to increase their 
efficiency against OPs. Of particular interest is the differential hydrolysis of the 
enantiomeric OPs: the Sp enantiomers are all more toxic than the Rp enantiomers, but 
PTE,22 PON1,113 and DFPase114 are all more efficient at hydrolysis of the less-toxic Rp 
enantiomers. The kcat/Km values for PTE against the Sp enantiomer of a nerve-agent 
simulant is enhanced by more than three orders of magnitude by modifying three 
residues in the binding pocket, whereas the kcat/Km for each enantiomer of sarin and 
soman were more greatly enhanced with two mutations.22 Similarly, the specific 
activities of DFPase for racemic DFP, sarin, soman and cyclosarin were improved.114 
Notably the specific activity for racemic sarin was improved 7.8-fold, with the ratio of 
Sp:Rp hydrolysis increased from 0.89 to 5.11. kcat/Km values of 1.4×107 M-1·min-1 and 
2.9×107 M-1·min-1 were also achieved for the more toxic Sp enantiomers of sarin and 
cyclosarin, respectively, which reach the threshold of usefulness Gupta et al. 
proposed.113 
Directed evolution is also being used to enhance the catalytic properties of the 
enzymes. PON1 is exciting due to its lack of immunogenicity, but is severely limited 
by its low activity, and therefore has been subjected to directed evolution. Gupta et 
al. achieved a greater-than 86000-fold improvement in kcat/Km for the Sp enantiomer 
of a G-series nerve-agent simulant, and a 135-fold improvement for the Sp enantiomer 
of authentic sarin, by combining random and targeted mutagenesis with high-
throughput screening.113 Similarly, Goldsmith et al. used directed evolution to 
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enhance the activity of PTE to nerve agents; notably, the activity versus VX was 
improved 583-fold115 through 5 rounds of directed evolution, totalling 7 mutations.116 
Other groups are looking to improve the circulation time, in vivo stability, and 
reduce the immunogenicity of the enzymes. Gaidukov et al. anchored PON1 to a high-
density lipoprotein, increasing its stability.117 Using a directed-evolution form of PON1 
in this complex, the authors achieved significant protection against oral gavage 
administered 1×LD50 chlorpyrifos oxon when the complex was injected intravenously 
5 minutes or 3 hours prior to OP exposure, with a protein dose of 0.4 mg·mouse-1. 
Crucially, no histopathology indicating immunogenicity was observed. 
A common method of increasing circulation time and reducing immunogenicity 
is addition of polyethylene glycol (PEG) to the surface of proteins. When applied to 
OPH, an enhancement of the elimination half-life from 0.86–32.49 hours, and a 
reduced antibody response versus the unmodified protein was observed.118 This was 
suggested to be due to reduced susceptibility to proteolytic degradation and slowed 
renal excretion. A slight increase in kcat/Km against paraoxon but a decrease against 
demeton-S, a V series analogue, was also reported. When DFPase was modified with 
PEG, a minor decrease in activity against DFP was observed, but a protective effect 
against a dose of 3×LD50 soman was observed in rats.73 71 mg·kg-1 PEGylated-
DFPase was required to have a protective effect, while a PEGylated mutant DFPase 
with enhanced activity against the Sp enantiomer of soman was effective at 35.8 
mg·kg-1. Non-PEGylated-DFPase had no protective effect. The PEGylation was 
shown qualitatively to reduce the immunogenicity of DFPase, and it was posited that 
the enhanced protection against OP exposure was also due to increased stability 
against proteases and reduced renal excretion. 
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In the future, a combination of these approaches may be applied. For example, 
Gupta et al. suggested that their mutant-PON1 may require PEGylation to offset any 
increase in immunogenicity resulting from directed evolution before being used in a 
clinical setting.113 
1.2.5 OpdA for detoxification of OPs 
This novel research uses the OP-detoxifying activity of OpdA () from the soil 
bacterium Agrobacterium tumefaciens. Further to OpdA already having demonstrated 
some utility for in vivo detoxification of OPs,2,71,111 OpdA has also been shown to 
hydrolyse paraoxon near the diffusion limited rate,119 and is able to hydrolyse both 
nerve agents112 and pesticides.80 Moreover, OpdA mutants have been produced with 
enhanced activity against specific substrates, demonstrating tractability.116,120,121 
Therefore, OpdA is a promising candidate for producing an artificial membrane-
binding enzyme as a prophylactic for OP poisoning. 
1.3 Protein surface reengineering for cell-membrane binding 
Proteins have evolved over millennia to increase the survival of their host 
organisms, and their function is closely tied with their structure. However, it has been 
shown that the surface of proteins is amenable to modifications, without affecting the 
overall fold of the protein.122,123 Therefore, reengineering the surface of the protein is 
a feasible approach to target cell membranes. Before doing so, however, one must 
consider the membrane composition. 
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1.3.1 Cell membranes 
The phospholipid membrane is a complex selectively-permeable barrier: only 
small hydrophobic or uncharged polar molecules, or those transported through 
specialised transporter proteins, may cross the membrane.124 This is crucial for 
compartmentalising the milieu of cytosolic components. Fundamentally, the 
phospholipid bilayer comprises phospholipids with hydrophobic tails and hydrophilic 
heads that form the membrane leaflet, although the composition of lipids is 
variable,125 and is asymmetric between inner and outer leaflets.126 The structure is 
highly dynamic, with lipids flipping, flopping, scrambling and diffusing.127 Typical cell 
membranes also comprise myriad glycolipids, cholesterols, integral proteins, and 
glycoproteins (Figure 1-15). Phospholipid membranes are typically 30–40 Å, 
depending on their composition.128,129 
 
Figure 1-15 Typical features of the biological plasma membrane. Lipids form the main 
structure, with cholesterol modulating fluidity and permeability. Integral proteins, of which 
transport proteins are a subset, have diverse structures and functions. Peripheral membrane 
proteins partially insert into the membrane, and typically serve a regulatory purpose. Certain 
proteins are modified post-translation to target them to the inner membrane. Glycoproteins 
and glycolipids are used for cell–cell interactions. 
Glycolipids and glycoproteins serve as cell-cell recognition molecules,130 
particularly by the immune system.131,132 Cholesterol modulates the fluidity of the 
membrane and their permeability to polar molecules.133 Integral proteins are diverse 












proteins, move molecules across the membrane, powered either by ATP-hydrolysis 
or electrochemical gradients.134 The orientations of proteins in membranes database 
provides spatial and topological data on more than 1200 integral and peripheral 
proteins.135 The membrane and its associated components are frequently remodelled 
via endocytosis, which may affect the lifetime of membrane-bound proteins. 
1.3.2 Endocytosis 
Proteins bound to the surface of membranes may be internalised through 
endocytosis (Figure 1-16). Endocytosis covers several mechanisms through which 
proteins may be internalised: clathrin-mediated, caveolae-mediated, and clathrin-
independent.136 Liquid-phase extracellular material may also be internalised by 
micropinocytosis and phagocytosis, although these are primarily performed by 
macrophages, neutrophils and dendritic cells.137 Some highly-charged peptides, 
known as cell-penetrating peptides, may also directly penetrate the bilayer in a non-





Figure 1-16 Endocytic processes. A) The coat-based endocytic processes: clathrin- and 
caveolae-mediated endocytoses. Transmembrane receptor proteins change their 
conformation upon binding, initiating coat assembly of either clathrin or cavaeolin proteins, 
assisted by various scaffolding and adaptor proteins. Assembly of the coat leads to 
deformation of the membrane, known as pit formation. Upon sufficient deformation, dynamin 
pinches off the vesicle, leading to internalisation and uncoating before further processing. B) 
Clathrin-independent endocytic processes: macropinocytosis and phagocytosis. Each 
process is heavily dependent on polymerisation of the actin cytoskeleton, causing ruffling of 
the membrane. The ruffles fold back on themselves, non-selectively encapsulating 
extracellular material. 
Clathrin-mediated endocytosis occurs via clathrin-coated pit formation in the 
membrane induced by clathrin light and heavy chains polymerisation, supported by 
several adaptor and scaffolding proteins.141 It is an energy dependent process, as 





























vesicles requires the ATPase HSC70.143 The observed upper-limit of the diameter of 
these vesicles is approximately 200 nm,144 and they have a lifetime of approximately 
1 minute.145 The primary function of clathrin-mediated endocytosis is the 
internalisation of receptors carrying metabolites;144 extracellular molecules trigger 
clathrin pit formation through conformational changes of the receptor.146 
Caveolae-mediated endocytosis is dependent on the caveolin family of proteins, 
particularly caveolin-1, producing comparatively smaller vesicles 50–100 nm in 
diameter.147 As with clathrin-mediated endocytosis, caveolae-mediated endocytosis 
requires dynamin to pinch off vesicles.148 Furthermore, caveolae-vesicle assembly 
can be triggered by a number of ligands,147 but is also thought to be involved in 
cellular cholesterol homeostasis.149 The process is highly dynamic, with caveolae-
vesicle lifetimes ranging from less than 2 seconds to more than 7 minutes.150 
Clathrin-independent endocytosis covers a range of diverse endocytic 
mechanisms. Some receptors have specific internalisation pathways, such as those 
for interleukin-2 and endothelial growth factor that each require, although these are 
less-well characterised.151 Macropinocytosis152 and phagocytosis153 are each clathrin-
independent, instead utilising the actin cytoskeletal machinery to engulf extracellular 
material. 
1.3.3 Artificial membrane-binding protein approaches 
The cellular membrane presents many opportunities for binding. Proteins may 
be used to target specific moieties at the cell surface with high-affinity and specificity, 
e.g. antibodies targeting cell-surface antigenic proteins, or integrins; these targeting 
proteins may then be conjugated to other proteins. Highly positively-charged proteins 
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interact with cells via electrostatic interactions with the negatively-charged 
glycocalyx. The bilayer regions of the membrane itself may be targeted via the 
hydrophobic effect. Here, the different approaches to artificially introducing 
membrane binding to proteins are explored. 
1.3.3.1 Target–receptor approaches 
Target–receptor binding is abundant and ubiquitous in nature, and may be 
highly-specific and high-affinity. A commonly-used target–receptor pair is the biotin-
(strept)avidin system (Figure 1-17). Avidin (from egg whites) and streptavidin (from 
Streptomyces avidinii) differ in that avidin is a glycoprotein, which leads to greater 
non-specific binding. Both avidin and streptavidin bind biotin, otherwise known as 
vitamin B7, via hydrogen bonding,154 with extremely high-affinity: the dissociation 
constant of the bond is of the order of 10-15 M, and is among the strongest non-
covalent bonds.155 Biotin is a small molecule at 244 Da, and can be easily conjugated 
to proteins using NHS chemistry. However, avidin and streptavidin are approximately 
60 and 66 kDa, respectively. Biotinylating the cell-surface can mediate the 
endocytosis of protein–avidin complexes, although the mechanism of endocytosis 
was not investigated.156 Similarly, biotinylation of the cell-surface has been used to 





Figure 1-17 Streptavidin–biotin binding. A) A streptavidin tetramer, with each monomer 
binding a single biotin molecule. Purple, α-helices; yellow, β-sheets; cyan, turns; coils, white. 
B) The hydrogen bonding network of streptavidin. White, carbon; red, oxygen; blue, nitrogen; 
yellow, sulphur; dotted lines, hydrogen bonds. 
The cell-surface presents many natural targets that may be bound by proteins. 
Lectins are ubiquitous, and bind to specific sugars found on glycoproteins, 
glycolipids, and glycans.158 Similarly, the LysM (lysin motif) domain, found in over 
4000 proteins in both prokaryotes and eukaryotes, binds to glycans present at cell 
surfaces.159 There are myriad proteins that bind to glycosaminoglycans protruding 
from the cell membrane, although these are non-specific, interacting mostly via 
electrostatic interactions.160  
Antibodies are available for many naturally occurring membrane-bound targets, 
and antibody–protein conjugates may be produced to bind proteins to specific 
targets. There is a therapeutic strategy system termed ADEPT (antibody-directed 
enzyme prodrug therapy) utilising antibody-enzyme conjugates to convert prodrugs 
into their active form at specific sites within the body, aimed at treating cancers.161,162 
While promising, this technique is yet to reach phase 2 clinical trials.163 
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1.3.3.2 Cationised and supercharged proteins 
Proteins with a high positive surface charge density may form electrostatic 
interactions with glycocalyx, proteoglycans, glycosaminoglycans and negatively-
charged lipid headgroups. Cronican et al. found 309 natively supercharged human 
proteins in the Swiss-Prot database,164 including β-defensin 3, a protein known to 
permeabilise membranes.165 However, most highly-charged proteins are produced by 
mutation or chemical-modification of surface residues to impart large positive 
charges. 
Lawrence et al. used computational methods to design recombinantly-
cationised mutants of superfolder-GFP (sfGFP) and streptavidin, and an anionised 
glutathione-S-transferase (GST).122 Recombinantly-supercharged sfGFP, known 
simply as supercharged-GFP (scGFP) was produced, achieving a net charge of +36, 
as was a supercharged streptavidin with a net charge of +52. Each was found to be 
resistant to both thermal and chemical denaturation, thought to be due to 
electrostatic repulsion preventing aggregation and the subsequent α-helix–β-sheet 
transition. scGFP was found to rapidly penetrate cell membranes, and therefore may 
be used to deliver DNA, siRNA or protein payloads.166-168 scGFP was shown to 
penetrate cells by binding cell-surface sulphated proteogylcans prior to energy-
dependent endocytosis.166 Similarly, Fuchs and Raines found that a patch of 5 
arginine residues on the surface of GFP was sufficient for membrane penetration, but 
this was dependent on cell-surface glycosaminoglycans for internalisation.169 
Glutathione-S-transferase was produced via the same methodology employed for 
scGFP and was found to be similarly aggregation-resistant, however the kcat was only 
one-third that of the wild-type enzyme.122 
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The first use of a chemically-cationised molecule was in 1972 by Danon et al., 
using cationised ferritin to label negatively-charged membranes.170 The chemically-
cationised ferritin achieved a net charge of approximately +65 with no apparent loss 
of structure. Similarly, Correia Carreira et al. used chemically-cationised 
magnetoferritin to magnetise cell membranes.171 However, cationised ferritin has 
been seen to be internalised within 5 minutes.172 Rapid internalisation of cationised 
proteins was also seen for RNase, immunoglobulin and GFP.173 This has been 
exploited to improve the cell uptake of antibodies with intracellular targets.174 
However, chemical cationisation may also affect the function of proteins. For 
example, Armstrong et al. noted an increase in oxygen binding affinity by cationised 
myoglobin,175 whereas Brogan et al. observed an 85% and 98% decrease in the 
turnover rate of two cationised lipases.176 Moreover, cationised enzymes have never 
been applied to cell membranes. 
While supercharging and cationisation have been used for cell-membrane 
interactions, highly-charged proteins are rapidly internalised by cells. Therefore, 
further modifications must be made to enhance the persistence at the cell membrane. 
To achieve this, polymer surfactant conjugation may be used. 
1.3.3.3 Protein–polymer conjugates 
In nature, sequence-specific covalent attachment of lipids to membrane-
anchoring proteins is widespread, with nearly 1000 functionally and structurally 
diverse proteins known to be modified this way.177 Glycosylphosphatidylinositol (GPI) 
tails are added to the C-terminus of many eukaryotic proteins of varying structures 
and functions via post-translational modification in the endoplasmic reticulum of 
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eukaryotes.178 GPI-tails bind protein to the outer leaflet of the cell membrane, and are 
believed to interact specifically with lipid rafts on the membrane surface.179 
Perriman et al. developed a methodology using protein–polymer conjugation to 
produce proteins that are stable in solvent-free environments,180 organic-solvents,181 
and at extremely high-temperatures.182 In these cases, a surfactant comprising a 
lipophilic tail, a PEG central moiety, and an anionic headgroup was used to form a 
surfactant corona on the surface of cationised proteins (Figure 1-18). The anionic 
head group electrostatically grafts the surfactant to the protein surface, and the 
amphiphilic PEG group confers protein stability and enables functional protein 
dynamics. The lipophilic tail of the surfactant is buried in aqueous solutions, but 
dynamically reconfigures in low-dielectric environments to expose the lipophilic 
tail.183 As the inner leaflet of the cell membrane is a low-dielectric environment, 
proteins modified in this way will spontaneously insert their lipophilic tails into the 
membranes, anchoring them to the cell surface. Armstrong et al. used this approach 
to produce an artificial membrane-binding myoglobin construct that mitigated central 
cell necrosis in tissue constructs by supplementing cells with oxygen,175 and Burke 





Figure 1-18 The polymer-surfactant conjugation approach used by Perriman et al. Firstly, the 
protein is cationised by the addition of a small diamine to acidic residues. Then, a polymer 
surfactant, in this case ethylene glycol ethoxylate lauryl ether, is electrostatically grafted to the 
cationised residues. Figure from Brogan et al.182 
Significantly, the technique developed by Perriman et al. may also be used with 
enzymes. Brogan et al. used the method to produce lipases that functioned in 
solvent-free environments, and were resistant to high temperatures.176 The same 
approach was used by Sharma et al. to produce enzymatically-active films.185 
Furthermore, Farrugia et al. produced a multi-enzyme film for cascade reactions.186 
None of these enzyme-polymer surfactant conjugates have been developed for cells, 
however. Accordingly, by applying these methodologies, it should be possible to 
anchor enzymes to the cell surface, increasing its systemic persistence, whilst 
retaining its enzymatic activity. 
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1.3.4 Enzymatic activity at the cell surface 
Cell-surface enzymes are ubiquitous, and are required to modulate extracellular 
conditions, secrete proteins, and remodel membranes. Cell surface carbonic 
anhydrases maintain acidic extracellular pH required for tumour growth;187 isozyme 
IV binds the membrane via a post-translational GPI tail,188 whereas the other 
extracellular-facing isozymes (IX, XII, XIV, XV) have membrane-spanning α-helical 
domains.189 The secretase family of transmembrane proteins cleave the GPI anchors 
of proteins, thus releasing them into extracellular fluid, and have a role in Alzheimer 
disease.190 AchE is bound at the membrane via a GPI-anchor until exposure to 
acetylcholine, at which point it is cleaved from the surface into the synaptic cleft.191 
In Bacillus subtilis, a suite of surface cell-wall hydrolase enzymes is required for 
vegetative growth, which are in turn controlled by a cell-wall protease.192 OPH was 
found to be membrane-bound through a twin-arginine translocation motif, albeit 
periplasm-facing on the inner membrane.193 
Artificial cell-surface enzymatic activity is being used by synthetic biologists to 
produce biorefineries with enhanced efficiency.194 For example, yeast displaying 
cellulolytic enzymes at the surface are able to break down cellulose into cellobiose, 
which is then internalised and converted into ethanol through glycolysis for the 
production of biofuel.195-197  
These methods require genetic modification to produce recombinant proteins, 
which is unsuitable for use in OP-poisoning treatments. However, these systems may 
be exploited in ex vivo detoxification systems, for example, bacterial microreactors. 
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1.4 Bacterial microreactors 
Pesticide run off from crops toxifies sources of drinking water,198,199 and impacts 
on aquatic ecosystems.200 3 million people per year are estimated to be poisoned 
from pesticides per year, with 10% of the cases being fatal.201 Bioremediation of 
OPs,1 as well as heavy metals202 and nuclear waste,203 is being investigated. The use 
of whole-cell genetically modified organisms requires strict containment,204 therefore 
recombinant bacteria must be well entrapped. To this end, microreactors present a 
solution. 
Microreactors are devices with features less than 1 mm in size in which chemical 
reactions occur.205 Bacteria are an obvious choice for inclusion in microreactors due 
to their ability to catalyse myriad reactions, as well as their rapid growth, robustness, 
and tractability. Indeed, the use of biocatalysis is gaining in popularity, albeit mostly 
with cell-free, immobilised enzyme systems.206  
Microreactors with entrapped bacteria have been used in microfluidic devices 
as biosensors: organisms that generate a measurable output, such as fluorescence 
or luminescence, when exposed to specific triggers.207 For example, Mulchandani et 
al. produced an OP biosensor by immobilising E. coli in agarose gel on a nylon 
membrane, and probing for chromophoric reaction products with fibre optics linked 
to a photomultiplier detector system.208 
Beyond sensing, bacterial microreactors may also be used in the production of 
chemicals. A key advantage of biological systems employing enzymes is their 
enantioselectivity, which is highly sought after in the fine chemicals markets, 
especially pharmaceuticals.209 Wachtmeister and Rother identified several benefits 
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and challenges for whole-cell biocatalysis techniques.210 Chiefly, preparing whole-cell 
biocatalysis is cheaper than immobilising enzymes due to not requiring purification 
and supplementation with cofactors. Further, cells may be more stable in 
‘unconventional media’, for example, Hibino and Ohtake used the organic-solvent 
tolerant bacterial strain Rhodococcus rhodochrous to produce α-(trifluoromethyl) 
benzyl alcohol from 2,2,2-trifluoroacetophenone, reaching 97% yield in 48 hours.211 
The primary limitation of whole-cell catalysis is mass transfer across the cell 
membrane, although this can be mediated by membrane permeabilisation techniques 
or cell-surface display of enzymes. 210 
Most bacterial microreactors are produced by immobilising bacteria on plastics, 
entrapping them between filters, or casting them within hydrogels, however 3D 
bioprinting offers automated precise spatial deposition that will increase the 
achievable complexity of these devices.210 
1.4.1 3D bacterial bioprinting as a new paradigm for microreactor design 
Bioprinting is a subsection of 3D printing in which the deposited material, known 
as the bioink, contains cells.212 The bioink is either deposited or polymerised from a 
reservoir layer-by-layer to build up complex structures (Figure 1-19). The different 
bioprinting approaches have been extensively reviewed by Burke et al.213 Bioink may 
be continuously deposited from a syringe via mechanical force or through pneumatic 
pressure, or deposited in droplets via ejection from a nozzle using either thermo or 
piezoelectric actuators, Rayleigh instability of a continuous flow through a small 
orifice, or ejection from a substrate using laser-induced forward transfer. 
Alternatively, a reservoir of bioink may be cured via photopolymerisation using either 
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laser-light or projected light. Stereolithography typically uses UV-light to 
photopolymerise bioinks, which may affect cellular health, 214 and droplet-producing 
methods are limited by the depth of structures they may produce.215 Extrusion-based 
systems, however, may be used to print relatively large structures whilst maintaining 
high cell viability.216 To date, there are few examples of bacterial bioprinting. Kyle, 
however, predicts that the bioprinting of bacteria will be the ‘next frontier in 
biofabrication’.217 
 
Figure 1-19 Bioprinting approaches. Biomaterials are: driven out of a syringe via mechanical 
force (piston or screw-driven) or pneumatic pressure; ejected from a nozzle in droplets via 
thermo or piezoelectric actuators, or Rayleigh instability of a continuous flow through a small 
orifice; ejected from a substrate using laser energy; or a reservoir of biomaterial is cured via 
photopolymerisation using lasers or projected light. Adapted from Burke at al.213 
Only a few examples of bacteria being exploited in 3D bioprinting processes 
have emerged. Schaffner et al. have used 3D bioprinting to produce functional 
complex materials: firstly, they printed a bioink containing a bacterial strain of 
Pseudomonas putida capable of degrading phenol for bioremediation, and secondly 
Acetobacter xylinum was printed to produce nanofibrillated cellulose scaffolds.218 Liu 
et al. have produced complex bioprinted devices, including a ‘living tattoo’, that 
respond to external stimuli.219 
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In this thesis, the 3D bioprinting of OpdA-expressing E. coli was explored with 
the view to produce high surface-area OP-degrading devices, using a bioink initially 
developed to print hMSCs for tissue engineering. 
1.5 Thesis structure 
This thesis further comprises three results chapters, and a concluding remarks 
chapter. The first results chapter describes the synthesis of the artificial membrane-
binding OpdA constructs, and subsequent characterisation comprising structural 
analyses and function assays. Furthermore, two novel approaches to producing 
artificial membrane-binding proteins are investigated: genetic cationisation, and dual-
surfactant conjugation. In the second results chapter, the constructs described in the 
previous chapter are investigated for how they interact with human mescenchymal 
stem cells through in vitro cell binding assays, cytotoxicity assays, and assays to 
determine the activity of the enzyme constructs at the cell surface. The final results 
chapter explores bioprinting bacteria-laden hydrogel devices as an ex vivo 
detoxification technique, including the design of a bioprinting system, a novel bioink, 
and preliminary data for a printable OP-degrading device utilising OpdA-expressing 
E. coli. 
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2 The synthesis and characterisation of OpdA-based nanoconstructs 
2.1 Introduction 
The methodology previously developed by Armstrong et al. enabled the artificial 
plasma membrane-binding of myoglobin and green fluorescent protein 
nanoconstructs to the surface of stem cell membranes,1 and synthesis of the 
nanoconstructs was inspired by the solvent-free liquid protein systems.2-9 The 
methodology comprises two stages: supercharging the protein via chemical 
cationisation of acid residues to achieve a homogenous positive charge across the 
surface of the protein, and electrostatically grafting polymer surfactants to this 
surface, forming a dynamic surfactant corona (Figure 2-1A). The constructs formed 
will then spontaneously insert into the lipid bilayer of cell membranes and remain at 
the surface for several days. While these modifications have been made to lipases2 
and alkaline phosphatase8 to produce solvent free liquid enzymes, albeit with only 
limited activity, these constructs were not tested for cell membrane binding. Logic 
dictates that the covalent and electrostatic modifications would alter the structure of 
the enzymes, and so it is counterintuitive that activity would be maintained. For 
example, EDC, the crosslinking agent used, has been previously used to inhibit the 
activity of enzymes,10-12 and surfactants such as SDS and Triton-X are frequently used 
as protein denaturants. Therefore, it is pertinent to study in-depth the effects of the 
modification on the structure and function of OpdA. 
This chapter describes the adaptation and optimisation of this technology to 
produce and characterise the first artificial membrane-binding enzyme, based on 
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OpdA. Moreover, three approaches to producing an OpdA-based artificial 
membrane-binding enzyme are developed. The first is an adaptation of the 
methodology of Armstrong et al. (Figure 2-1A). The second and third approaches aim 
to negate the need for the chemical cationisation step. The first of these looks to 
create a supercharged-OpdA mutant that can be conjugated immediately post-
purification (Figure 2-1B), with the design informed by data produced from analysis 
of the cationised system. The final method utilises a positively-charged surfactant to 
interact with the negatively-charged surface residues (Figure 2-1C). 
 
 
Figure 2-1 Schematic of artificial membrane-binding protein production processes. A) The 
methodology of Armstrong et al.; B) using a supercharged-OpdA instead of chemically-
cationising the native protein; C) using both cationic and anionic surfactants. Red, negatively 




2.2 Materials and methods 
All chemicals were purchased from Sigma Aldrich, UK, and were not further 
processed unless stated otherwise. Deionised water was produced at a resistivity of 
18.2 MΩ·cm by a Millipore Milli-Q Reference Water Purification System using a 
Quantum TIX polishing cartridge. Sequences of genes, primers, and proteins are in 
the Appendix. 
2.2.1 Preparative 
2.2.1.1 OpdA expression 
A pETMCS1 plasmid containing the opda gene (pETMCS1–OpdA) was provided 
by Eleanor Campbell from the Australian National University (Canberra, Australia). The 
plasmid was amplified and purified before use using a QIAprep Spin Miniprep Kit 
(QIAGEN, UK) according to the manufacturer’s instructions. The prepared DNA was 
stored at -20°C before further use. 
50 μL aliquots of BL21(λDE3) Escherichia coli cells (New England Biolabs, UK) 
were transformed with approximately 100 ng pETMCS1–OdpA plasmid via 
electroporation using a Gene Pulser (Bio-Rad, UK) set at 2.5 V with a pulse of 
approximately 4.2 ms in an ice-cold 0.4 cm electrocuvette (Bio-Rad). The cells were 
then immediately transferred to a 14 mL conical tube with 1 mL of yeast extract–
nutrient broth (YENB) preheated to 37°C and left in a shaking incubator at 37°C, 180 
rpm for 30 minutes. 50 μL of the cell suspension was then spread across lysogeny 
broth (LB)–0.15% agar plates, supplemented with 0.8% glucose and 50 μg·mL-1 
carbenicillin. The plates were incubated at 37°C overnight. 
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A single colony from the LB–agar plates was picked to inoculate 1 L of 
autoclaved terrific broth (TB; Fisher, UK) supplemented with 100 μM CoCl2 and 50 
μg·mL-1 carbenicillin in 2.5 L UltraYield Flasks (Generon, UK). The flasks were left in 
a shaking incubator at 37°C, 180 rpm overnight, or at 30°C, 180 rpm over two nights. 
These cultures were then spun at 4500×g for 30 minutes, 4°C, the supernatant 
discarded and the pellet frozen at -20°C before further use. 
2.2.1.2 OpdA purification 
Frozen pellets were thawed in approximately 20 mL HEPES buffer (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid; 30 mM, pH 8) supplemented with 100 
μM CoCl2, with vortexing to ensure homogeneous suspension. A few grains of 
lyophilised deoxyribonuclease I from bovine pancreas were added at this point to 
degrade contaminating DNA, which concomitantly reduced the viscosity of the 
solution. The resuspended cells were then lysed on ice via pulsed sonication using a 
vibra cell VCX 1500 (Sonics & Materials, US) at 65% amplitude, with 1 second on, 1 
second off pulsing. The lysed cells were then centrifuged at 20000×g for 45 minutes 
at 4°C, to pellet out cell debris. The supernatant was then further clarified using a 
0.22 μm syringe-filter. 
Before applying the supernatant, a column containing 50 mL DEAE–Sepharose 
anion-exchange resin (GE Healthcare, UK) was equilibrated with at least 5 column-
volumes of HEPES buffer (30 mM, pH 8) supplemented with 100 μM CoCl2. 
Approximately 30 mL of the supernatant was injected at 2 mL·minute-1. HEPES buffer 
was then flowed through the column at room temperature using an ÄKTApurifier (GE 
Healthcare), with 5 mL fractions collected. OpdA loosely bound to the resin, and was 
eluted from the column after approximately 120 mL. Fractions containing OpdA were 
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pooled and subjected to size exclusion chromatography using a Superdex 200 pg 
HiLoad 26/600 column (GE Healthcare) in HEPES buffer (30 mM, pH 8) supplemented 
with 100 μM CoCl2 at room temperature to purify further. 
2.2.1.3 Cationisation of OpdA 
OpdA was added to pH-neutralised N,N’-dimethyl-1,3-propanediamine (DMPA) 
at a molar ratio of 1:10,000, and the solution adjusted to pH 5.1 with 6M HCl. N-(3-
dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDC) was added at a ratio 
of 50 equivalents EDC per anionic residue in 2 half-additions, 4 hours apart. The 
reaction was buffered with 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffer. 
The solution was left to stir at 4°C for a further 20 hours, before being centrifuged at 
10000×g to remove large aggregates. The remaining protein was then buffer 
exchanged into HEPES buffer (30 mM, pH 8) supplemented with 100 μM CoCl2 using 
10K MWCO VivaSpin Turbo concentrators (Sartorius, UK) to achieve a minimum 
1×106 dilution of the salts. Size exclusion chromatography was performed using a 
Superdex 26/600 column (GE Healthcare) to remove crosslinked proteins. The 
cationised product is termed cOpdA. The number of acid residues modified, can be 
calculated using , where MwcOpdA is the molecular weight of cOpdA and MwOpdA is the 
molecular weight of native OpdA, each determined with mass spectrometry, and 
MwDMPA-H2O is the mass of DMPA minus the mass of H2O due to the condensation 








2.2.1.4 On-column refolding 
scOpdA-expressing cells were lysed, pelleted, and washed three times with 8 
M urea, 1.5 M NaCl, 5% Triton X-100 to remove contaminating cell debris. The 
resulting pellet was then dissolved in 6 M guanidine HCl to unfold the inclusion 
bodies. Concurrently, a Ni–nitrilotriacetic acid (Ni–NTA) column was equilibrated in 6 
M guanidine HCl with 50 mM imidazole and HEPES buffer (30 mM, pH 8). The 
dissolved scOpdA was then flowed through the column, the flow-through collected, 
and flowed through again to maximise loading. A buffer gradient was then set up with 
6 M guanidine HCl to no guanidine HCl, each with 50 mM imidazole and HEPES buffer 
(30 mM, pH 8), over 3 hours at 2 mL·min-1. Bound proteins were then eluted with 500 
mM imidazole in HEPES buffer. 
2.2.1.5 Oxidation of IGEPAL CO-890  
2 g IGEPAL CO-890 dissolved in 50 mL deionised water was mixed with 30 mg 
2,2,6,6-tetramethyl-1-piperidinyloxyl (TEMPO), 50 mg NaBr, and 5 mL NaClO solution 
containing 10–15% available chlorine. The solution was periodically adjusted to pH 
11 and stirred for 24 hours. The reaction was quenched with ethanol and adjusted to 
pH 1. Solvent extraction was performed with 3 washes of 80 mL aliquots of 
chloroform, then 3 washes with 80 mL aliquots of deionised water adjusted to pH 1. 
The resulting solution was dried under reduced pressure at 40°C. The remaining solid 
was redissolved in 40 mL ethanol, recrystallised at -20°C, the ethanol decanted, and 
the crystals dried under reduced pressure at 65°C. Successful oxidation was 
confirmed using Fourier-transform infrared spectroscopy (FTIR). 
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2.2.1.6 Conjugation of cOpdA 
The surfactant–conjugate of cOpdA, namely [cOpdA][S], is produced via simple 
electrostatic engraftment of a surfactant, oxidised IGEPAL CO-890 (S). A 10 mg·mL-
1 solution of S in HEPES buffer (30 mM, pH 8) supplemented with 100 μM CoCl2 was 
added to a solution of cOpdA equimolar to the cationic residues. Unbound S was 
removed prior to analyses via dialysis. The conjugation efficiency may be calculated 
using  above, where Absobs is the measured absorbance at 280 nm, [cOpdA]BCA is the 
concentration of cOpdA as determined by a bicinchoninic acid (BCA) assay, εcOpdA is 
the extinction coefficient of cOpdA (29160 M-1·cm-1), [S]Added is the known 
concentration of S added, and εS is the extinction coefficient of S (1183 M-1·cm-1). 





2.2.1.7 Dual-surfactant conjugation 
The dual-surfactant conjugated OpdA, termed [OpdA][E][S], is formed via 
sequential conjugation of Ethoquad HT/25 (E) and S. Each surfactant was dissolved 
at a concentration of 10 mg·mL-1 in HEPES buffer (30 mM, pH 8). E was added first, 
allowed to stir for a minimum of 10 minutes, before the addition of S with further 
stirring. 
2.2.1.8 Gibson assembly 
Gibson assembly was used to insert the scOpdA gene into the pETMCS1 
plasmid. A solution comprising 20 μL autoclaved deionised water, 1 μL 10 ng·μl-1 
scOpdA gene, 2 μL 10 pmol·μl-1 of each of the forward and reverse primers, and 25 
μL Gibson assembly master mix (New England Biolabs), comprising exonuclease, 
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polymerase, and ligase activity, was heated to 50°C for 1 hour. The resulting plasmid 
was analysed and purified using agarose-gel electrophoresis before use. 
2.2.2 Analytical 
2.2.2.1 Sodium dodecylsulfate–polyacrylamide gel electrophoresis 
Theory 
To measure the molecular mass of proteins through electrophoresis, two 
conditions must be met: the protein must be denatured so that the shape does not 
affect mobility, and the protein must carry a negative charge so that it migrates 
towards the anode. The use of sodium dodecyl sulfate (SDS) achieves both of these; 
the hydrophobic tail penetrates the buried portions of the protein and exposes them, 
while the negative headgroup imparts a large negative charge such that the native 
charge is negligible. Reducing agents, such as dithiothreitol, are used to reduce 
disulfide bonds. By applying an electric current, samples are drawn towards the 
anode according to their electrophoretic mobility. The samples move through pores 
in the gel, with larger proteins experiencing greater drag. After running, the samples 
may be stained by protein-specific stains, such as Coomassie and its derivatives. 
Coomassie stains are triphenylmethane based, and interact with proteins through a 
combination of hydrophobic and electrostatic interactions.13 By running samples 
alongside proteins of known mass, the mass of samples can be determined by visual 
comparison, or more accurately with linear regression. 
Method 
Sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS–PAGE) was 
used to analyse the purity of protein preparations. Protein samples were heated to 
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95°C in sample application buffer (SAB; 80 mM Tris 
[tris(hydroxymethyl)aminomethane] buffer, 2% SDS, 10% glycerol, 0.0006% 
bromophenol blue, 0.1 M dithiothreitol) for 10 minutes to ensure denaturation of 
proteins. A Novex 4–20% Tris–Glycine polyacrylamide gel (Thermo Fisher, UK) was 
loaded into an XCell Surelock electrophoresis system (Thermo Fisher) and covered in 
SDS running buffer (25 mM Tris, 200 mM glycine, 0.1% SDS). 10 μL of sample was 
loaded into each well, with a single well reserved for PageRuler Plus Prestained 
Protein Ladder (Thermo Fisher) as a reference. 200 V was applied to the system for 
up to an hour, or until the sample front reached the bottom of the gel. The gel was 
then released from its cartridge, covered in PhastGel Blue R stain (prepared 
according to the manufacturer’s instructions), and microwaved until hot to the touch. 
The gel was then rinsed with tap water, and left to destain overnight. 
2.2.2.2 UV–visible spectrophotometry 
Theory 
UV–visible light can be absorbed by electrons, causing transitions to higher 
excitation states. Discrete energy steps between electronic states mean that only 
photons with energy equal to the energy required for excitement are absorbed. 
Spectra are obtained by exciting the sample with monochromatic light across a range 
of wavelengths and measuring the amount of light absorbed by the sample. Certain 
moieties have distinctive absorbance patterns. For example, the aromatic protein 
residues tryptophan and tyrosine absorb light strongly at 280 nm, and DNA absorbs 
260 nm light. By measuring samples of known concentration, extinction coefficients 
can be calculated using the Beer–Lambert law (), allowing the quantification of 
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molecules based on their signature absorbance. The Beer–Lambert law states that 
the absorbance of a sample is directly proportional to the extinction coefficient and 
the concentration of a sample, and the path length. 
𝐴 = 𝜀 ∙ 𝑐 ∙ 𝑙 
Equation 2-3 The Beer–Lambert law. 
Method 
Spectrophotometric analyses were performed using a Cary 60 UV–Vis (Agilent 
Technologies, UK) using a 1 cm quartz cuvette. A blank comprising the buffer 
component of the sample was read and subtracted from all subsequent reads. 
2.2.2.3 Mass spectrometry 
Theory 
Matrix assisted laser desorption ionisation time-of-flight mass spectrometry 
(MALDI–TOF MS) is a technique used to determine the mass of molecules within a 
sample. Samples are mixed with a highly-absorbing, highly-charged, and volatile 
matrix solution before spotting on a target plate. The matrix rapidly dries and 
crystallises the sample solution, creating spots of high-concentration sample with 
high-charge. Furthermore, the matrix has a large extinction coefficient, allowing it to 
absorb large amounts of energy. When laser light from the instrument is shone at the 
sample spots, the matrix rapidly heats, causing sublimation of the sample. This 
releases gaseous ions, which are then subjected to a strong electric field, propelling 
them towards a detector. The instrument records the delays from the laser excitation 
of the sample to collision of each molecule with the detector; this is known as the 
time-of-flight (TOF). The TOF is proportional to the mass and the charge of the 
protein, i.e. a doubly-charged molecule will travel twice as fast as a singly-charged 
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molecule of the same mass, but will be equivalent to a singly-charged molecule of 
half the mass. Instruments are calibrated against controls of known mass, and are 
able to determine mass to sub-dalton resolutions. 
A limitation of MALDI–TOF MS is that it is not quantitative. The composition of 
each sample-spot and the amount of sample desorbed upon excitation is stochastic. 
Moreover, the quality of the data depends strongly on the quality of the sample 
crystals, and therefore the matrix solution. Many matrices are available, with different 
matrices more appropriate for different samples. Sinapinic acid was successfully 
used for proteins, whereas α-cyano-4-hydroxycinnamic acid provided better data for 
surfactants. 
Method 
MALDI–TOF MS was performed using a ultrafleXtreme MALDI–TOF/TOF mass 
spectrometer (Bruker, UK). Protein solutions were briefly mixed in a 1:1 ratio with a 
saturated solution of sinapinic acid in 50% methanol, with 0.1% trifluoroacetic acid. 
1 μL of this mixture was then spotted on a ground steel target plate, and left to dry at 
room temperature. When dried, the sample was analysed using the linear positive 
mode of the instrument. Surfactant samples were mixed in a similar solution, using 
α-cyano-4-hydroxycinnamic acid in place of sinapinic acid. 
2.2.2.4 Bicinchoninic acid assay 
Theory 
The quantification of proteins via the BCA assay exploits the reduction of Cu2+ 
ions to Cu+ by bonds within protein samples. Two equivalents of BCA then chelate 
Cu+ ions, forming a complex that absorbs light at 562 nm. By comparing samples to 
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standards of known concentration, linear regression can be used to determine the 
concentration of the samples. At room temperature, the primary reduction of Cu2+ 
ions is due to cysteine, tryptophan, and tyrosine residues, whereas at temperatures 
37–60°C, Cu2+ is reduced non-specifically by peptide bonds.14 Therefore, incubating 
samples at increased temperatures reduces sample variability. 
Method 
OpdA with a concentration determined by UV–visible spectrophotometry was 
diluted across a range of concentrations, to produce a standard curve, and added to 
a 96-well plate. The [cOpdA][S] sample of unknown concentration, and a blank 
control were also added to the plate. A Pierce BCA Protein Assay Kit (Thermo Fisher) 
was used to perform the assay according to the manufacturer’s instructions. Briefly, 
20 μL of the samples were mixed with 200 μL of a 50:1 mix of the A and B proprietary 
reagents, respectively, and incubated at 37°C for 30 minutes. The resulting colour 
formation was measured by absorbance at 562 nm. Linear regression was then used 
to calculate the concentration of the [cOpdA][S] sample from the standard curve. 
2.2.2.5 Dynamic light scattering and zeta potentiometry 
Theory 
Dynamic light scattering (DLS) uses visible light to indirectly determine the 
hydrodynamic size of proteins, implementing autocorrelation functions to reach 
precision well beyond the diffraction limit of light. A polarised laser is beamed through 
a sample solution, and the backscatter is measured at 173°. Temporal intensity 
fluctuations are recorded, and analysed. The rate of decay of autocorrelation is 
proportional to the translational diffusion coefficient (Dt) of a particle, which in turn is 
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proportional to its size. A limitation of DLS is that it cannot distinguish shape, and 
instead reports the hydrodynamic diameter (Dhyd) of particles, which corresponds to 
the diameter of a sphere with Dt equal to that of the particle. An indicator of sample 
quality is the dispersity value (Đ): a perfectly monodisperse sample has a Đ value of 
0, and broadly dispersed samples are closer to 1. The Malvern Instruments 
whitepaper15 states that samples with Đ ≥ 0.7 are unsuitable for DLS measurements. 
Furthermore, the elastic scattering intensity of light is proportional to the radius to the 
sixth power, therefore the intensity of larger particles is greatly emphasised over that 
of small particles. To counter this, Mie’s theory can be used to convert the intensity 
values into a number distribution of scattering particles.16 
Zeta potentiometry works on principles similar to DLS, and may be performed 
with the same instrumentation. The technique determines the potential difference 
between the double layer at the surface of a particle and the surrounding medium by 
measuring electrophoretic mobility. As with DLS, the temporal fluctuations in the 
intensity of scattered light (measured at 13° for zeta potentiometry) is measured, 
however, in zeta potentiometry an electric field is applied across the cuvette. The zeta 
potential can be calculated from Henry’s equation (), where UE is the electrophoretic 
mobility, ε is the dielectric constant of the surrounding medium, ζ is the zeta potential, 
F(κα) is the Henry function that is set to 1.5 using the Smoluchowski approximation, 









DLS and zeta potentiometry were performed using a ZetaSizer Nano ZSP 
(Malvern Instruments, UK), and the data analysed using the ZetaSizer software 
(Malvern Instruments). A 1 mg·mL-1 sample was analysed in either a 1 cm semimicro 
polystyrene cuvette (Thermo Fisher), or a 1 cm DTS 1070 plastic cuvette (Malvern 
Instruments) for DLS and zeta potentiometry, respectively. Samples were dissolved 
in HEPES buffer (20 mM, pH 7), and filtered through a 0.22 μm filter prior to analysis. 
Results are presented as number distributions for DLS. The Smoluchowski 
approximation was used for zeta potentiometry. 
2.2.2.6 Synchrotron radiation circular dichroism 
Theory 
Circular dichroism (CD) exploits the differential absorption of circularly polarised 
UV-light by different protein folds to extract secondary structure information. For 
example, α-helices absorb right-polarised light more than left-polarised light in the 
208 and 222 nm regions, giving characteristic negative peaks in spectra.18 The 
spectral fingerprints of β-sheets are more complex, depending on various structural 
parameters: length, extent, direction, degree of twist, distortion, and orientation of 
neighbouring β-strands.19 While changes to a sample’s spectrum may indicate 
changes to the structure, algorithms have been developed using databases with both 
crystal structures and CD spectra to predict the structural composition of proteins 
with high accuracy.19 The secondary-structure composition of a protein is determined 
by fitting the experimental CD spectrum to the basis spectrum of each of the eight 




Synchrotron-radiation circular dichroism was performed on the B23 beamline at 
the Diamond Light Source, Oxford. Samples were desalted into 20 mM Tris base, 
adjusted to pH 7 with acetic acid, and supplemented to 100 μM ZnSO4. Spectra were 
collected from 185 to 260 nm, using a cuvette with a pathlength of 200 μm. The beam 
slit width was 1 mm, the current was 300 mAmps, and the integration time was 2 
seconds. For thermal studies, data were collected from 20 to 90 to 20°C at 5°C 
intervals with 1 minute incubation time. Data deconvolution was performed using the 
BeStSel web service.19  
2.2.2.7 Small angle X-ray scattering 
Theory 
Small angle X-ray scattering (SAXS) is used to determine the three-dimensional 
structure of samples by beaming X-rays through and measuring the scattering pattern 
produced by the photons interacting with electron clouds surrounding particles. The 
intensity of scattered light is measured across a 2D detector. For non-crystalline 
samples the scattering intensity is isotropic, therefore the detector image can be 
radially averaged. The scattering pattern contains a wealth of information on the 
particles in solution; chiefly, three-dimensional structural properties can be 
determined, but the flexibility of the sample and intermolecular interactions can be 
elucidated given sufficiently high sample quality. A limitation of SAXS is that 
background subtractions have a large influence on the resulting sample quality. The 
scattering intensity is a function of the scattering vector, q (), in reciprocal space units 
of Å-1, but may be converted into a real space radial probability distribution, p(r), using 
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a Fourier transformation. The p(r) distribution can then be used in ab initio algorithms 
to produce bead-models, which are collections of spherical beads assembled in 
space such that they would produce a scattering pattern equivalent to that measured. 





Equation 2-5 The scattering vector q, where θ is the incidence angle of the beam, and λ is 
the wavelength of the beam. 
The radius of gyration, Rg, of a sample can be approximated by linear regression 
of the natural logarithm of the scattering intensity, I, vs q2 at low-q, known as the 
Guinier approximation, following Error! Reference source not found.:20 





The flexibility of a sample determined by SAXS is described using the Porod 
exponent, P, which may be determined by linear regression of the Porod–Debye 
region of a lnI(q) vs ln(q) plot, where the slope is the negative of the Porod exponent. 
A Porod exponent of 4 corresponds to an inflexible particle, whereas an exponent of 
2 corresponds to a highly flexible particle.21 A Kratky plot of q2I(q) vs q can be used 
to show flexibility: a well-folded protein will show an initial parabolic peak followed by 
a return to baseline, whereas a flexible protein will show the parabolic peak followed 




Small angle X-ray scattering was performed on the B21 beamline at the 
Diamond Light Source, Oxford. The B21 beamline produces 12.4 keV X-rays at a 
wavelength of 0.1 nm, with a flux of 1011 photons per second. The detector measures 
from 0.0038 to 0.42 Å-1 at a fixed camera length of 4.014 metres. Samples are 
automatically loaded into a 100 μm capillary tube for measurement by a bioSAXS 
robot.23 
Samples were concentrated with 10K MWCO spin concentrators and flow-
through retained for use as backgrounds. The samples were then spun through 1M 
MWCO spin concentrators to remove large contaminants. Samples were exposed for 
18 frames of 10 seconds each. Data analyses were performed with the ScÅtter 
software package (developed by Robert Rambo, Diamond Lightsource, UK), using 
ATSAS plugins.24 
2.2.2.8 Michaelis–Menten kinetics 
Theory 
Michaelis–Menten kinetics applies the law of mass action to the activity of 
enzymes to describe two intrinsic properties: the turnover rate per enzyme molecule, 
kCat, and the substrate affinity, Km. In this model, the reaction is presumed to follow 
the following steps: 
, 
Equation 2-7 
where E is the enzyme, S is the substrate, ES is the enzyme–substrate complex, 







enzyme–substrate complex, kf, the rate of substrate release, kr, and the substrate 






and corresponds to the substrate concentration at which the rate is equal to half 
the maximum rate, Vmax. 
The Michaelis–Menten variables are typically empirically determined by varying 
the concentration of the substrate in a reaction and measuring the initial rate of 
reaction. When the substrate concentration is sufficiently large that the population of 
free enzyme is negligible, the rate approaches the Vmax. This value is divided by the 
amount of enzyme present in the assay to give the rate per enzyme molecule. 
The Michaelis–Menten equation describing the rate, v, of a reaction relative to 







OpdA, cOpdA and [cOpdA][S] were diluted to a working concentration of 2 nM 
in 30 mM HEPES, 100 μM CoCl2, pH 8 buffer. 100× paraoxon stocks were prepared 
in isopropanol, with working concentrations 1000, 400, 200, 100, 50, 10, and 0 μM. 
Formation of 4-nitrophenolate was followed by measuring absorbance at 405 nm, 
using an empirically determined extinction coefficient of ε405 = 12013 M-1·cm-1. Assays 
were performed on a Synergy Neo 2 multimode plate reader (BioTek, UK) at room 
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temperature. Non-linear regression was performed with the SciPy Python library to 
determine the Michaelis–Menten parameters. 
[OpdA][E][S] and its corresponding OpdA control were run with Eleanor 
Campbell, Australian National University, under modified conditions: each was 
diluted to 5 nM in 20 mM Tris, 100 μM ZnCl2, 100 mM NaCl, and 1 mg·mL-1 bovine 
serum albumin, pH 8.5. 100× paraoxon stocks were prepared in ethanol, with working 
concentrations 300, 200, 100, 50, 30, 10, 6, and 1 μM. Formation of 4-nitrophenolate 
was followed by measuring absorbance at 405 nm, using an empirically determined 
extinction coefficient of ε405 = 17700 M-1·cm-1. Assays were performed on an Epoch 
microplate spectrophotomer (BioTek). Non-linear regression was performed with the 
SciPy Python library to determine the Michaelis–Menten parameters. 
2.2.2.9 Proteomics 
Theory 
Proteomics is typically used to identify proteins within a mixture. However, in 
this project, the techniques were exploited to identify the modified sites of cOpdA. 
To determine the presence of a protein in a mixture, the mixture is first separated into 
its components, generally using SDS–PAGE. Next, each of these components is 
subjected to digestion by a protease with a known cleavage site, typically trypsin. 
The small peptides produced are then analysed using mass spectrometry. The mass-
peaks are compared against a database of known protein sequences to identify the 
proteins present. 
In this project, cOpdA was subjected to proteomics analysis. While only cOpdA 
was present in the sample, the stochastic nature of the cationisation reaction 
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produces a distribution of differently-modified species. The OpdA sequence is 
known, and the mass corresponding to the addition of DMPA to acid residues is 
known. Therefore, the peptides within OpdA can be identified with or without the 
modifications from their mass signature. A limitation of this method is that acid 
residues that are not separated by a trypsin cleavage site cannot be resolved. 
Method 
Proteomic analysis was performed by Dr Kate Heesom from the University of 
Bristol. 
cOpdA was reduced with 10 mM tris(carboxyethyl)phosphine at 55°C for 1 hour, 
alkylated with 40 mM iodoacetamide at room temperature for 1 hour, then further 
reduced with 40 mM dithiothreitol at room temperature for 1 hour. This was then 
digested using 5% (w/w) sequencing-grade trypsin (Promega, US) overnight at 37°C. 
The resulting peptides were then desalted using a SepPak cartridge (Waters, US) 
according to the manufacturer’s instructions. The eluate was then evaporated to 
dryness and resuspended in 1% formic acid. This suspension was then injected onto 
an Acclaim Pepmap C18 Nano-Trap column (Thermo Fisher) and washed with a 
solution of 0.5% acetonitrile and 0.1% formic acid. To resolve the peptides, a 7-
segment gradient was run at 300 nl·min-1 using 0.1% formic acid (solvent A) and 80% 
acetonitrile in 0.1% formic acid (solvent B) according to .  
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Order Percentage solvent B / % Gradient time / minutes 
1. 1–6 1 
2. 6–15 58 
3. 15–32 58 
4. 32–40 5 
5. 40–90 1 
6. 90 6 
7. 90–1 1 
Table 2-1 Details of elution gradient for proteomics. 
Tandem mass spectrometry was performed on the resolved peptides using an 
LTQ–Orbitrap Velos mass spectrometer controlled using Xcalibur 2.1 software 
(Thermo Scientific). The peptides were ionised via nano-electrospray ionisation at 2.1 
kV and 250°C using a stainless-steel emitter with an internal diameter of 30 μm. The 
Orbitrap was set to analyse the survey scans at 60,000 resolution at m/z 400 in the 
mass range m/z 300– 2000 and the top twenty multiply charged ions in each duty 
cycle selected for MS/MS in the LTQ linear ion trap. Charge state filtering, where 
unassigned precursor ions were not selected for fragmentation, and dynamic 
exclusion (repeat count, 1; repeat duration, 30 seconds; exclusion list size, 500) were 
used. Fragmentation conditions in the LTQ were as follows: normalised collision 
energy, 40%; activation q, 0.25; activation time 10 ms; and minimum ion selection 
intensity, 500 counts. 
The data files were processed using Proteome Discoverer 1.4 software (Thermo 
Scientific) and searched against the UniProt E. coli database (4417 sequences) and 
the OpdA sequence using the SEQUEST algorithm. Peptide precursor mass tolerance 
101 
 
was set at 10ppm, and MS/MS tolerance was set at 0.8Da. Search criteria included 
carbamidomethylation of cysteine (+57.0214) as a fixed modification and oxidation of 
methionine (+15.9949) and BC_Diamine (glutamic acid, aspartic acid, lysine: 
+86.121Da) as variable modifications. Searches were performed with full tryptic 
digestion and a maximum of 2 missed cleavages were allowed. The reverse database 
search option was enabled and all peptide data was filtered to satisfy false discovery 
rate (FDR) of 1%. 
2.2.2.10 Agarose gel electrophoresis 
Theory 
Agarose gel electrophoresis separates DNA by size by applying an electric 
current across a cast agarose gel. Agarose gel is nanoporous, allowing small 
molecules to pass through. As DNA is highly negatively charged, it will migrate 
towards the anode of an electric current. Larger DNA molecules will experience more 
drag when migrating through the agarose gel, and will therefore migrate less distance 
than smaller molecules. The DNA may be stained using DNA-binding fluorophores 
such as the SYBR-Safe stains for visualisation. The DNA sample may then be cut out 
of the gel for further use. 
Method 
A 1% (W/V) agarose gel was prepared in 40 mM Tris, 20 mM acetic acid, 1mM 
ethylenediaminetetraacetic acid (EDTA) buffer, and SYBR-Safe green stain (Thermo 
Scientific) added. The gel was then cast in a gel tank, with lane combs inserted. Once 
cooled and set, 5 μL of the DNA sample was loaded into the lane, alongside 1 kb 
DNA ladder (New England Biolabs). A 200 V voltage was applied across the gel for 
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50 minutes. After running, the DNA of interest was cut out. The DNA was then 
amplified using a QIAprep Spin Miniprep Kit (QIAGEN), according to the 
manufacturer’s instructions. 
2.2.2.11 Fourier-transform infrared spectroscopy 
Theory 
FTIR is similar to UV-vis spectrophotometry, in that it measures the absorbance 
of light at different wavelengths, however FTIR uses broadband illumination and an 
interferometer instead a monochromatic lightsource. The resulting signal is then 
deconvolved using a Fourier transformation to yield the absorbance at each 
wavelength. The absorbance of infrared energy corresponds to the resonant 
frequencies of vibrational states of bonds, as opposed to the excitation of electrons 
into increased electronic states by UV–vis spectrophotometry. 
Method 
A small amount of sample was placed under the probe and run in transmission 
mode on a Spectrum One FTIR spectrometer (Perkin Elmer, UK) between 4000 and 
650 cm-1. 
2.2.2.12 Proton nuclear magnetic resonance spectroscopy 
Theory 
Proton nuclear magnetic resonance spectroscopy (1H NMR) can be used to 
determine the structure of compounds by probing the nuclear spin of protons. When 
a magnetic field is applied, two spin states may exist: +1/2 and -1/2, aligning with, 
and opposing the magnetic field, respectively. When excited with a radio wave pulse 
corresponding to the energy between the two states, protons resonate between the 
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two states at a frequency proportional to the strength of the magnetic field. However, 
the resonant frequency also depends on the environment the proton is in: electrons 
shield the proton from the radio waves, therefore if an electronegative group is bound 
to the hydrogen, it will deshield the proton, reducing the resonance intensity. The 
difference in the resonant frequency from the standard value is known as the 
chemical shift, and is measured in parts per millions (ppm). As hydrogen atoms in a 
molecule will have characteristic chemical shifts, it is possible to determine its 
structure. Furthermore, integrals of the peaks correspond to the stoichiometry of 
each proton environment, therefore 1H NMR is semi-quantitative. 
Method 
1H NMR was performed with assistance from Dr William Zhang. 
Approximately 50 mg of IGEPAL CO-890 and oxidised IGEPAL CO-890 were 
dissolved in 500 μL of deuterated chloroform, and placed in a Norell Standard Series 
5 mm NMR tubes (Sigma). The samples were then run on a Bruker 400 Nano (Bruker, 
UK) 400 MHz NMR spectrometer. Each spectrum was an average of 16 scans, with 
acquisition time of 4 seconds, and a dwell time of 10 seconds. 
2.2.2.13 Titration 
Theory 
As oxidised IGEPAL CO-890 is a weak acid, its concentration can be 
determined by stepwise addition of a strong base. With each addition of base, the 
pH is recorded and plotted against the volume of base added. The pH will gradually 
increase in a sigmoid-like fashion. The inflexion point is where the amount of base 
added is equal to the amount of acid. Given a known amount of oxidised IGEPAL 
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CO-890 was dissolved into the solution, the conversion efficiency can be calculated 
from the amount of base added at the inflexion point divided by the initial amount 
added. 
Method 
35 mg of oxidised IGEPAL CO-890 was dissolved in 5 mL of deionised water to 
give a 3.5 mM stock. 250 mg of NaOH was dissolved in 12.5 mL to give a 500 mM 
stock, which was diluted 200-fold to 2.5 mM for use. The initial pH of the surfactant 
solution was recorded. 100 μL of 2.5 mM NaOH was added, left to stir until 
equilibrated, and the pH recorded. This was repeated up to 10 mL of NaOH solution. 
The resulting plot of volume 2.5 mM NaOH added vs pH was inspected visually for 
the point of inflexion. This value was then used to calculate the concentration of acid 
corresponding to oxidised IGEPAL CO-890, and compared against the known 
amount added to give the conversion efficiency.  
2.2.2.14 Molecular dynamics 
The full model of OpdA was built upon a previously published structure 
(PDBID:2D2J)25 using UCSF Chimera26 to add the flexible tails of OpdA that were not 
determined by X-ray crystallography, and to include known mutations. This model 
was then minimised using GROMACS27 before further use.  
To cationise the model, a Python script adapted from Bianca Perez (Aarhus 
University, Denmark) utilising UCSF Chimera’s toolset to add DMPA sidechains to 
selected acid residues was used. Modified sidechains that were overlapping other 




To conjugate the cationised model, the Bristol University Docking Engine 
(BUDE) was used. A model of the oxidised IGEPAL CO-890 was manually 
constructed by Dr Richard Sessions (University of Bristol) using UCSF Chimera. 
The models were simulated in a box comprising either water or acetonitrile at 
298 K, 1 bar, for 100 ns using GROMACS on the University of Bristol supercomputer, 
Blue Crystal. Data analyses were performed using Python scripts (Appendices 6.3) 
for interatom distances and electrostatic interactions, and a TCL script for solvent-





2.3.1 Expression and purification of OpdA 
Dr Colin Jackson and his group at the Research School of Chemistry (Australian 
National University) kindly provided a pETMCS1 plasmid containing an OpdA gene 
with two stabilising mutations relative to the wild-type sequence: V56A and R161K. 
The pETMCS1 vector is based on the popular pET family of plasmids, and was 
constructed by Neylon et al.28 The plasmid contains an ampicillin resistance gene, 
ampr, encoding a β-lactamase, which can be used to ensure plasmid retention. 
Carbenicillin was used in place of ampicillin due to its enhanced stability. Expression 
of the gene in pETMCS1 is driven by the bacteriophage T7 promoter, and so must be 
transformed into T7 RNA polymerase expressing bacteria. The E. coli strain 
BL21(λDE3) (New England Biolabs) was used for expression, which is a lysogen of 
the λDE3 bacteriophage and deficient in proteases Lon and OmpT to reduce protein 
degradation. The T7 RNA polymerase is under the control of a lacUV5 promoter, and 
so expression of the polymerase, and therefore OpdA, should only occur when 
induced with lactose or an analogue. However, OpdA was found to give yields of up 
to 200 mg·L-1 post-purification without the need for induction. Conveniently, the 
bacterial growth did not need to be monitored and the cultures could be harvested 
after overnight incubation at 37°C, or after 2 days if incubated at 30°C. 
The purification of OpdA was similarly facile. To reach high purity, a combination 
of anion exchange and size exclusion chromatography was used. Anion exchange 
was performed using a diethylaminoethyl (DEAE) resin, which has a tertiary amine 
that acts as a weak anion exchanger. A manually-packed column with a void volume 
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of approximately 50 mL was used. OpdA interacts weakly with the resin and flowed 
through after most contaminants at approximately 100 mL without the need for salt 
or pH elution gradients (Figure 2-2A). The fractions collected were estimated to be 
95% pure based on SDS–PAGE analysis (Figure 2-2B), therefore a further polishing 
step was necessary. For this, size exclusion chromatography was performed using a 
Superdex 26/600 column. The UV trace showed a single major peak corresponding 
to OpdA (Figure 2-2C), and SDS–PAGE analysis showed a single band after this step 
(Figure 2-2D), indicating high-purity. Approximately 200 mg of high-purity OpdA was 
obtained per litre of culture. This 2-step purification protocol does not require elution 
steps that introduce imidazole or salts as a His-tag or cation exchange-based 
protocol would, and the so the OpdA may be used immediately. This simple, high-
yield expression and purification protocol makes OpdA a viable candidate for larger-
scale operations. 
 
Figure 2-2 UV traces of OpdA being purified. A) crude cell lysate run through a DEAE anion 
exchange column, B) The corresponding SDS–PAGE gel, C) DEAE-purified OpdA run through 















2.3.2  Chemical cationisation of OpdA 
Cationisation of proteins in the process of producing polymer-surfactant 
conjugates is required to impart a homogenous positive charge across the surface of 
the protein, which enables the electrostatic binding of an anionic polymer surfactant 
and subsequent formation of the surfactant corona surrounding the surface of the 
protein (Figure 2-3). 
 
Figure 2-3 Schematic representing the hypothetical conjugation mechanism of cOpdA. 
Firstly, a surfactant micelle comes into proximity with cOpdA. If the micelle successfully 
collides with cOpdA, the micelle will then destabilise, due to the cationic protein residues 
attracting the anionic surfactant headgroups. When the micelle destabilises, it will dynamically 
reorganise to bury the hydrophobic tails of each surfactant, forming the surfactant corona. 
By cationising the protein, the probability of the anionic surfactant-headgroup 
colliding with a cationic residue is largely increased. Furthermore, the destabilisation 
of the surfactant micelle will be enhanced by the increased cationic charge-density 
at the protein surface. Thereby, according to the Arrhenius equation the rate of 





where A is the frequency of collisions in the correct orientation, Ea is the 
activation energy, R is the ideal gas constant, and T is the temperature.  
The chemical cationisation protocol comprises the addition of a small reactive 
diamine to the carboxylic acid groups of the protein. To achieve this, EDC, a zero-
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length crosslinker, reacts with the carboxylic acid groups to form a more reactive O-
acylisourea intermediate. The diamine, DMPA, then attacks the electron-rich carbon 
centre, and displaces the O-acylisourea group via nucleophilic substitution, yielding 
the diamine-modified residue and an isourea byproduct (Figure 2-4). Each 
modification made yields a +2 net charge on the protein as the -1 charge of acid is 
reversed to a +1, making this a powerful supercharging technique. 
 
Figure 2-4 Cationisation reaction scheme. A lone pair on singly-bonded oxygen atom of 
aspartic acid (1) attacks the electron-deficient carbon of EDC (2), forming the O-acylisourea 
intermediate (3). A lone pair from a nitrogen atom of DMPA (4) then attacks the electron-
deficient carbon of the activated ester. This nucleophilic substitution yields the diamine-

































2.3.2.1 Optimising the cationisation reaction 
A number of considerations must be made in optimising the cationisation 
reaction. In the first stage, EDC reacts with carboxylic acids to form a reactive O-
acylisourea intermediate, which is then attacked by amines. However, the O-
acylisourea group rapidly hydrolyses to the original carboxylic acid and an unreactive 
N-acylisourea, with a half-life of approximately 2–3 seconds,29 leading to reduced 
efficiency. Furthermore, the amine groups present in lysine sidechains will react with 
the intermediate, thus forming undesirable crosslinked proteins. The molar ratios of 
these components must be tuned to mitigate these side reactions: a high excess of 
DMPA will limit protein crosslinking, while a slight excess of EDC will ensure sufficient 
amounts of reactive O-acylisourea groups. The EDC crosslinking reaction is reported 
to be most efficient at pH 4–6,30 however, the reaction consumes two protons per 
modification, increasing the pH as it progresses. Therefore, buffering the reaction 
must be considered. 
In optimising the cationisation reaction, two outcomes were measured: molar 
yield of soluble protein and modification efficiency. Molar yield is simply the molar 
quantity of modified protein produced relative to the starting quantity, and is 
important to ensure sufficient product is formed for further steps. Modification 
efficiency refers to the number of available carboxylic acid groups modified, which is 
estimated using MALDI–TOF MS to determine the increase in mass of the protein 
after cationisation (Figure 2-5), and then using the known molecular weight of the 
DMPA to calculate the number of molecules added. To optimise the cationisation 
reaction for modification efficiency and yield, adjustments were made to the reaction 
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conditions (protein concentration, reactant concentration, pH) until they converged 
on acceptable results. 
 
Figure 2-5 Representative MALDI–TOF MS spectra showing the difference in molecular mass 
between OpdA and cOpdA. 
Using concentrations of DMPA and EDC reported previously1 meant that these 
conditions required little tuning to reach satisfactory results. There were no significant 
correlations drawn from analyses of these components. This suggests that the 
components were in excess of their requirement. Systematic variation of the 
components may yield optimal values for their concentrations, but this is beyond the 
requirements of this project. 
The pH of the reaction, however, did have a significant effect on the efficiency 
and yield. Plotting modification efficiency against pH reveals a significant negative 
correlation (Spearman’s rank; rs=-0.75, P<0.0001) in the range pH 4.86–6.90 (Figure 
2-6), which is in line with previous reports.30 Reducing the pH further would likely lead 
to increased modification efficiencies, but would probably cause denaturation of the 
protein. Plotting pH against molar yields did not reveal any trends, however. Solvent 
exposure analysis performed using PDBePISA31 shows 27 carboxylic acid groups, or 
77% of the total number of carboxylic acids, with a relative surface area greater than 













0.1. Modification of non-solvent exposed residues may be indicative of denaturation. 
From these analyses, it was concluded that the best compromise between 
modification efficiency and yield would be to perform the reaction between pH 5.0–
5.4.  
After settling on these conditions, an average modification efficiency of 53±13% 
was achieved, corresponding to 19±4 modified residues, producing a net charge 
increase of +38±8. The net charge of native OpdA is +5, therefore the cationised 
constructs averaged a charge of +43, exceeding the +37 charge of the 
computationally designed supercharged green fluorescent protein produced via gene 
mutation.32  
 
Figure 2-6 The effect of pH on the modification efficiency of cationisation of OpdA. 
2.3.2.2 Structural analysis of cOpdA 
Further characterisation of the cationised OpdA construct, termed cOpdA, was 
performed in order to determine any effects the process may have had on structural 
properties and activity. The addition of the small molecule DMPA to the acidic 
residues on the OpdA surface should result in size increase of the order of several 






















angstroms. Conversely, protein denaturation resulting in aggregation from exposure 
of buried hydrophobic residues would increase the particle size by orders of 
magnitude. Directly probing proteins at the angstrom level requires the use of X-rays, 
or neutron beams, and structure may be determined via nuclear magnetic resonance, 
each of which are complex and time-consuming. DLS, however, uses visible-light to 
determine the size of molecules in solution using simple and readily-available 
instrumentation. DLS analysis of OpdA and cOpdA showed no significant differences 
with hydrodynamic diameters of 5.29±0.21 and 5.32±0.25 nm, and dispersity values, 
Đ, of 0.40±0.17 and 0.63±0.19 (n=5 for each), respectively (Figure 2-7). This suggests 
that the OpdA did not unfold and aggregate after the cationisation process. 
 
Figure 2-7 A) Number distribution of DLS analyses of OpdA and cOpdA with B) corresponding 
dispersity values. Samples were run at room temperature at a concentration of 10 μM, with 5 
repeats for each. 
By modifying acid residues of OpdA with DMPA, a large increase in the surface 
charge is expected. Zeta potentiometry was used to determine the zeta potential of 
OpdA and cOpdA, which is indicative of surface charge. cOpdA was found to have a 
significantly greater charge than OpdA (27.3±4.00 vs -0.05±0.95, n=4 and 5, 
respectively; p=0.0015), signifying successful cationisation of the protein. Isoelectric 
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focusing (IEF) is a technique commonly used to separate proteins by their isoelectric 
point, pI, however it is only suitable for proteins with pIs between pH 3–10. IEF was 
attempted with cOpdA, but it did not migrate through the gel. A predicted pI of cOpdA 
was determined by changing 19 acid residues to lysines in the sequence, and using 
the Isoelectric Point Calculator web service.33 The predicted pI was 11.6±0.2 and 
hence outside of the effective range for IEF. 
 Protein folding is dependent on the interactions between the sidechains of 
residues. It was postulated that reversing the charges of a number of acid residues 
would perturb these interactions and have deleterious effects on folding. In particular, 
intramolecular salt bridges, which are electrostatic attraction forces between 
oppositely charged molecules, would be reversed, instead introducing a repulsive 
electrostatic force. Therefore, it was prudent to study the effect that the cationisation 
process had on protein folding. For this purpose, CD was employed. Native OpdA 
has an (α/β)8 triose-isomerase (TIM) barrel-like structure, as determined by X-ray 
crystallography.25 This structure was uploaded to the BeStSel web service19 to predict 
the abundance of the secondary structure components. Synchrotron radiation CD 
(SRCD) was performed using Beamline B23 on OpdA and cOpdA at the Diamond 
Light Source, which has far greater photon flux than benchtop instruments, improving 
the signal:noise ratio.34 Overlaying the spectra normalised to the difference in 
absorbance between left and right-polarised light (Δε) shows minimal differences 
(Figure 2-8A). Deconvoluting the data using the BeStSel web service19 provides 
information on the percentage abundance of each structural component; for 
simplicity, the subcategories of α-helices and β-sheets were summed and compared 
against the model data (Figure 2-8B). Relative to the predicted structure composition, 
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OpdA was similar. It had 11.5% less α-helix, 6.7% more β-sheet, 3.3% more turn, 
and 1.6% more unfolded structure. Significantly, cOpdA maintained much of its 
folded structure: 1% less α-helix, 8.3% less β-sheet, 1% more turn, and 8.2% more 
unfolded structure than the native OpdA sample. 
 
Figure 2-8 A) SRCD spectra of OpdA and cOpdA, and B) the corresponding deconvoluted 
data, compared to a predicted structure from an X-ray model. Samples were run at 25°C, and 
deconvoluted using the BeStSel web service.19 
Previous studies of supercharged proteins report improved thermal 
resilience.3,35 Therefore, temperature dependent SRCD experiments were performed 
on the constructs between 20 and 90°C. OpdA began unfolding at approximately 
60°C, was fully denatured at 90°C, and did not refold. cOpdA, however, did not 
appear to unfold at any point (Figure 2-9A,B). Deconvoluting the thermal data using 
the BeStSel web service revealed an α-helix to β-sheet transition indicative of 
aggregation,36 while the structural composition of cOpdA did not change significantly 
(Figure 2-9C,D). This resilience to thermal denaturation and aggregation is likely due 
to the formation of a molten-globule state, whereby the native-like secondary 
structure is maintained, but intraprotein charge repulsion and disruption of salt 
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bridges increases the flexibility and thus entropy in the system, as seen by Brogan et 
al. for cationised myoglobin under solvent-free conditions.3 
 
Figure 2-9 SRCD temperature ramp spectra of A) OpdA and B) cOpdA. The spectra are 
coloured from red (20°C), through purple (90°C) to blue (cooling to 20°C) in 5°C steps, with 
90°C marked as green. C,D) Deconvoluted data from C) OpdA and D) cOpdA. Data 
deconvoluted using the BeStSel web service.19 
While CD analyses provide information of the secondary structure composition 
of proteins, it does not provide information pertaining to tertiary and quaternary 
structure. OpdA was shown to be dimeric by X-ray crystallography, although the 
dimer equilibrium constant was not determined.37 Analysing the crystal structure with 
the PDBePISA web service31 shows 36 residues at the dimer interface, of which 6 are 
acid residues. Of the 6 acid residues, 2 form salt bridges and hydrogen bonds, and 1 
forms only hydrogen bonds; the remaining 3 acid residues have positive solvation 
energy effects, therefore negatively affecting dimer formation (Table 2-2). It is 
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therefore important to determine if cationisation affects the tertiary and/or quaternary 
structure. SAXS may be used to determine the low-resolution of structures and 
assess the oligomeric state of proteins in solution. 
Residue Position Bonding ASA / Å2 BSA / Å2 ΔiG / kcal·mol-1 
SER 38 H-bond 36.6 35.1 0.2 
ALA 39  44.7 34.6 -0.0 
GLY 40  52.2 25.0 0.3 
PHE 41  47.1 46.9 0.8 
ARG 43  188.6 98.5 -0.1 
ALA 44  86.3 84.5 0.6 
TRP 45  138.2 119.8 1.7 
PRO 46  33.5 9.7 0.2 
GLU 47 H-bond, salt bridge 113.1 30.4 -0.3 
PHE 48  66.7 20.0 0.3 
PHE 80  62.6 53.0 0.9 
ARG 84  18.1 2.3 -0.1 
TRP 107  38.7 5.4 0.1 
PHE 108  82.2 12.7 0.2 
ASP 109 H-bond, salt bridge 78.7 64.0 -0.6 
PRO 111  50.4 32.4 0.5 
LEU 112 H-bond 101.1 77.4 1.2 
SER 113 H-bond 83.5 83.5 0.1 
MET 114  24.4 24.4 0.5 
ARG 115 H-bond, salt bridge 114.8 15.3 -0.3 
MET 116  133.2 62.9 1.2 
ARG 117 H-bond 90.2 86.6 -2.7 
GLU 121 H-bond 82.9 45.4 -0.4 
LEU 122  0.7 0.7 0.0 
GLN 124  116.1 8.4 0.1 
PHE 125  43.4 43.1 0.7 
ARG 128 H-bond, salt bridge 99.8 71.7 -1.2 
GLU 129  4.1 4.0 0.2 
HIS 132  111.2 3.8 -0.1 
GLU 135  72.5 52.9 0.6 
ASP 136  117.5 3.6 0.0 
Table 2-2 Results from PDB ePISA analysis of OpdA, with acid residues emphasised. ASA, 
accessible surface area; BSA, buried surface area upon dimer formation; ΔiG, change in free 
energy of solvation upon dimer formation. 
The B21 SAXS beamline at the Diamond Light Source was used as it has been 
optimised for biological samples, and using the same capillary tube for each sample 
allows accurate background subtractions and therefore large signal:noise ratios and 
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reliable data at high Q ranges. OpdA and cOpdA were each run, and the data 
processed and analysed using Scåtter software (Figure 2-10 and Figure 2-11). There 
was a small increase in the radius of gyration, Rg (30.5 vs 29.4 Å), and volume (104000 
vs 97500 Å), and decrease in the Porod exponent (3.45 vs 3.71) for cOpdA and OpdA, 
respectively, indicating increased size and flexibility. The p(r) distributions of each 
were similar, and were more similar to the predicted p(r) distribution of the dimer than 
the monomer (Figure 2-12A). Ab initio bead modelling was performed using Scåtter 
software with ATSAS plugins.24 Briefly, a number of densely packed beads are 
simulated using Monte Carlo searching to construct a model that would give a 
scattering pattern to fit the experimental data.38 Crucially, the bead model of OpdA 
overlapped well with the X-ray crystal structure, as did the bead model produced 
from cOpdA (Figure 2-12B). These data confirm that cOpdA maintains the dimer state 




Figure 2-10 A) SAXS scattering curves for OpdA (black) and cOpdA (grey) at room 
temperature, and corresponding Kratky plots of B) OpdA and C) cOpdA; the accentuated 




Figure 2-11 Guinier plots, fits, and corresponding residuals of A) OpdA and B) cOpdA, from 




Figure 2-12 A) Radial probability distributions for OpdA, and cOpdA, compared with 
monomer and dimer OpdA models. C) Bead models of OpdA (blue) and cOpdA (red) 
overlaying an OpdA crystal structure (white; PDBID:2D2J25). 
2.3.2.3 The impact of cationisation on activity 
In combination, the DLS, CD, and SAXS data confirmed that the structural 
features of OpdA are maintained post-cationisation. Accordingly, the effect of 
cationisation on the activity of OpdA was assessed. OpdA has previously been 
reported to hydrolyse the OP substrate paraoxon-ethyl near the diffusion-limited 
rate.39 This extreme activity is one of the reasons OpdA was selected, as even 1% of 
the activity maintained would be beneficial in detoxifying OPs. The hydrolytic activity 
of OpdA and cOpdA against paraoxon-ethyl was assessed. Each had to be diluted 
to nanomolar concentrations in order to capture the initial rate. Michaelis–Menten 
parameters of cOpdA were not significantly different to those of OpdA (Figure 2-13A–
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C). This is encouraging, as previous work by Brogan et al. with lipases from 
Rhizomucor miehei and Thermomyces lanuginosus reported a 98% and 85% 
reduction in substrate-turnover rate post-cationisation. The specific activity, kcat/Km, 
for both the native and cationized enzyme was approximately 50-fold slower than the 
literature value. This discrepancy may be due to the reaction conditions, i.e, Jackson 
et al. supplemented their reaction with 150 mM NaCl and 1 mg·mL-1 bovine serum 
albumin (BSA). BSA supplementation was not used in this study due to concerns 
about the possibility of different interactions of OpdA and cOpdA with BSA, which 
would be difficult to account for. 
 
Figure 2-13 Comparisons of the Michaelis–Menten parameters of OpdA and cOpdA for the 
substrate paraoxon at room temperature. A) The turnover rate, kcat, B) the Michaelis–Menten 
constant, Km, and C) the specificity constant, kcat÷Km. ns: no significance. The large errors in 
Km arise from a narrow substrate-concentration range. 
By optimising the cationisation reaction, primarily through modifying the pH of 
the reaction, approximately 19 carboxylate groups can be reliably cationised, leading 
to a +38 increase in net charge. The chemical cationisation of OpdA has been shown 
through CD to have only minor effects on the secondary structure, and no apparent 
changes to the tertiary or quaternary structures were evident using DLS and SAXS. 
In fact, the cationisation improved its thermal stability, likely through aggregation 
resistance from electrostatic repulsion. Significantly, the cationisation did not 
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significantly impact its hydrolytic activity, which is unprecedented. Next, an 
alternative method of cationising OpdA was explored. 
2.3.3 Genetic cationisation of OpdA 
Encouraged by the successful chemical cationisation of OpdA without 
deleterious effects, and by the previous reports of supercharged proteins,35 an 
attempt at producing a supercharged-OpdA mutant was made. However, instead of 
using a computational protocol such as AvNAPSA35 or ROSETTA40, which select 
residues to mutate based on solvent-accessibility and preserving surface 
interactions, respectively, the results of cationisation were used to inform the sites to 
mutate. As well as the advantage of being able to express a mutant that requires less 
processing to produce membrane-binding nanoconstructs, the mutant may also offer 
insight into the properties of the chemically-cationised counterpart. 
2.3.3.1 Selection of residues for mutation 
To determine the sites modified by cationisation, tryptic digestion LC–MS was 
performed by Kate Heesom of the University of Bristol’s proteomics facility. Across 2 
independent samples, 14 sites were found to be cationised with high confidence 
(<1% FDR), and a further 13 sites were reported with low confidence (>5% FDR), with 
no samples solely in the medium confidence band (1–5% FDR). The results are 
presented in Table 2-3. Significantly, the carboxylated lysine in the active site at 
position 145 was not modified, nor the aspartic acid at position 277 in the active site.  
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High confidence Low confidence 
Asp Glu Asp Glu 
76 120 81 24 
85 121 208 47 
97 135 209 129 
109 239 265 186 
136 320 270 193 
184  299 195 
211   314 
212    
229    
 
Table 2-3 Sites modified by cationisation of OpdA. High confidence corresponds to a false 
discovery rate of <1%, low confidence is >5%. 
In preparing a mutant, only residues confirmed to be modified with high 
confidence were considered. Modifications at sites 85 and 229 were rejected as they 
were close to active site residues. The modification at position 320 was also rejected. 
Therefore, 11 acid residues were mutated to lysines: D76, D97, D109, E120, E121, 
E135, D136, D184, D211, D212, and E239 (Figure 2-14), bringing the net charge to 
+27 (including a hexahistidine tag). This construct was termed supercharged OpdA 
(scOpdA). For comparison, the OpdA model was run through the AvNAPSA-positive 
protocol35 on the ROSIE web service,41 which suggests the most solvent-exposed 
acid residues to mutate. This selected the following 12 residues to be mutated to 
lysines to reach a charge of +20 (excluding a hexahistidine tag): E24, E57, E120, 
D136, Q182, D211, E239, Q254, N288, D291, E314, E320. The acids at E120, D136, 
D211 and E239 were selected by both methods, although the chemical cationisation 
also suggested mutations with lower relative solvent exposures, as calculated using 
Chimera software (Table 2-4). Furthermore, a hexahistidine tag was added to the N-
terminal to simplify the purification, as the anion exchange used with native OpdA 




Figure 2-14 Acidic residues modified by the cationisation reaction. The sidechains of the 
modified residues are yellow, while unmodified acidic sidechains are shown in grey and the 





Amino acid Position Relative solvent exposure 
D  11 0.735032760763 
E  24 0.71355458576 
E  32 0 
E  47 0.706865402345 
E  57 0.690247494888 
D  76 0.19065937043 
D  81 0.232860278182 
D  85 0.564942009307 
E  91 0.682437167689 
D  97 0.684301307548 
D  109 0.503387950417 
E  120 0.760023054863 
E  121 0.462611018304 
E  129 0 
E  135 0.574962852456 
D  136 0.936193529678 
E  157 0.547810838366 
D  184 0.26365363106 
E  186 0.691377769103 
E  193 0.592331619212 
E  195 0.409678535595 
D  208 0 
D  209 0.602734116298 
D  211 0.727890928379 
D  212 0.561259687466 
D  229 0.183052610469 
E  239 0.727285686334 
D  265 0.78801119464 
D  270 0.72062330087 
D  277 0.285152617221 
D  291 0.72028920847 
D  294 0.585514096259 
D  299 0.640436758892 
E  314 0.919362063806 
E  320 0.833044803385 
Table 2-4 Relative solvent exposure of acid residues in OpdA. Chemically-cationised residues 
shown in bold, ROSIE-suggested mutations are highlighted blue. 
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2.3.3.2 Assessment of scOpdA feasibility 
To assess the feasibility of scOpdA, a search of the UniprotKB/Swiss-Prot 
database for similar proteins was made using a purpose-written Python script 
(Appendix 6.3). Of the more than 550000 protein sequences in the database, 25775 
had crystal structures associated with them, suggesting they could be expressed and 
purified, and had stable structures. From this 25775, 24 fell within 10% of the mass 
and charge of scOpdA, and only a single protein was native to E. coli. Interestingly 
the data revealed E. coli to have the narrowest mass:charge distribution when 
compared to yeast and human proteins (Figure 2-15), likely due to the lack of 
chromatin complexes. It is known that highly positively-charged proteins are often 
difficult to express in soluble form,42 however Lawrence et al. were able to express 
several supercharged protein mutants.35 The Protein–Sol web service43 estimates the 
solubility of proteins given a sequence, and assigned a score of 0.449 for the scOpdA 
sequence, which is close to the average of 0.45. 
 
Figure 2-15 Mass:charge distribution of proteins in the UniProtKB/SwissProt database that 
had associated structures in the Research Collaboratory for Structural Bioinformatics Protein 
Data Bank.44 



















2.3.3.3 scOpdA expression and purification 
The final amino acid sequence of scOpdA was codon-optimised for E. coli 
expression using the Gene Optimizer (Thermo Fisher) web service. The DNA for the 
gene and corresponding primers were ordered from Eurofins, and inserted into the 
pETMCS1 vector using Gibson assembly.45 
Initial attempts at scOpdA expression were performed using the protocol for 
OpdA, however, little cell growth was observed. This may have been due to the leaky 
expression of the gene causing cell death, leading to low cell yields. To counter this, 
tighter control of expression was required. There are E. coli strains that can be 
purchased containing a pLysS plasmid encoding a T7 lysozyme. The T7 lysozyme is 
an inhibitor of the T7 RNA polymerase, and is expressed through the pLysS plasmid 
at high enough levels to repress background polymerase activity, but low enough to 
have an insignificant effect on induced polymerase activity.46 The pLysS plasmid also 
encodes genes for chloramphenicol resistance, and so its retention is ensured when 
bacteria are grown in chloramphenicol-supplemented media. Equally, expression of 
the T7 RNA polymerase can be inhibited through catabolite repression. In the 
presence of glucose, the preferential carbon source of E. coli, expression of lac-
promoter controlled genes is repressed through the dephosphorylation of EIIAglc, 
causing deactivation of adenyl-cyclase and leading to low cyclic adenosine 
monophosphate (cAMP) concentrations and deactivation of catabolite activator 
protein (CAP), which must bind cAMP in order to distort DNA for the T7 RNA 
polymerase to bind the lac promoter.47 Auto-induction media contain a balance of 
glucose and lactose, such that E. coli grows to high-density under catabolite 
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repression, but gene expression is subsequently induced when glucose is depleted 
and lactose is metabolised.48 
scOpdA was grown in a simplified version of Studier’s ZYM-5052 auto-induction 
media,48 as described on OpenWetware.org,49 with the addition of 500 μM calcium 
chloride and magnesium sulfate. Growing in this culture medium for 36 hours at 25°C, 
200 RPM gave cell yields of approximately 20 g·L-1, far greater than initial attempts in 
terrific broth with no T7 polymerase repression. The lower temperature was used to 
reduce the risk of inclusion body formation.50 The resulting cell pellet was lysed using 
pulsed sonication in the presence of DNAase, as DNA will bind tightly to highly-
charged proteins, and centrifuged at 30000×g. The supernatant was analysed for 
activity against 1 mM paraoxon-ethyl, and was found to have none. Therefore, it was 
likely that scOpdA had formed inclusion bodies. To extract the inclusion bodies from 
other cellular debris, two cycles of washes with 8 M urea, 1.5 M NaCl and 2% Triton 
X-100 were performed, each time centrifuging at 10000×g and collecting the pellet. 
SDS–PAGE analysis revealed that scOpdA was indeed in the inclusion body fraction 
(Figure 2-16A). On-column refolding of scOpdA was then performed, using the highly-
chaotropic guanidine HCl as the denaturant. Tracking the elution UV profile revealed 
no protein in the eluent. SDS–PAGE analysis was therefore performed on the column 
flow-through, and revealed that a large portion of scOpdA did not bind to the column 
(Figure 2-16B). This may be due to incomplete unfolding with the hexahistidine tag 
unable to bind to the column, low-affinity binding of scOpdA to the column that was 








Figure 2-16 A) SDS–PAGE analysis of inclusion body extraction of scOpdA-expressing cells. 
1., PAGE-ruler plus protein ladder; 2., lysate; 3., 8 M urea wash; 4., 1.5 M NaCl wash; 5., 2% 
Triton X-100 wash; 6–8, second wash cycle; 9., resulting inclusion bodies. B) SDS–PAGE 
analysis of the on-column refolding experiment. 1., PAGE-ruler plus protein ladder; 2., lysate; 
3., wash with 8 M urea, 1.5 M NaCl, 5% Triton X-100; 4–5., repeat washes; 6., blank; 7., 
column flow-through. The mass of scOpdA is 37.8 kDa. 
2.3.3.4 scOpdA activity screening 
To determine if scOpdA was active prior to inclusion body formation, E. coli cells 
transformed with the scOpdA-encoding plasmid were grown on LB–agar plates 
supplemented with 100 μM coumaphos, an OP substrate that hydrolyses to the 
fluorescent molecule chlorferon. In this way, if scOpdA was active at any point during 
expression, some fluorescence would be observed. Native OpdA-expressing cells 
were used as a positive control, and an empty plate used as a negative control. The 
plates were inspected after 48 hours. The scOpdA plate grew a large number of 
colonies, but was not visually more fluorescent than the negative control, which in 




Figure 2-17 LB–agar plates supplemented with 100 μM coumaphos. A) Negative control, B) 
OpdA and C) scOpdA. 
2.3.3.5 Conclusions 
Despite encouraging results from other supercharging experiments, scOpdA 
was not able to be extracted from cells in a soluble form, and did not demonstrate 
significant activity at any point. Further work should look towards optimising 
expression conditions to avoid inclusion-body formation, perhaps using C43(DE3) 
cells, which are known for expressing toxic proteins.51 Moreover, repeats of the 
proteomics analysis would provide better statistics on which residues are frequently 
modified. Extensive work may be required to develop an active, soluble supercharged 
OpdA construct, which is beyond the scope of this project. Regardless, these findings 
highlight the chemical cationisation success: by modifying proteins post-folding, 
stable supercharged constructs can be simply produced that do not express stably. 
2.3.4 Polymer-surfactant conjugation of OpdA 
The second stage in producing artificial membrane-binding nanoconstructs is 
conjugation. Conjugation in this context comprises the electrostatic grafting of 
polymer-surfactants with negatively-charged headgroups to the positively-charged 
sites on the cationised protein (Figure 2-1A). 
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Surfactants are compounds comprising hydrophobic chain(s) with hydrophilic 
headgroups. The structure of the surfactant impacts on the properties it imparts. The 
hydrophile–lipophile balance (HLB) is a measure used to indicate solubility and hence 
mesophase behaviour; values above 7 suggest a surfactant is more soluble in water 
than organic solvents, surfactants with HLB 12–16 are generally solubilising when 
working with proteins, whereas values greater than 20 suggest the surfactant to be 
denaturing.52 HLB values were originally calculated empirically, however Davies 
presented an equation for calculating HLB values using empirically-determined group 
numbers, i.e. contributions to HLB by chemical groups.53 Guo et al. built upon the 
Davies equation to better fit surfactants containing polyethylene oxide groups by 
incorporating effective chain lengths.54 
2.3.4.1 Surfactant preparation 
Oxidised IGEPAL CO-890 was used to conjugate cOpdA, due to its previous 
success in forming artificial membrane-binding proteins.1 It consists of a hydrophobic 
nonylphenyl tail, an amphipathic polyethylene glycol repeat region, and a terminal 
carboxylate group. The carboxylate form of IGEPAL CO-890 is not commercially 
available, and so a simple oxidation reaction was carried out on the commercially 
available alcohol form, followed by characterisation to confirm presence of the acid 




Figure 2-18 TEMPO-based oxidation of IGEPAL CO-890, adapted from 
https://www.sigmaaldrich.com/technical-documents/articles/chemistry/tempo-catalyzed-
oxidations.html 
2.3.4.2 Surfactant characterisation 
Following oxidation, characterisation of the surfactant was necessary to ensure 
presence of the acid headgroup. FT–IR was used to confirm the oxidation of the 
alcohol to the carboxylate. FT–IR probes the chemical structure of compounds by 
measuring the absorbance of IR light, which varies according to the vibrational 






















cm-1 corresponding to the carboxylic acid carbonyl stretch was present in the 
oxidised sample and not the precursor (Figure 2-19). Another prominent peak is seen 
at 2887 cm-1, which corresponds to the O–H stretch present in both samples. 
 
Figure 2-19 FT–IR spectra of IGEPAL CO-890 in its alcohol form (ROH) and its oxidised form 
(ROO-). A) Full range spectra and B) spectra emphasising carboxylic acid carbonyl stretch at 
1750 cm-1. 
 MALDI–TOF MS was also performed on the oxidised surfactant. There was a 
clear increase in mass from the precursor to the oxidised form (Figure 2-20). The 
theoretical change in mass would be +14 Da, corresponding to the addition of an 
oxygen atom, with the loss of two hydrogen atoms, and a periodicity of 44 Da from 
the PEG repeat units. While there was a clear periodicity of 44 Da, the mass increase 
from oxidation varied across the spectra, possibly indicating incomplete conversion, 




Figure 2-20 MADLI-TOF MS spectra of IGEPAL CO-890 (black) and the corresponding 
oxidised form (magenta). A) Full range and B) reduced range demonstrating peak shift 
ambiguity. 
To further assess purity and conversion efficiency, H1-NMR was used (300 
MHz, CDCl3). H1-NMR may be used to determine the molecular structure of a 
compound in solution, by measuring the chemical shifts of each hydrogen present. 
Spectra for IGEPAL CO-890 and the product of oxidation were assessed (Figure 
2-21). Peaks corresponding to the nonyl tail, the phenyl ring, the PEG repeat units, 
and the terminal PEG group were identified, with the deuterated chloroform used as 
a reference with δ 7.260 ppm. The chemical shifts corresponding to the terminal PEG 
group change accordingly: the chemical shift for the γ-carbon hydrogens increases, 
shifting to δ 4.14 ppm. There appears to be some non-oxidised surfactant in the 
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product, as the β- and γ-carbon hydrogen peaks from the reactant remain, albeit 
reduced in intensity. Due to the complexity and flexibility of the surfactant structure, 





Figure 2-21 NMR spectra of A) IGEPAL CO-890 and B) the product of its oxidation to a 
carboxylic acid, with stacked raw (blue) and oxidised (black) spectra highlighting the β- and 




Finally, an acid–base titration was carried out to quantify the conversion 
efficiency of the oxidised surfactant. A 3.5 mM solution of surfactant was titrated 
against 2.5 mM NaOH. The neutralisation point was determined by double 
differentiation, then used to calculate the concentration of the acid, i.e. oxidised 
IGEPAL CO-890, in the sample. This way, the conversion efficiency was found to be 
approximately 94%.  
 
Figure 2-22 Titration curve of oxidised IGEPAL CO-890 against NaOH. The dotted line 
represents the point of inflexion, i.e. the neutralisation point, used to calculate the conversion 
efficiency. 
2.3.4.3 cOpdA conjugation 
With the oxidised surfactant sufficiently characterised, conjugation of cOpdA 
was carried out. Briefly, the surfactant was dissolved into HEPES buffer, pH adjusted 
to 8, and added equimolar to the number of cationic sites of cOpdA. The surfactant 
was added at a concentration above its critical micelle concentration (CMC) which 
was previously determined to be 0.79 mg·mL-1,55 and therefore likely interacts with 
cOpdA as micelles. Adding the surfactant at a concentration below its CMC leads to 
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the formation of ‘clusters’, which comprise partially-conjugated proteins that self-
assemble into discrete particles approximately 100 μm in diameter.8 
To confirm the engraftment of the surfactant to the cOpdA surface, the sample 
was dialysed against surfactant-free buffer to remove unbound surfactant, and 
analysed using UV–visible spectrophotometry. The phenyl moiety of the surfactant 
absorbs 280 nm light with an extinction coefficient of 1324 M-1·cm-1, and so the 280 
nm absorbance had to be decoupled from the absorbance corresponding to aromatic 
residues of the protein. A BCA assay was used to determine the protein 
concentration, and its known 280 nm extinction coefficient, 29160 M-1·cm-1, was used 
to calculate its absorbance, and then this was subtracted from the total absorbance 
(Figure 2-23). The conjugation efficiency was thus determined to be 93%, or 
approximately 50 surfactant chains per monomer. 
 
Figure 2-23 Contributions of protein and surfactant to the absorbance at 280 nm, used to 
calculate conjugation efficiency. 
The equilibrium between bound and unbound surfactant would depend on the 
volume, therefore dialysis may cause a shift to the unbound surfactant state. Using 
an excess of surfactant may have brought a shift toward the bound surfactant state, 




















as unconjugated sites would more rapidly interact with free surfactant. Furthermore, 
surfactant binding would be cooperative due to burying of the hydrophobic sites, and 
therefore excess surfactant may lead to conjugation efficiencies of greater than 
100%. A 1:1 stoichiometry of surfactant to cationic sites minimises free surfactant in 
solution, and so was used throughout. 
2.3.4.4 Structural analysis of [cOpdA][S] 
As with cationisation, conjugation should cause an increase in size. The 
magnitude of the size increase is expected to be larger due to the longer chain lengths 
of the surfactant over the DMPA molecules, however the hydrophobic effect burying 
the nonylphenyl moiety will cause the surfactant to wrap around the surface of the 
protein, forming a surfactant corona. DLS was used to evaluate the difference in size 
between cOpdA and [cOpdA][S] (Figure 2-24). A 2.9 nm increase in diameter was 
observed (8.2 vs 5.3 nm), corresponding to the addition of the surfactant corona.  
 
Figure 2-24 Number distribution of DLS analyses of cOpdA and [cOpdA][S] with B) 
corresponding Đ values. Each sample was run at room temperature, at a concentration of 10 
μM, with 5 repeats for each. 
The electrostatic grafting of the negatively-charged surfactant to the cationic 
groups of cOpdA should lead to charge neutralisation. Therefore, zeta potentiometry 
was used to assess the effect of conjugation. [cOpdA][S] was less positively-charged 
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than cOpdA (12.5±1.8 vs 27.3±4.0 mV, n=5) and significantly, reported a single peak, 
suggesting [cOpdA][S] was a single species, and not a mixture of free surfactant and 
cOpdA. 
Oxidised IGEPAL CO-890 was calculated to have an HLB of 34.8 by the Guo 
method,54 which is similar to that of SDS (38.4), and suggests denaturing properties. 
To ensure that surfactant conjugation does not cause unfolding, circular dichroism 
was employed. The spectrum of [cOpdA][S] displayed significant overlap with the 
spectrum of cOpdA (Figure 2-25). Deconvolution yielded 4.4% more α-helix, 1.1% 
less β-sheet, 0.7% more turn, and 4.0% less disorder, relative to cOpdA (Figure 
2-25B), suggesting a marginal stabilising effect with less of an α-helix–β-sheet 
transition, possibly due to charge neutralisation. Moreover, the enhanced thermal 
stability of cOpdA was seemingly maintained in [cOpdA][S], although the quality of 
the data was reduced (Figure 2-25C,D). While Oxidised IGEPAL CO-890 has a similar 
HLB to SDS, the presence of the amphiphilic polyethylene glycol chain in IGEPAL 
may bury the nonylphenyl tail via hydrophobic interactions, whereas the dodecyl tail 




Figure 2-25 CD analysis [cOpdA][S], compared to cOpdA. A) CD spectra collected at 20°C, 
and B) corresponding deconvoluted data. C) Raw thermal data; the spectra are coloured from 
red (20°C), through purple (90°C) to blue (cooling to 20°C) in 5°C steps, with 90°C marked as 
green. D) corresponding deconvoluted data. 
SAXS was used to evaluate the effects of conjugation on the tertiary and 
quaternary structure (Figure 2-26A). Relative to cOpdA, [cOpdA][S] showed a 17.1 Å 
increase in Rg from 30.5 to 47.6 Å, corresponding to the addition of a surfactant 
corona, with a decrease in the Porod exponent from 3.4 to 2.8, indicating increased 
flexibility, likely due to the dynamicity of the surfactants. Critically, bead modelling of 
the radial probability distribution showed good overlap with the OpdA crystal 





Figure 2-26 A) SAXS scattering curve for [cOpdA][S] at room temperature. B) Kratky plot of 
the data showing flexibility in the system. C) Guinier plot, from which the radius of gyration 
was calculated D) Radial probability distribution of [cOpdA][S], compared against cOpdA. 




2.3.4.5 Impact of conjugation on activity of cOpdA 
With confirmation of near-native secondary, tertiary, and quaternary structures, 
the conjugate was subjected to kinetic analysis. Previously, Brogan et al. reported a 
further 55% and 40% reduction in substrate turnover rate from cationised to 
conjugate for lipases from Rhizomucor miehei and Thermomyces lanuginosus, 
respectively.2 [cOpdA][S], however, showed a significant increase in kcat (92.4±3.6 vs 
78.2±3.3 s-1) and a significantly lower Km (25.0±4.5 vs 39.0±7.0 μM), indicating 
improved substrate affinity. Combined, this results in a 1.8-fold increase in the 
specificity constant (3.70±0.68 vs 2.01±0.36 μM-1·s-1; Figure 2-27) against cOpdA, 
and a 2.2-fold increase over wild-type OpdA. This increase in activity is 
unprecedented for chemical modifications of proteins.  
  
Figure 2-27 Michaelis–Menten kinetics of [cOpdA][S] compared against OpdA and cOpdA. A) 
The turnover rate, kcat, B) the Michaelis–Menten constant, Km, and C) the specificity constant, 
kcat÷Km. ns, no significance; **, P<0.01; ***, P<0.001; ****, P<0.0001. The large errors in Km 
arise from a narrow substrate-concentration range. 
Crowding agents, such as PEG, BSA, and polysaccharides, have previously 
been shown to improve the efficiency of some enzymes, albeit modestly and not 
universally.56 They are thought to primarily affect enzymatic rates in 2 ways: hard and 
soft interactions. Hard interactions assume the crowding agents act as inert, hard 
particles that act through steric effects and by excluding volume, which in turn 
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increases the effective concentration of both enzyme and substrate. The 
concentration of protein is known to affect structural stability and therefore the 
apparent activity. Structural stabilisation may lead to more optimal states, be it 
improved secondary, tertiary, or quaternary structure, with increased turnover rates 
or efficiency, binding, decreased substrate release, or combinations thereof. More 
recently, soft interactions have been proposed, whereby specific interactions 
between the crowding agent and the protein of interest lead to improved rates.57,58 
As conjugation of the surfactant to cOpdA would cause negligible volume 
exclusion, the effect must be a result of soft interactions. The dilution of OpdA and 
cOpdA for the assay would shift the equilibrium towards the monomer form, whereas 
the surfactant corona could constrain the [cOpdA][S] construct in a dimer form. Due 
to the extremely low concentration of protein in the assays, it is difficult to determine 
the oligomeric state of OpdA in the assay samples. Similarly, the low concentrations 
of the protein may cause unfolding,59 which could be prevented by the conjugation. 
It was also postulated that the surfactant corona may interact with the substrate. With 
the decrease in Km and increase in kCat, the ratio kf:kr must be increased. If paraoxon 
partitions into the surfactant corona, then the concentration of substrate proximal to 
OpdA would be increased. Furthermore, if kf is sufficiently rate limiting in the 
surfactant-free system, then its increase would lead to a decrease in the observed 
Km. Paraoxon is an oily substance, with an octanol:water partition coefficient of 1.98,60 




2.3.4.6 Molecular dynamics simulations of a [cOpdA][S] model 
With a well-characterised system, molecular dynamics simulations (MD) provide 
detail at resolutions far beyond what can be measured empirically. MD had previously 
been performed on myoglobin and lysozyme constructs by Brogan et al.61 Up to this 
point, the mechanism of surfactant binding to OpdA has only been theorised as 
electrostatic binding, and MD offers insight into structural changes on a molecular 
level, as opposed to the ensemble probing of empirical techniques. Therefore, MD 
on OpdA was run in collaboration with Dr Richard Sessions, University of Bristol. 
Firstly, a more complete OpdA structure was built upon the X-ray resolved 
structure (PDBID:2D2J25) by manually adding the residues not resolved due to 
flexibility. Then, using the proteomics data from the supercharging OpdA 
experiments, a cationised OpdA model was produced by adding DMPA to the 
residues that were modified in the cationisation reaction: D76, D97, D109, E120, 
E121, E135, D136, D184, D211, D212, and E239. This model was then minimised, 
and then subjected to surfactant docking using the Bristol University Docking Engine 
(BUDE). BUDE randomly inserts a given number of surfactant molecules around the 
surface of the model in an extended conformation, pointing away from the model. In 
reality, the surfactants are micellar before interaction. While the simulation does not 
reflect the initial micelle-protein interactions, a more realistic simulation involving 
these structure would be too computationally expensive for atomistic modelling. 
However, BUDE results in the cOpdA molecule with a complete surfactant corona as 
expected, and not a partially-conjugated molecule that is produced when sub-CMC 
levels of surfactant are introduced. The produced model was then simulated for 100 
ns, in both water and acetonitrile solvents (Figure 2-28). Crucially, in both solvents 
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the simulated protein maintained its structure. In water, the surfactant corona rapidly 
enveloped the protein, burying the hydrophobic nonylphenol tail moieties. However, 
the corona did not cover the entirety of the protein; many of the charged residues 
were still exposed, with the surfactants forming flattened micelles. The channel to the 
active site was left open. In the acetonitrile solvent, the hydrophobic tails of the 
surfactants were extended, while the PEG units buried the charged residues. 
Acetonitrile was used to represent the hydrophobic interface of a cell membrane 
without the extra computational power required to simulate a bilayer. Both the water 
and acetonitrile solvated simulations produced similar structures to the simulations 




Figure 2-28 Molecular dynamics simulations of [cOpdA][S] in A) water and B) acetonitrile. Red, 
negatively charged residues; blue, positively charged residues; white, uncharged residues; 
green, surfactants. The arrow in A indicates the channel to the active site of one of the 
monomers; the other is on the opposite side. 
The interatom distances of the surfactants in each system were compared over 
time (Figure 2-29). In the aqueous system, the surfactants quickly collapse into 
flattened micelles, with a maximum interatom distance of approximately 110 Å. The 
aqueous system also has two peaks in its distribution: approximately 25 and 75 Å. 
The smaller peak corresponds to the individual flattened micelles, whereas the larger 
peak corresponds to the distance between each flattened micelle. The acetonitrile-
solvated system yields a maximum interatom distance of approximately 150 Å, and 
shows a single peak. When in acetonitrile, the surfactants cover more of the protein 
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surface to bury the polar residues due to the hydrophobic effect. The surfactants do 
not form the same flattened micelles and spread out more evenly. 
 
Figure 2-29 Histograms of interatom distances of the surfactants in the [cOpdA][S] system in 
A) water and B) acetonitrile. The plots are coloured blue through purple to red according to 
the time point. Inset are the maximum interatom distances (dMax) over time. 
The interactions of the carboxylate groups of the surfactants with the positively 
charged residues of the protein were investigated. In the H2O-based simulation, many 
of the surfactant heads were not bound via electrostatic interactions; only 
approximately 50% of the surfactants’ terminal oxygens were within 4 Å of a 
positively-charged residue after 100 ns, although this was gradually increasing over 
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time (Figure 2-30A,B). In the acetonitrile-based simulations, the surfactant 
headgroups were closer overall to the positively-charged residues; approximately 
80% were within 4 Å after 100 ns, and this was also increasing gradually (Figure 
2-30C,D). The relative mobility of the surfactant headgroups in the H2O vs acetonitrile 
simulations is likely due to solvation effects: in H2O, the surfactant carboxylates may 
bind positively-charged residues or be solvated, however the solvation of the 
headgroups by acetonitrile is disfavoured, therefore they bind the positively-charged 
residues and/or are buried by the hydrophobic effect. 
 
Figure 2-30 Analysis of electrostatic interactions between surfactants and positively-charged 
sidechains of [cOpdA][S] simulations in A,B) H2O and C,D) acetonitrile. A,C) Minimum 
distance from surfactants’ terminal oxygens to a positively charged residue; B,D) fraction of 
surfactant terminal oxygens within 4 Å of a positively charged residue. 
The SASA over time was also investigated. In both simulations, the SASA 
reduced over time, and this was predominantly due to reorganisation of the 
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surfactants. Furthermore, SASA was greater in the acetonitrile simulation due to the 
projection of the hydrophobic tails away from the protein and into the solvent (Figure 
2-31A,B). Crucially, the protein component of the SASA in each sample decreased 
as it was buried by the surfactants, and was not seen to increase, which would be 
indicative of denaturation. The protein component of the SASA was lower in the 
acetonitrile simulation relative to the H2O simulation, and this was shown to be due 
to the burying of polar residues; indeed, the SASA of the hydrophobic residues was 
slightly increased (Figure 2-31C,D). 
 
Figure 2-31 SASA analysis of the [cOpdA][S] simulations in A,C) H2O and B,D) acetonitrile. 
A,B) SASA from the combined protein and surfactants; C,D) SASA of the protein alone, further 
separated into polar and hydrophobic residues. 
Using the FoXS webservice,62,63 a p(r) distribution of the final aqueous 
[cOpdA][S] simulation frame was produced to compare with empirical data in section 
2.3.4.4 (Figure 2-32). While the distribution was broader for the modelled [cOpdA][S], 
it represents a single, rigid conformation, whereas the experimental [cOpdA][S] 
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sample distribution is highly flexible and comprises myriad conformations. To fully 
validate the simulated data, a number of MD repeats should be performed. 
 
Figure 2-32 Radial probability distribution of the molecular dynamics simulation of [cOpdA][S] 
(solid line) compared to the empirical distribution of [cOpdA][S] (dashed line). 
The computational modelling of the surfactant-conjugated system provides 
useful insight into the atom-level arrangements of the surfactant molecules that are 
hidden in the sample-averaged results of empirical studies. The flattened-micelle 
conformation due to the discrete burial of the hydrophobic tails in the water-solvated 
simulation vs the surface coverage and lipid tail projection of the acetonitrile-solvated 
simulation demonstrates the dynamicity of the corona. Furthermore, the steady net-
increase in the fraction of surfactants electrostatically bound to the protein suggests 
the surfactant corona is stably bound. 
A drawback of MD, however, is the low statistical power due to it being time-
consuming and costly to perform multiple times. Moreover, simulations that better 
resemble reality, i.e. a surfactant micelle colliding with a cOpdA model, may be too 
computationally strenuous to perform within a reasonable timeframe. Nevertheless, 
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these data are adjunctive to the empirical data collected, and help to inform where 
empirical studies are not practical. 
2.3.5 Dual-surfactant conjugation of OpdA 
A further method of producing an enzyme-polymer surfactant conjugate using 
two oppositely charged surfactants was explored. In contrast to the prior method, no 
cationisation step is required. Instead, the negative residues are first bound to a 
positively-charged surfactant, the excess removed, before conjugation with the 
negatively-charged surfactant as before. Both surfactants are required, as using only 
one would likely lead to spare coverage of the protein surface. A major benefit of this 
approach is the lack of covalent modifications required, but also the simplicity of the 
process. 
For the positively-charged surfactant, there were very few commercially-
available amphiphilic surfactants with a positively-charged headgroup. Ethoquad 
HT/25 is a quaternary amine comprising two amphiphilic PEG chains, a hydrophobic 
hydrogenated tallow chain, and a methyl group (Figure 2-33). The nitrogen atom’s 
positive charge is independent of pH. Ethoquad did not require further processing 
before use. A downside of Ethoquad is that it does not have a spectral signature to 





Figure 2-33 Structure of Ethoquad HT/25. Ethoquad comprises a central quaternary amine 
with 2 PEG chains, an alkane chain, and a methyl group. 
2.3.5.1 Structural analysis of [OpdA][E][S] 
In line with the characterisation of the other constructs, the effects of the dual-
surfactant conjugation on OpdA structure were evaluated. Circular dichroism 
revealed little change relative to OpdA, with similar spectra (Figure 2-34), and 
secondary structure composition: 4.6% more α-helix, 5.4% less β-sheet, 0.9% more 
turn, and 0.1% less disorder. There was a slight increase in thermal stability, although 
not as great as with the cationisation; a sharp α-helix to β-sheet transition was 













Figure 2-34 CD analysis [OpdA][E][S], compared to OpdA. A) CD spectra collected at 20°C, 
and B) corresponding deconvoluted data. C) Raw thermal data; the spectra are coloured from 
red (20°C), through purple (90°C) to blue (cooling to 20°C) in 5°C steps, with 90°C marked as 
green. D) corresponding deconvoluted data. 
SAXS analysis of [OpdA][E][S] was performed (Figure 2-35). The [OpdA][E][S] 
construct correlated well with OpdA, but had a lower Rg value (27.7 vs 47.6 Å), and a 
marginally greater Porod exponent (3.0 vs 2.8) relative to the cationised-conjugate, 
[cOpdA][S]. The p(r) distribution of [OpdA][E][S] overlapped well with [cOpdA][S], 
although [OpdA][E][S] had a reduced maximum (Figure 2-36A). Together, these 
suggest that the dual-surfactant corona is more compact than that of the surfactant 
corona produced from the anionic surfactant alone. This is likely due to the branched 
structure of Ethoquad, with each branch being much shorter than the length of the 
oxidised IGEPAL CO-890 surfactant. Crucially, bead modelling showed tight overlap 
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with the OpdA X-ray crystal structure (Figure 2-36B), confirming that the quaternary 
structure was maintained. 
 
Figure 2-35 A) SAXS scattering curve for [OpdA][E][S] at room temperature. B) Kratky plot, 





Figure 2-36 A) Radial probability distribution of [OpdA][E][S] compared against OpdA and 
[cOpdA][S]. B) Bead model of [OpdA][E][S] (pink) overlaying a crystal structure of OpdA (white; 
PDBID:2D2J25). 
2.3.5.2 The impact of dual conjugation on activity 
[OpdA][E][S] was subjected to kinetic analysis with paraoxon and compared 
against OpdA. The dual conjugation gave a significant increase in kcat (39.7±1.2 vs 
26.7±0.56 s-1, n=3 and 2 respectively, P=0.001), with no significant change in Km 
(12.7±1.8 vs 14.7±1.3 μM, P=0.291), leading to an overall 1.7-fold increase in the 





Figure 2-37 Michaelis–Menten kinetics of [OpdA][ES] with paraoxon at room temperature, 
compared against OpdA. A) The turnover rate, kcat, B) the Michaelis–Menten constant, Km, 
and C) the specificity constant, kcat÷Km. ns, no significance; *, P<0.05; ***, P<0.001. 
In light of the facile nature of the dual conjugation reaction, this method presents 
a promising alternative to the cationisation–conjugation method previously described 
for producing artificial membrane-binding proteins. This approach had little effect on 
secondary structure, and no apparent effect on tertiary and quaternary structure, as 
was also seen in the cationisation–conjugation approach. The thermal stability of 
[OpdA][E][S] was only marginally improved over OpdA, unlike the cOpdA system. 
However, a significant increase in turnover rate was observed, with no significant 
change observed in Km, therefore, either an increase in the rate of formation, kf, or a 
decrease in the rate of release of product, kr, must have occurred. 
2.4 Conclusions and further work 
Here, the formation of enzyme–polymer surfactant hybrid constructs from 
expression, through cationisation, to the conjugation has been detailed, and the 
characterisation process described. Furthermore, alternative methods of producing 
artificial membrane-binding proteins have been explored. 
The cationisation step introduced minor changes in secondary structure, but 
tertiary and quaternary structures were retained. Crucially, cationisation had no 
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significant effect on the kinetic efficiency of OpdA. The thermal stability of OpdA was 
greatly increased by cationisation, likely due to increased electrostatic repulsions and 
intraprotein salt bridge disruption that formed a molten globule state. While this does 
not directly benefit artificial membrane-binding proteins, it should be explored further 
for use in other applications, such as biocatalysis in industry where increased 
temperatures are required in the workflow, and with other proteins that may be useful 
in high-temperature environments. Moreover, increased thermal stability may also 
indicate increased resilience to chemical denaturants, as was observed in previous 
work with myoglobin.3 
Conjugation of cOpdA had no significant effect on the structure of cOpdA, and 
made no further changes to the thermal stability. The activity of [cOpdA][S], however, 
was significantly increased relative to OpdA and cOpdA, with an increase in kCat and 
a decrease in Km, indicating a change in the kf:kr ratio. This may be due to either the 
stabilisation of the dimer state, or due to shuttling of the substrate to the enzyme. MD 
of [cOpdA][S] provided insight into the surfactant-corona formation that is not 
possible to determine empirically, and revealed the compact flattened micelle from 
burying the hydrophobic chains in water, whilst in acetonitrile, representing a 
hydrophobic interface, the charged residues were buried by the PEG chains with the 
nonylphenyl groups extending out. Coarse-grained simulations of surfactant micelles 
colliding with cOpdA may be used to provide insight into how the surfactants come 
to coat the protein surface in a more realistic, less precise manner, as coarse grained 
modelling is computationally cheaper than atomistic modelling. 
The scOpdA construct did not have significant activity, and was unable to be 
purified in a folded state. This work was exploratory, and with more focus an active 
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mutant could likely have been expressed. Employing different expression strategies, 
be it more tightly-regulated expression strains or culture conditions, may yield soluble 
constructs. Moreover, different refolding techniques such as diluting the sample and 
performing step-wise dialysis to remove the guanidine may yield active enzyme.64 
Performing proteomics on a greater number of chemically-cationised samples would 
provide statistics on which sites are cationised, and increase confidence in their 
selection. Furthermore, an evolutionary approach may help to stabilise the 
supercharged constructs by mutating residues proximal to the modified sites. In 
producing a supercharged-OpdA mutant, the established avNAPSA35 or Rosetta65 
protocols available through the ROSIE web service41 may provide more immediate 
results, however a further aim of the experiment was to develop an empirical method 
of informing supercharged-construct design, of which there are currently none. 
Conversely, the dual-surfactant conjugation method gave exciting results. In line with 
the established conjugation technique, there was little change in secondary structure 
and tertiary and quaternary structure was maintained. Moreover, the activity 
increased similarly to that seen with [cOpdA][S]. The advantage of this system is the 
simplicity and speed: dual-surfactant conjugation requires only the sequential 
addition of two surfactants, which can easily be done within an hour; the current 
cationisation protocol, however, requires approximately 30 hours. 
In conclusion, the cationisation–conjugation method of producing artificial 
membrane-binding proteins has been adapted for use with OpdA, and has been 
shown to have no deleterious effects as have been seen previously with enzymes, 
whilst enhancing the activity. Furthermore, a novel method to impart the surfactant 
corona without covalent modification has been explored, and was found to be 
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promising. In the following chapter, the interaction of these constructs with cell 
membranes will be investigated. 
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3 Cellular interactions and activity at the cell surface 
3.1 Introduction 
Artificial membrane-binding proteins have previously been used to reduce 
hypoxia-induced central-cell necrosis in cartilage tissue constructs,1 and to enhance 
cell–scaffold adhesion while enhancing proliferation.2 Armstrong et al., used eGFP as 
a model protein to demonstrate that the cationised and conjugated constructs 
interacted with cell membranes of hMSCs in two distinct manners: cationised eGFP 
predominantly bound to the negatively-charged glycocalyx, whereas the cationised 
and conjugated eGFP bound in a glycocalyx-independent manner, instead 
interacting with the cell membrane directly via hydrophobic interactions (Figure 3-1). 
Conjugated eGFP was observed on cells 10 days post-exposure, whereas cationised 
eGFP persisted only for 6 days, and cationised eGFP was found to be more cytotoxic 




Figure 3-1 Schematic showing the proposed membrane-binding mechanism. The dynamic 
surfactant corona rearranges upon collision with the bilayer, inserting its hydrophobic tails 
into the membrane leaflet. 
Here, the artificial membrane-binding protein methodology is applied to OP-
degrading enzyme, OpdA. As OPs are typically lipophilic, they are sequestered into 
fatty tissue and leach out over time, leading to prolonged toxicity.3 Injecting OpdA 
intravenously post-OP exposure is efficacious for short periods of time, with a 
systemic half-life of approximately 45–60 minutes,4 but this needs to be extended to 
have real therapeutic benefit. 
Here, we investigate the interaction of OpdA-based constructs with cell 
membranes. Confocal fluorescence imaging was used to determine the localisation 
of the cells using dye-labelled OpdA constructs. Moreover, the localisation of 
[cOpdA][S] was also investigated in adipocytes, where OPs are known to sequester. 
The effects of each of the OpdA constructs on cellular health are investigated, 
including the novel dual-surfactant conjugated system, which has not previously 
been investigated. Crucially, the activity of the enzymes at the cell surface is assayed. 
As artificial membrane-binding enzymes do not follow the classical Michaelis–Menten 
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enzyme kinetics model, new methodologies for measuring enzymatic activity at the 
cell surface are explored. In investigating the activity of membrane-bound OpdA-





3.2 Materials and methods 
All chemicals were purchased from Sigma Aldrich, UK, and were not further 
processed unless stated otherwise. Deionised water was produced at a resistivity of 
18.2 MΩ·cm by a Millipore Milli-Q Reference Water Purification System using a 
Quantum TIX polishing cartridge. Protein constructs were produced as described in 
Chapter 2.2. 
3.2.1 Preparative 
3.2.1.1 Dye labelling 
To enable the fluorescence imaging of cOpdA and [cOpdA][S] constructs, 
cOpdA was labelled with either 5(6)-carboxyfluorescein or rhodamine, using their 
amine-reactive N-hydroxysuccinimide derivatives. A 10 mg·mL-1 solution of the dye 
was prepared in dimethylsulfoxide and added at a 15:1 ratio of dye to protein. The 
reaction was left for 2 hours at 4°C before being dialysed against HEPES buffer (30 
mM, pH 8) supplemented with 100 μM CoCl2 to remove any unreacted dye. The 
degree of labelling could then be assessed with mass spectrometry. The labelled 
cOpdA was either used as-is, or conjugated to form the dyed [cOpdA][S] construct. 
These dye-labelled constructs were used to prime cells as described previously, 
before either confocal or widefield microscopy. 
3.2.1.2 Cell culture 
Human mesenchymal stem cells (hMSCs) were kindly provided by Southmead 
Hosptial, Bristol. 
hMSCs were harvested from the proximal femur bone marrow of osteoarthritic 
patients undergoing total hip replacement surgery, in full accordance with Bristol 
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Southmead Hospital Research Ethics Committee guidelines (reference #078/01), and 
having received informed consent from all patients. All cells were cultured at 37°C, 
5% CO2. hMSCs were cultured in low-glucose (1000 mg·dm-3) Dulbecco’s Modified 
Eagle’s Medium (DMEM), supplemented with 10% foetal bovine serum (FBS), 2 mM 
GlutaMAX (Gibco, US), 100 units·mL-1 penicillin, 100 μg·mL-1 streptomycin. hMSCs 
were cultured up to a passage 5. 
Rat brain stem neurons were harvested from day 16 embryos by Óscar Cordero 
Llana, University of Bristol. Cells were cultured in a polylysine-treated 96 well plate, 
with Neurobasal medium supplemented with 2% B27, 2 mM Glutamax, 100 units·mL-
1 penicillin, 100 μg·mL-1 streptomycin. 
SH-SY5Y cells were cultured in DMEM–F12 Ham supplemented with 10% FBS, 
2 mM GlutaMAX, 100 units·mL-1 penicillin, 100 μg·mL-1 streptomycin, and 1% non-
essential amino acids. 
3.2.1.3 Cell trypsinisation 
Adherent cells in a T175 flask were first washed with PBS to remove the trypsin 
inhibitors present in the media. The cells were then incubated in 5 mL of trypsin–
EDTA (Gibco) for 5 minutes at 37°C, 5% CO2, and gently struck to encourage 
resuspension. 8 mL of culture medium was then added to inhibit the trypsin, and the 
mixture centrifuged at 1500×g to pellet the cells. The supernatant was discarded, and 
the cells resuspended in culture medium. 10 μL of the cell suspension was pipetted 
into a haemocytometer for cell counting. The cells were then replated at known 
seeding densities for further use. 
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3.2.1.4 Cell priming 
Plated cells were washed using phosphate buffered saline (PBS). A 1:1 mixture 
of PBS and a 2× solution of [cOpdA][S] was then added to the cells, and left to 
incubate at 37°C, 5% CO2 for 10 minutes. The cells were then washed with PBS to 
remove loosely bound material. The appropriate cell medium was then applied for 
further use. 
3.2.1.5 3’,6’-bis(diphenylphosphinyl) fluorescein synthesis 
3’,6’-bis(diphenylphosphinyl) fluorescein (DPPF) was synthesised by Dr Hugo 
Rego Campello. In an oven-dried Schlenk flask, diphenylphosphinic chloride (1.9 mL, 
10 mmol) was dissolved in freshly distilled THF (75 mL) under nitrogen, trimethylamine 
(2.0 mL, 14.2 mmol) was added and the solution stirred for 5 minutes at room 
temperature. In a separate flask, sodium fluorescein (1.66 mg, 5 mmol) was dissolved 
in THF (50 mL) and then added dropwise over 15 min. The reaction mixture was 
stirred at 60°C for 30 minutes. The solution was cooled to room temperature, filtered 
and concentrated. The residue was dissolved in ethyl acetate (25 mL), washed with 
ammonia (15 mL, 5% aq. sol.), water (15 mL) and brine (15 mL). The organic phase 
was dried over MgSO4, filtered and concentrated in vacuo. The residue was dissolved 
in benzene, the insoluble solids were filtered, and the solvent was removed. 
Purification by flash column chromatography [EtOAc:n-Hexane (3:1)] afforded DPPF 





hMSCs were trypsinised and plated at known concentrations in a 96-well plate 
as previously described, and left to adhere overnight. The sample cells were primed 
with a range of cOpdA or [cOpdA][S] concentrations as described previously, and the 
standard curve cells were treated with PBS and HEPES buffer (30 mM, pH 8) 
supplemented with 100 μM CoCl2. The cells were washed thoroughly with PBS before 
applying 10% Alamar Blue (Thermo Fisher) solution in PBS. The plate was then 
incubated at 37°C, 5% CO2, for approximately 4 hours, or until a visible colour 
gradient evolved across the standard curve wells. The fluorescence corresponding 
to cellular metabolism of the Alamar blue substrate was then read using a Synergy 
Neo 2 plate reader (Biotek) with excitation at 554±9 nm, and emission read at 593±10 
nm. Linear regression was used to calculate the number of live cells from the standard 
curve cells. 
3.2.2.2 Cell loading 
10000, 5000 and 2000 cells were primed with a range of [cOpdA][S] loads. After 
10 minutes, a BCA assay was performed on the supernatants as described in 1, with 
known amounts of [cOpdA][S] generating a standard curve. Values from control wells 
with either no cells or no protein applied were subtracted from the sample values. 
3.2.2.3 Ellman assay for acetylcholinesterase activity 
The activity of AChE was measured via an indirect method known as the Ellman 
assay.5 Upon enzymatic hydrolysis of the acetylthiocholine substrate, Ellman’s 
reagent (5,5'-dithiobis-(2-nitrobenzoic acid), DTNB) rapidly reacts with the thiol 
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group-containing product to produce the chromophore 2-nitro-5-thiobenzoate 
(TNB−), allowing the colourimetric determination of AChE activity. Diethyl 
chlorophosphate (DECP), a colourless OP, was used as a nerve-agent simulant. Rat 
day-16 embryonic brain stem neurons or SH-SY5Y cells were plated in a 96 well plate 
at 10,000 cells per well, and washed with PBS immediately prior to use. Samples 
were either exposed to 100 μM DECP and then treated with 10 μM [cOpdA][S], or 
pre-treated with 10 μM [cOpdA][S] before exposure to DECP. Positive controls were 
not exposed to DECP, and negative controls were not treated with OpdA at any time. 
Acetylthiocholine and DTNB were added to give final concentrations of 450 μM and 
300 μM, respectively. The colour change produced was measured by absorbance at 
412 nm. 
3.2.2.4 1-Naphthylacetate assay for acetylcholinesterase activity 
1-Naphthylacetate is a substrate for AChE that forms the fluorescent molecule 
1-naphthol upon hydrolysis, with fluorescence excitation and emission maxima at 
300 nm and 460 nm, respectively. 
SH-SY5Y cells were plated in a 96 well plate at 10,000 cells per well, and 
washed with PBS immediately prior to use. Samples were either exposed to 100 μM 
DECP and then treated with 10 μM [cOpdA][S], or pre-treated with 10 μM [cOpdA][S] 
before exposure to DECP. Positive controls were not exposed to DECP, and negative 
controls were not treated with OpdA at any time. 1-naphthol acetate was added to 
each sample at a concentration of 100 μM before activity was determined by 
measuring the fluorescence intensity increase at 460±10 nm over time using a 
Synergy Neo 2 plate reader (BioTek). 
174 
 
3.2.2.5 Neutron reflectometry 
Theory 
As neutrons are highly-penetrating, interacting only with the nuclei of atoms, 
neutron reflectometry can be used to determine the thickness, roughness, hydration 
and scattering length density of multi-layer samples by measuring the specular 
reflectivity of a collimated neutron beam as a function of the scattering vector q ( 
above). The reflectivity is calculated by dividing the reflected intensity by the incident 
intensity. From the reflectivity, the Abeles matrix formalism method can be used 
computationally to deconvolute the data via non-linear regression methods. Briefly, 
the theoretical reflectivity is calculated from matrix calculations of the Fresnel 
reflection coefficient describing reflection and transmission through a refractive 
medium, the scattering length density, layer thickness, and interfacial roughness. The 
theoretical values are then fitted to the experimental data via genetic algorithms. The 
RasCAL software package automates this process.6 
Method 
Neutron reflectometry was performed on the INTER beamline at the Isis facility 
in collaboration with Dr Robert Barker. Floating bilayers of 3:1 2-oleoyl-1-palmitoyl-
sn-glycero-3-phosphocholine (POPC) and 1-palmitoyl-2-oleoyl-sn-glycero-3-
phospho-(1'-rac-glycerol) (POPG) were assembled on a silicon block with a 1-
Palmitoyl-2-[16-(acryloyloxy)hexadecanoyl]-sn-glycero-3-phosphorylcholine (al-PC) 
monolayer covalently bound to the silicon substrate, using the Langmuir–Blodgett 
trough deposition method. OpdA constructs were loaded at concentrations of 0.2 
and 5 μM, and loosely bound material washed with buffer. Measurements were 
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performed at two angles, 0.7 and 2.3°, and the data merged. Data deconvolution was 





3.3.1 Fluorescence analysis of cellular interactions 
To monitor the interaction of the cOpdA and [cOpdA][S] constructs with cell 
membranes using confocal fluorescence microscopy, dye analogues were 
synthesised. A range of click-chemistry-based dyes are available, and 5(6)-
carboxyfluorescein (CF) NHS was selected due to its high-fluorescence yield, simple 
protocol, high stability, and relatively low cost. NHS esters react efficiently with 
primary amines, which are present in the N-terminus amine and lysine residues in a 
protein, via an acyl nucleophilic substitution mechanism (Figure 3-2).  
 
Figure 3-2 Reaction scheme of 5(6)-carboxyfluorescein N-hydroxysuccinimide (1) with a lysine 
residue (2), producing an amide-bonded fluorescein–protein conjugate (3) and an N-
hydroxysuccinimide waste product (4). 
It was postulated that the addition of a large number of hydrophobic fluorescein 
































affinity. Therefore, mass spectrometry was used to calculate the number of 
fluorescein molecules bound to OpdA. A peak-split corresponding to the sub-
stoichiometric addition of 1 fluorescein molecule per molecule of OpdA to give CF-
OpdA was observed (Figure 3-3A). As fluorescent dyes are susceptible to 
photobleaching, whereby fluorescence is lost over time when exposed to light, dye-
modifying cOpdA to yield CF-cOpdA was also explored to negate the requirement of 
performing cationisation in low-light conditions for the cOpdA and [cOpdA][S] 
samples. Mass spectrometry revealed that 1–2 molecules of fluorescein were 
covalently bound to cOpdA after the reaction (Figure 3-3B). 
 
Figure 3-3 Mass spectra of cOpdA and dyed cOpdA 
With CF-OpdA and CF-cOpdA minimally, yet successfully, dye labelled, the 
interaction of the constructs with cell membranes was evaluated using confocal 
fluorescence microscopy. hMSCs were used as a model cell so that direct 
comparisons could be made with the seminal artificial membrane-binding protein 
work by Armstrong et al.,1 although the mechanism of membrane interaction is 
thought to be non-specific to cell type. Confocal fluorescence microscopy allows the 
imaging of samples within a single plane; focused light illuminates a portion of the 
sample, and the resulting fluorescence passes through a pinhole that blocks out-of-
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focus light before reaching the detector. This resolution is necessary for determining 
the localisation of the OpdA constructs, as in widefield microscopy it is difficult to 
distinguish protein in the cytoplasm from those immobilised on the plasma 
membrane. Representative images of each construct are presented in Figure 3-4, 
each being a slice from the middle focal plane of the cells. Native OpdA had negligible 
interaction with the cells as expected given its lack of charge or hydrophobic surface 
groups. cOpdA was seen to rapidly penetrate the cells, and its seemingly ordered 
distribution suggests interaction with the cell microtubule cytoskeleton, which is 
negatively charged.7 The membrane penetration behaviour is consistent with that of 
supercharged proteins, which are rapidly endocytosed, and have previously been 
used to deliver macromolecular payloads.8,9 The cells exposed to cOpdA also 
displayed blebbing morphologies indicative of apoptosis. [cOpdA][S] assembled at 




Figure 3-4 Confocal micrographs of OpdA-based nanoconstructs at 63× and 10× 
magnification with both fluorescence (corresponding to 5(6)-carboxyfluorescein fluorescence) 
and brightfield channels. The constructs were applied to human mesenchymal stem cells in 
a glass-bottomed dish at a concentration of 10 μM for 10 minutes, washed, then imaged 
immediately. 
OPs sequester into fat deposits and leach out over time, prolonging the 
treatment time required for obese OP-poisoned patients.3 While surface-anchored 
[cOpdA][S] constructs may protect pre-treated cells from OP poisoning and prevent 
leaching of OPs post-exposure, detoxification of OPs sequestered within fat droplets 
prior to leaching would be advantageous. CF-[cOpdA][S] was therefore added to 
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hMSC-derived adipocytes to investigate the interactions with fat deposits. The results 
show that while the construct preferentially labels cell membranes, the intracellular 
fat droplets are also weakly labelled (Figure 3-5). This was expected, as [cOpdA][S] 
was not observed to penetrate the membrane in the hMSC experiments, although the 
fatty vacuoles may push up against the membrane and so small amounts could 
transition, or perhaps small amounts of [cOpdA][S] that penetrate the membrane 
localise at the fatty vacuole. 
 
Figure 3-5 Localisation of [cOpdA][S] (left; green) on adipocytes. Brightfield image (right; grey) 
for reference. 3D image represented as maximum-intensity z-projection. Scale bar=20 μm. 
3.3.2 Construct cytotoxicity 
In producing artificial membrane-binding enzymes, it is prudent to determine 
the effect that the constructs have on cellular health, especially in light of the blebbing 
observed in cOpdA-treated cells. The broadest measure of cellular-health effects is 
cell viability, which can be primarily evaluated in two ways: as a ratio of live:dead cells 
as determined using dyes and imaging; or via the metabolism of a chromogenic 
substrate compared to a standard curve. While metabolism is not strictly linked to 
cell viability, it is generally considered to be a good indicator.10 Measuring metabolism 
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was selected due to its amenability to high-throughput processing. The Alamar Blue 
cell viability solution was used, which exploits the reduction of resazurin (blue) to 
resarufin (pink) by respiring cells, and contains redox stabilisers to slow the further 
reduction to hydroresorufin (colourless).11 OpdA was not tested, as it did not interact 
with cells. cOpdA was found to significantly reduce cell viability even at 2 μM 
(P<0.0001 for all relative to control, n=2; Figure 3-6). Armstrong et al. reported that 
cationised enhanced green fluorescent protein (cEGFP) with a net charge of +35 
exhibited cytotoxicity at 12 μM.12 Conversely, McNaughton et al. found no significant 
cytotoxicity of the +36 net-charged supercharged GFP (scGFP) at 2 μM.9 The 
differences in cytotoxicity may be due to the distribution of the charge at the protein 
surface, or differences in protocol: McNoughton et al. measured cytotoxicity 24 hours 





Figure 3-6 Cytotoxicity of cOpdA at varying concentrations. n=2. 10,000 cells per well were 
challenged with varying concentrations of cOpdA for 10 minutes, washed, and assayed with 
Alamar Blue. Fluorescence corresponding to Alamar Blue turnover by the cells was measured 
and compared with control cells forming a standard curve. 
[cOpdA][S] was not significantly cytotoxic up to concentrations of 15 μM (Figure 
3-7). This is in line with the findings by Armstrong et al., who reported that cationised 
and conjugated eGFP were not cytotoxic up to 18 μM.1 The increased viability upon 
conjugation may be due to the surfactant headgroups shielding the highly-charged 
protein surface, reducing deformation of the cell membrane from electrostatic forces 
on lipid headgroups. The assembly at the cell surface seen in the confocal 
microscopy also indicates that membrane integrity is maintained, unlike the 
cationised protein, which rapidly penetrates the cell membrane. The neat surfactant 




Figure 3-7 Cytotoxicity of [cOpdA][S] at varying concentrations. n=8; *, P<0.05. 
 [OpdA][E][S] was cytotoxic to cells above 1 μM (Figure 3-8). Adding free 
Ethoquad to the cells at a concentration equivalent to that of 1 μM of [OpdA][E][S] (35 
μM Ethoquad) lead to less than 10% cell viability, whereas 1 μM [OpdA][E][S] leads 
to no significant death. This shows that the Ethoquad is independently cytotoxic, but 
suggests the cytotoxicity is mitigated when bound to the protein at low 
concentrations. However, should any Ethoquad be released from [OpdA][E][S], it will 
lead to cell death, and at increasing concentrations of [OpdA][E][S], the equilibrium 
amount of free Ethoquad will increase. Cationic surfactants may cause cell lysis by 
disrupting the cell membrane, but have also been shown to cause death in yeast at 
sub-lysing concentrations, with charge reversal of the membrane shown to be the 
cause.13 As [OpdA][E][S] has been shown to rapidly penetrate the membrane, the 
cytotoxicity may also be caused intracellularly, through interactions with RNA or 
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DNA.14 A study on HeLa cells with different surfactants suggests increasing 
hydrophobic chain and PEG lengths leads to increased toxicity,15 and a separate 
study found the toxicities of cationic surfactants varied with different headgroups: 
toxicity seemed to increase with ionic radius of the headgroup.14 Therefore, it may be 
possible to reduce the cytotoxicity of the dual-conjugation system by utilising cationic 
surfactants of different compositions. [OpdA][E][S], however, was deemed unsuitable 
for cell-binding, and was therefore not explored further. 
 
Figure 3-8 Cytotoxicity of [OpdA][E][S] at varying concentrations tested on 10000 cells. 
Control, 10000 cells treated with buffer only; 1E, free Ethoquad at a concentration of 
equivalent to that of 1 μM [OpdA][E][S], equal to 35 μM. n=8 for each. 
3.3.3 [cOpdA][S] cell loading 
The cell-membrane binding capacity of [cOpdA][S] was assessed by analysing 
the supernatant construct concentration of cell cultures post-priming using a BCA 
assay across different cell numbers and construct concentrations (Figure 3-9A–D). 
10000 cells primed with 10 μM [cOpdA][S], as per the priming protocol, led to 4.5±25 
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billion constructs per cell. The results were highly variable, leading to large errors that 
led to no significant trends in these data. However, for each loading concentration, 
more constructs seemingly bound per cell in the 2000-cell well than in those seeded 
with more cells, an unexpected result that warrants further investigation. It may be 
that cells plated at a lower density adopt a morphology with greater surface area 
available for construct binding. 
 
Figure 3-9 The binding capacity of [cOpdA][S] on cells. [cOpdA][S] was loaded at up to 20 
μM on A) 10000, B) 5000 and C) 2000 cells. The supernatant was then assessed via a BCA 
assay for protein concentration. From the difference in concentration of protein loaded vs 
protein in supernatant, the amount of protein bound was calculated. D) The protein bound 
was converted into the number of constructs per cell.  
Armstrong performed a similar experiment using an eGFP-based construct as a 
fluorescent model protein, using the depletion of fluorescence intensity to quantify 
protein binding. He found that saturation binding occurred at approximately 6 billion 
constructs per cell, and also that construct-binding equilibration time decreased with 
increased loading concentration, suggesting cooperative binding.12 This is supported 
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by Brogan et al., who showed using molecular dynamics that the surfactant tails of 
the constructs interdigitate when in close proximity.16 
3.3.4 Protective effects of [cOpdA][S] on cells 
A method for quantifying the activity of OpdA on cells is to measure the activity 
of AChE in the presence of OPs, i.e., if OpdA remains active, the amount of OP and 
therefore the inhibition of AChE should be markedly reduced. This method 
concomitantly demonstrates the potential of the technology to be exploited in 
enzyme-based therapies for OP poisoning. 
A commonly used assay for determining AChE activity is Ellman’s assay;5,17-19 it 
is also commonly used in the indirect determination of OP-hydrolysing enzyme 
activities.20-22 Using acetylthiocholine (ATCh) as a substrate, the activity is measured 
indirectly by 5,5-dithio-bis-(2-nitrobenzoic acid) (DTNB), which is reduced to yellow-
coloured 2-nitro-5-thiobenzoic acid (TNB) by free thiol groups liberated in the 
hydrolysis of ATCh (Figure 3-10). As TNB has a known extinction coefficient, the 




Figure 3-10 Reaction scheme of the Ellman assay for the indirect quantification of AChE 
activity. The chromophore, TNB, is highlighted in yellow. 
Preliminary experiments were performed using Rat day-16 embryonic brain 
stem neurons, generously provided by Óscar Cordero Llana from the School of 
Cellular and Molecular Medicine, University of Bristol. A colourless OP, diethyl 
chlorophosphate, was used to avoid interfering with the TNB signal. The results 
seemed to show AChE activity was maintained despite the OP challenge, although 
the OpdA-treated, OP challenged samples gave higher rates than the non-treated, 










































Figure 3-11 Results of Ellman assay measuring AChE activity performed on Rat Embryonic 
Day-16 cells. ***, P<0.001  
Subsequent Ellman assays were performed on SH-SY5Y cells derived from a 
neuroblastoma, as this cell line is known to have high AChE activity.23 These 
experiments also included an extra control comprising OpdA-treated cells without an 
OP challenge. Data were collected at time points day 0, 1, and 5 seemed to show 
that cells primed with [cOpdA][S] prior to the OP challenge maintained greater AChE 
activity than non-treated cells, albeit greater than the non-treated, non-challenged 
cells as per the rat-cell experiments (Figure 3-12). However, the additional control of 
cells treated with [cOpdA][S] without the OP-challenge yielded far greater apparent 
activity than either the non-treated, non-challenged cells or the treated and 
challenged cells. Furthermore, large sample variation lead to no significant difference 




Figure 3-12 Results of Ellman assay measuring AChE activity performed on SH-SY5Y cells on 
days 0, 1, and 5. N=12 for each sample. 
DTNB can be used to quantify thiol groups, i.e. cysteine residues of proteins, 
therefore signal arising from the 2 cysteine residues of OpdA may interfere with the 
signal from ATCh turnover. To test this hypothesis, a range of concentrations of 
[cOpdA][S] was tested with the reagents used in the Ellman assays. The resulting 
concentration–intensity plot had a positive linear trend, proving that [cOpdA][S] 
contributed to the DTNB signal in a concentration-dependent fashion. However, 
when [cOpdA][S] was incubated with DTNB and no ATCh, the increase in signal 
plateaued after approximately 1 hour, whereas with ATCh the hydrolysis rate 
persisted (Figure 3-13). This indicates that [cOpdA][S] is able to turnover ATCh, 




Figure 3-13 Effect of [cOpdA][S] on ATCh turnover. In the presence of [cOpdA][S], ATCh 
turnover increases. Data presented as mean of 2 repeats for each group. 
It was also considered that cell number may be affecting the results. Therefore, 
cell number was quantified using the CyQuant system. This way, no significant 
difference was found between the different conditions for each day (Figure 3-14). 
 
Figure 3-14 Cell number quantification of Ellman assay samples for each condition for days 
0, 1, and 5. Data presented as mean of 2 samples. 
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Despite the interference and sample variability, the data show [cOpdA][S] 
persists at the cell membrane for at least 5 days, and that [cOpdA][S] does not affect 
cell numbers during this time, each of which are significant results. 
Accordingly, a different method of quantifying the AChE activity of cells was 
sought out. Holas et al. reviewed the state-of-the-art cholinesterase quantification 
methods in 2012.18 From this review, 1-napthyl acetate (NA) was selected as a 
substrate as it can directly indicate AChE activity via spectrophotometry24 or 
fluorimetry25 and is commercially available. 1-Naphthol, the hydrolysis product of NA, 
has emission peaks at approximately 320 and 460 when excited with 300 nm light 





Figure 3-15 A) Emission spectrum of 1-naphthol, the hydrolysis product of 1-naphthyl acetate. 
B) Timecourse of 155 nM OpdA vs 300 μM 1-naphthyl acetate, excited at 300 nm and 
emission read at 460 nm. 
The AChE activity of SH-SY5Y cells with and/or without [cOpdA][S] and DECP 
was assayed with NA. The turnover rate of [cOpdA][S] for NA was much greater than 
that of the cells (Figure 3-16), although each sample had an approximate lag-time of 
30 minutes. No significant difference was observed between the cells and the cells 




Figure 3-16 AChE activity of SH–SY5Y cells challenged with diethyl chlorophosphate, with 
and without [cOpdA][S], assayed using 1-naphthyl acetate. Error bars represent SEM, n=12. 
ns, no significance; **, P<0.01; ****, P<0.0001. 
The lack of a significant difference in NA turnover rate between the SH-SY5Y 
cells with and without DECP suggests that the amount of AchE present in the samples 
was too low. This may be due to low AChE expression of the SH-SY5Y cells, as 
significance was observed in the rat embryonic neurons. Differentiating the cells into 
a more mature phenotype by supplementing the culture medium with 100 nM retinoic 
acid (RA) or 16 nM 12-O-tetradecanoyl-phorbol-13-acetate (TPA) for 4 days has been 
shown to increase their AChE activity 2- and 12-fold, respectively.26 
3.3.5 Activity at the cell membrane 
Artificial membrane-binding enzymes are novel constructs, and therefore there 
are no established methods for determining their activity. In designing activity assays 
for the constructs, several challenges were identified: determining the concentration 
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of enzyme at the cell surface is complex, the enzymes are immobilised within the 
reaction volume, and cellular components may interact with substrates or products. 
Furthermore, the Michaelis–Menten model of kinetics does not apply to artificial 
membrane-binding enzymes as the enzymes are not freely diffusing in solution, 
counter to assumptions made in its derivation according to the laws of mass action. 
Further complicating the activity at cell surfaces are the culturing conditions of 
the cells. The long-term culturing of cells typically requires the use of a serum 
supplement, such as foetal bovine serum (FBS), containing myriad growth factors 
and other undefined components. However, serum is known to contain AChE and 
BChE; it has been investigated as a potential prophylactic for OP poisoning.27 A 
limitation of this study is that any activity studies on cells require thorough washing 
as any remaining serum will interfere with results. Moreover, membrane-bound AChE 
is shed in response to AChR agonists,28 therefore cells cultured in serum containing 
ACh may have reduced membrane-bound AchE levels, with any released AChE 
washed away. However, AChE is also found intracellularly.23 
In lieu of determining Michaelis–Menten parameters for the constructs, initial 
experiments were designed to qualitatively discern activity of [cOpdA][S] at the cell 
membrane. Colourimetric assays may be affected by light-scattering of cells, 
therefore the use of fluorescent substrates was explored.  
A literature search for commercially-available OP-based pesticides that are 
intrinsically fluorescent found naftalofos, also known as maretin, which has previously 
been used in the study of cholinesterases.29,30 Naftalofos loses its fluorescence upon 
hydrolysis, therefore loss of fluorescence intensity corresponds to its turnover. 
Naftalofos was confirmed to be hydrolysed by OpdA (Figure 3-17). The maximum 
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excitation and emission wavelengths for naftalofos are approximately 355 and 400 
nm, respectively. 
 
Figure 3-17 Hydrolysis of naftalofos by OpdA, measured at 392 nm with 355 nm excitation. 
Conversely, several OP-based substrates with fluorescent leaving groups were 
identified from the literature: coumaphos,4,31 pyrenebutylmethylphosphonofluoridate 
(PBMPF),32,33 and diethylumbelliferyl phosphate (DEUP).34,35 
Coumaphos was initially used to investigate the relationship between cell 
number and OP-turnover with or without [cOpdA][S]. Coumaphos turnover was much 
more rapid in the [cOpdA][S]-primed cells, although the correlation between cell 
number and coumaphos was insignificant in both groups (Figure 3-18). However, this 
experiment also showed that the coumaphos turnover was rapid in the absence of 
cells, indicating that the [cOpdA][S] binds to the plate effectively. Therefore, to 




Figure 3-18 Turnover of coumaphos on a varying number of A) cells and B) cells primed with 
[cOpdA][S]. Error bars represent the SEM, n=6. 
Preliminary imaging experiments with naftalofos used hMSCs, however minimal 
fluorescence was observed at the membrane. Naftalafos was then added to 
adipocytes with greater success; naftalafos is a hydrophobic compound, and 
therefore will sequester into the fatty vacuoles of adipocytes with greater efficiency 
than the less-oily cell membranes. Accordingly, confocal microscopy showed 
naftalofos preferentially labelled fat deposits (Figure 3-19). 
  
Figure 3-19 Adipocyte loaded with naftalofos (blue; left). Brightfield image for reference (grey; 
right). 3D image represented as maximum-intensity z-projection. Scale bar=20 μm. 
Adipocytes challenged with naftalofos before loading with [cOpdA][S] initially 
showed naftalofos labelling the fat deposits, however over time, the fluorescence 
intensity of the adipocytes decreased, suggesting naftalofos hydrolysis; the 
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fluorescence intensity of adipocytes without [cOpdA][S] treatment did not change 
(Figure 3-20). 
 
Figure 3-20 Comparison of fluorescence intensity over time for cells treated with [cOpdA][S] 
(top) and the untreated control (bottom). Cells selected for analysis are shown in the brightfield 
images highlighted with yellow circles (left). Scale bar=50 μm. 
A major limitation of these intrinsically fluorescent OPs is that their peak 
excitation and emission wavelengths are approximately 350 nm, and 400–460 nm, 
respectively. Confocal microscopes typically have lasers operating at wavelengths 
down to only 405 nm, and near-UV lasers may cause cellular stress and death.36 The 
405 nm laser can excite these molecules, but the fluorescence intensity is greatly 
reduced. A fluorescein-based OP, DPPF,37 yields fluorescein upon hydrolysis, which 
is highly-fluorescent, and has peak excitation and emission at 488 nm and 512 nm, 
respectively. DPPF was therefore explored further. Unlike coumaphos, PBMPF and 
DEUP, DPPF was not commercially available; DPPF (Figure 3-21) was therefore 




Figure 3-21 Structure of 3’,6’-bis(diphenylphosphinyl) fluorescein, an OP that becomes 
fluorescent upon hydrolysis. 
The DPPF substrate showed no significant fluorescence in the absence of 
OpdA, but produced highly-fluorescent fluorescein upon hydrolysis. OpdA was also 
shown to hydrolyse DPPF efficiently over time (Figure 3-22). 
 
Figure 3-22 Hydrolysis of 100 μM 3’,6’-bis(diphenylphosphinyl) fluorescein at room 








DPPF has also previously been used as a fluorescent superoxide sensor, and 
was dissolved to 500 μM in DMSO, and used as 10 μM, 2% DMSO on cells.37 DPPF 
prepared this way was applied at a concentration of 1 mM to hMSCs primed with 10 
μM [cOpdA][S], and imaged over the course of 40 minutes (Figure 3-23). Fluorescence 
intensity increased at the surface of cells treated with [cOpdA][S] and not control 
cells, although background fluorescence intensity increased over time too. 
Fluorescein is soluble in water, so it diffuses into solution upon formation; the 
alternative, i.e. a product that does not freely diffuse away from the membrane, would 
not be a fair experiment as the product could be formed distant from cell membranes 
but sequester there. 
 
Figure 3-23 Filmstrip of 3’,6’-bis(diphenylphosphinyl) fluorescein being turned over at the 
surface of a cell painted with [cOpdA][S]. Each frame is approximately 8 minutes. Scale 
bar=50 μm. 
3.4 Conclusion and further work 
Here, the activity of an artificial membrane-binding enzyme has been 
demonstrated at the cell surface for the first time. Using amine-reactive dyes, the 
interaction of the OpdA-based constructs could be visualised through confocal 
fluorescence microscopy. As expected, native OpdA did not bind to membranes and 
was therefore not investigated further. 
cOpdA and [OpdA][E][S] each penetrated cell membranes and disrupted the 
model membranes. Each was also found to be cytotoxic to cells even at low 
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concentrations. Therefore, they were deemed not suitable for functionalising the cell-
surface. However, the improved thermal stability of cOpdA, and the significant 
increase in activity of [OpdA][E][S] over native OpdA warrant further investigation. The 
cytotoxicity of the dual-conjugate system may potentially be mitigated by using 
different surfactants. A systematic variation of head groups and alkane and PEG 
chain lengths of cationic surfactants may yield an optimal composition with minimal 
cytotoxicity, which would lead to a simplified approach to producing artificial 
membrane-binding proteins.  
[cOpdA][S] binds to cell membranes and forms an extramembranous layer 
without permeabilising them. Crucially, [cOpdA][S] was not cytotoxic up to 15 μM. 
[cOpdA][S] was found to persist at the surface of cells for up to 5 days, but it was not 
possible to quantify the protective effects of [cOpdA][S] using spectrophotometric 
methods due to low levels of AChE in the samples and OpdA turning-over 
acetylcholine analogues. Electrophysiological investigation of the cells or the use of 
a calcium-sensitive dyes may be used to determine the protective effects of 
[cOpdA][S] on cell depolarisation associated with neuronal transmission at a single-
cell level. Moreover, force transduction of muscle tissues exposed to OPs, with or 
without [cOpdA][S] priming, may be a simple method of investigating the protective 
effects without using whole-animal models. 
The binding of [cOpdA][S] to cells requires further quantitative investigation as 
BCA analysis was not sufficient to draw conclusions from due to large errors. Beyond 
static conditions, investigation into [cOpdA][S] binding and its activity under flow 
conditions mimicking the shear-stresses of circulation are imperative. If [cOpdA][S] 
demonstrates significant efficacy under flow, then in vivo experiments similar to those 
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performed by Jackson et al4,38 should be performed. Neutron reflectometry may be 
used to investigate the mechanism of the constructs’ interactions with membranes. 
Preliminary data has been collected, and is presented in section 3.4.1. 
Beyond OpdA, and indeed OP-poisoning, other artificial membrane-binding 
enzymes should be explored. While these constructs would not offer the longer-term 
effects of gene or cell therapies, short to medium-term enzyme-based therapeutics 
may be viable. Possible areas to explore would be enzymes involved in metabolism, 
antimicrobial enzymes such as those within the peptidoglycan recognition protein 
class,39 or enzymes that may be used for detection, e.g. firefly luciferase. 
3.4.1 Preliminary neutron reflectometry 
Evidence as to the nature of the interaction between the constructs and cell 
membranes was sought. Armstrong et al,, using eGFP as a model protein, 
demonstrated that membrane association for both the cationised and conjugated 
species was reduced at low temperatures, but only the cationised species was 
affected when the synthesis of the anionic proteoglycans was inhibited using sodium 
perchlorate.12 It was thus hypothesised that the conjugated species interacted with 
the membrane lipids, whereas the cationic species interacted with both the anionic 
proteoglycans and the anionic membrane lipid headgroups.12 To elucidate the 
mechanisms of membrane interactions for each OpdA-based construct, neutron 
reflectometry was used in collaboration with Dr Robert Barker on the INTER beamline 
Isis, Oxford, and the D17 beamline, ILL, Grenoble. Neutron reflectometry can be used 
to probe layers within a sample at nanometer resolution, with data deconvolution 
yielding the thickness, density, roughness, and hydration of each layer. A model 
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membrane comprising a floating bilayer of 3:1 POPC and POPG was produced 
(Figure 3-24) using the Langmuir-trough deposition method.40 This lipid mix 
reproduces the negative potential of cellular membranes, utilising naturally-occurring 
lipids. The lipid monolayer and bilayer are separated by a solvent layer, with entropic 
forces preventing them from colliding.41 
 
Figure 3-24 Schematic of neutron reflectometry model membrane setup. The bilayer, which 
mimics the charge of natural cell membranes, is assembled above a lipid monolayer covalently 
bound to a silicon block. Entropic forces prevent the bilayer contacting the monolayer below. 
Samples were flowed across the top surface of the bilayer. After equilibrating and washing 
the bilayer, the system was analysed using neutron reflectometry, with the beam passing from 
bottom to top, i.e., through silicon block first. 
The samples were loaded at a concentration that was calculated to form a 
monolayer. OpdA has an approximate diameter, d, of 38 Å, therefore the cross-
sectional area (CSA) of each molecule can be calculated using: 





The reciprocal yields the number of OpdA constructs per unit area, and this can 






Given the area of the bilayer, AB, and the volume of the solution above the 





The bilayer has dimensions 50×80 mm, giving an area of 0.004 m2, and the 
volume of the sub-phase above the bilayer is approximately 2.5 ml. Therefore, the 
concentration of the loading solution to form a monolayer of OpdA was calculated to 
be approximately 0.2 μM. 
 The reflectivity of the model membranes changed when 0.2 μM of either 
cOpdA or [cOpdA][S] was applied (Figure 3-25A). Deconvolution of the reflectivity 
data using the RasCal package6 provides scattering length density vs depth 
information. cOpdA caused marked changes in both the bilayer and the monolayer 
beneath, indicating disruption and penetration (Figure 3-25B). Conversely, [cOpdA][S] 




Figure 3-25 Neutron reflectometry of cOpdA and [cOpdA][S] on a model bilayer. A) raw 
reflectivity data of the samples in D2O; unladen bilayers in hollow markers, fits for each overlaid 
in grey. B) scattering length density profile of the cOpdA system. C) scattering length density 
profile of the [cOpdA][S] system. The unladen-bilayer is shown as a dashed line in B and C.  
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cOpdA did not require the presence of transmembrane proteins, or glycocalyx 
to interact with the membrane, and penetrated the bilayer via an ATP-independent 
manner. Armstrong et al. have previously used inhibitor-based assays to show that 
endocytosis of cationised eGFP occurred via clathrin-mediated endocytosis,1 
whereas these data suggest that endocytosis of cationised proteins may also occur 
through passive membrane disruption and subsequent invagination. The high 
positive-charge density at the protein’s surface would interact with the negatively-
charged lipid headgroups, displacing them (Figure 3-26). This membrane disruption 
is likely to cause the significant cytotoxicity observed with cOpdA due to membrane 
permeabilisation. 
 
Figure 3-26 Schematic of membrane invagination by cOpdA. A) cOpdA makes initial contact 
with the bilayer, B) the high positive-charge density pulls on negatively charged lipid 
headgroups, deforming the natural curvature, and C) further deformation leads to rupturing 
of the bilayer. 
[cOpdA][S], however, did not cross the model bilayer. This may be due to the 
surfactants screening the cationic residues, preventing the same degree of lipid 
displacement. At greater concentrations, perhaps that causing cytotoxicity in hMSCs, 
it is probable that greater degrees of bilayer disruption would be observed. Using 
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contrast-matching by deuterating the surfactant, it would be possible to determine 
the orientation of the surfactant components and elucidate the nature of the 
interaction. Experiments varying concentration of the protein may also yield 
information on cooperative binding. 
A caveat of these neutron reflectometry experiments is that the bilayer is grossly 
simplified, and endocytosis may occur through many mechanisms, some of which 
may require the presence of membrane components such as cholesterol and 
transmembrane proteins, or varying localised lipid compositions, and may be ATP-
dependent. 
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4 Towards bioprinting a bacterial microreactor 
4.1 Introduction 
In Chapters 2 and 3, a robust expression system for OpdA was developed and 
the resulting polymer surfactant modified constructs were shown to be active with 
respect to the rapid detoxification of OPs in vitro. In this chapter, the focus is on the 
development of a new methodology where OpdA-expressing E. coli are 3D printed in 
a novel bioink to generate a rudimentary microreactor as a gateway to large scale OP 
detoxification.  
The most common OP exposures are through pesticide use. While many of 
these are deliberate poisonings with suicidal intentions,1 accidental exposures are 
commonplace in rural environments, particularly through pesticide runoff into 
waterways. This not only affects humans through toxifying sources of drinking 
water,2,3 but also has dramatic impacts on aquatic ecosystems.4 Current methods of 
detoxifying water exposed to OP-pesticides include oxidising agents, chemical 
hydrolysis5, UV-exposure,6 or extraction techniques such as activated charcoal 
adsorption.7 These techniques are not suitable for in situ decontamination of OPs in 
waterways. 
Bacterial bioremediation systems are being developed,8 finding applications in 
remediating heavy metal9 and nuclear waste.10 An issue with these systems is the 
requirement of containment to prevent the release of genetically-modified 
organisms.11 To mitigate this risk, enzymes isolated from cells may be purified and 
immobilised. OpdA has been immobilised into non-woven polyester fabric and 
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packed into glass columns for continuous-flow bioremediation of OP pesticides.12 
Purifying enzymes, however, is a time-consuming process, Additionally, if the enzyme 
requires cofactors, they may have to be added to reactant mixtures, whereas whole-
cells may synthesise their own cofactors.13 Here, bioprinting is investigated as a 
method to produce high surface-area, entrapped-cell OP-degrading devices. 
Bioprinting typically involves depositing bioinks comprising one or more 
hydrogels and cells, although there are some bioink-free systems that deposit cells 
directly. Alternatively, stereolithographic techniques crosslink bioinks within a 
reservoir via laser light or a projector.14 
Bioinks are printable materials containing cells, typically based on one or more 
hydrogels: polymeric materials that absorb large amounts of water to form gels.15 
Their high water content makes them permeable to oxygen and nutrient diffusion, 
therefore they are excellent candidates for supporting cells. To be suitable for 
bioprinting, bioinks must be able to maintain their structure during and after the print. 
Therefore, they must have a crosslinking mechanism to hold the components in 
place. Chemical crosslinking strategies can be used to bind components via covalent 
bonds, but they are typically cytotoxic.16 Prior to printing, polymers may be modified 
with reactive groups such as methacrylates to introduce photocrosslinking properties 
when combined with photoinitiators.17 There is, however, concern that photoinitiators 
and UV-light may also have adverse affects on cellular health.18 Some materials may 
be ionically crosslinked, either through electrostatic interaction of oppositely-charged 
molecules19 or chelation of ions.20 Collagen-based materials such as gelatin and 
Matrigel form stiff gels on cooling due to the formation of triple helices.21 Some of the 
poloxamer block-copolymers are thermoresponsive, stiffening at increased 
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temperatures and forming gels, and thinning and resolubilising at decreasing 
temperatures.22 
Sodium alginate (alginate) is a hydrogel commonly used in bioprinting. It is a 
naturally-occurring polysaccharide comprising guluronic and mannuronic acids, and 
is generally harvested from seaweed. It binds divalent cations, typically Ca2+, to form 
stiff crosslinked gels.23 Prior to gelation, alginate solutions are viscous liquids and are 
therefore unsuitable for printing 3D structures independently. Furthermore, alginate 
is a minimally shear-thinning solution,24 and therefore requires large pressures to 
extrude. Alginate is expressed by Pseudomonas aeruginosa, a pathogen causing 
pulmonary infections, and provides protection against many antibiotics.25 E. coli does 
not natively express alginate, instead primarily utilising cellulose and colanic acid in 
the formation of its biofilms.25,26 
F127 is a block copolymer comprising a central polypropylene glycol block 
flanked by polyethylene glycol blocks. It forms reversible gels when exposed to heat, 
but does not form permanent gels unless modified. The temperature of gelation, or 
critical micelle temperature, is dependent on its concentration.27 Over time, heat-
induced F127 gels will diffuse into solution, and it is therefore unsuitable for long-
term culture of cells. F127 is generally used as a sacrificial ink28,29 for this reason, 
however it may be modified to impart crosslinking properties.30,31 
The design of bioinks is a complex process. Bioinks must be extrudable through 
a nozzle and have mechanical properties enabling the layer-by-layer printing of 
complex shapes that are maintained for long periods of time, whilst providing 
sufficient support for growth of the embedded cells. Accordingly, some bioinks 
include additives to modify the properties of the resulting gel. For example, 
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methylcellulose can be added to bioinks to enhance the viscosity,32 or collagen can 
be added for cell adhesion cues.33  
Currently, bioinks are primarily designed to support eukaryotic cells, as 
producing human tissues is the principal driver of the technology. The native 
environment of mammalian cells is highly intricate, with myriad growth factors, 
extracellular matrices, binding sites, and mechanical cues affecting growth. Indeed, 
many mammalian cell types undergo apoptosis in the absence of anchorage to 
extracellular matrix components, a process known as anoikis,34 and multipotent cells 
may be driven down different differentiation pathways by environmental cues.35 
Mammalian cells also require sufficient oxygen to grow, therefore limiting the size of 
tissues without circulation.36  
Conversely, E. coli, as a unicellular organism, does not require as complex 
biological or mechanical cues to survive, and is a facultative anaerobe, therefore 
oxygenation is less important. While apoptosis does occur in bacteria, it is thought 
to be caused by stresses such as oxidation, radiation, nutrient starvation, and phage 
infection,37 and not anchorage dependence. 
Given the relative simplicity of bacterial growth, it was postulated that bioinks 
capable of supporting eukaryotic cells would likely be able to support bacterial cells. 
Previously, a cell-supporting bioink was designed and characterised for bioprinting 
hMSCs to be used in tissue engineering.38 By hijacking this technology to instead 
bioprint OpdA-expressing E. coli, a simple, low cost, persistent OP-degrading device 
can be produced. 
In this chapter, the design of a bioprinter and an OP-degrading bioink are 
described. The bioink is characterised, and OP-degrading bacterial prints are 
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produced. Preliminary characterisation of these prints is carried out, and the future 
work required to further the development of the device is described.  
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4.2 Materials and methods 
4.2.1 Preparative 
4.2.1.1 Bioink preparation 
Initially, the bioink was prepared by mixing two stock solutions: 10% sodium 
alginate was prepared in DMEM by using an overhead mixer; 40% Pluronic F127 was 
prepared in the appropriate media, autoclaved, and left to cool. These stocks were 
then combined to give final concentrations 6% (W/V) sodium alginate and 13% (W/V) 
Pluronic F127, stirred gently and UV-sterilised in a HeraSafe 2020 Class II biological 
safety cabinet (Thermo Scientific) for 1 hour prior to use. 150 μL of concentrated 
hMSCs were added when required. 
Later preparations of bioink were prepared using a SpeedMixer DAC 150.1 FVZ 
dual asymmetric centrifuge (Synergy Devices, UK). The superior mixing ability of this 
technology allowed the direct mixing of sodium alginate and Pluronic F127 without 
the need of stock solutions: a solution of 6% (W/V) sodium alginate and 13% (W/V) 
Pluronic F127 was prepared directly in the appropriate media, and spun at 3500 rpm 
until fully dissolved. The resulting mixture was then UV-sterilised prior to use. When 
printing bacteria, the bioink components were dissolved in terrific broth containing 
1% (V/V) bacterial culture grown to stationary phase. 
4.2.1.2 Bioprinting 
3D models prepared for printing were processed into 2D slices using Slic3r or 
Matter Control software, producing G-code files that instruct the movements of the 
printers. Alternatively, G-code was produced directly using Python scripts. 
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Prior to printing, the bed was heated to 37°C to ensure the sol–gel transition of 
the Pluronic F127 component. 5 mL syringes were loaded with bioink, and fitted with 
either a pipette tip or flat-tip needle of known inner diameter. The syringes were then 
inserted into a direct-extrusion system, mounted on either a Mendel Max v2 or v3 
(Makers Tool Works, US). Immediately after completion, the printed constructs were 
bathed in 100 mM CaCl2 in PBS for 10 minutes at room temperature to cross-link the 
alginate and drive the efflux of the Pluronic F127. The prints were then incubated in 
media supplemented with 5 mM CaCl2 until further use. 
4.2.2 Analytical 
4.2.2.1 Calcium uptake and leaching 
The concentration of Ca2+ in the media of square prints was measured using a 
Ca2+ ion-selective probe (VWR). A square-print was bathed in DMEM, and the change 
in voltage measured by the ion probe over time. The readings were compared against 
a standard curve to determine the concentration of Ca2+. For uptake experiments, an 
uncrosslinked square-print was bathed in DMEM supplemented with 100 mM CaCl2. 
For leaching experiments, a crosslinked square-print was bathed in unsupplemented 
DMEM. 
4.2.2.2 Scanning electron microscopy 
Theory 
Using a beam of focused electrons, images with a resolution at the nanometre 
scale may be produced. The electron beam scans across the surface of the sample, 
and interacts with the electron clouds of atoms. Secondary electrons are emitted 
from the sample after excitation by the beam, with the emission intensity relating to 
216 
 
the topography of the sample. The emission intensity is measured by a detector, and 
the intensity as a function of beam position is reconstituted into an image. 
Method 
Scanning electron microscopy was performed by Dr Madeline Burke. Bioink 
samples were dehydrated by immersion in 70%, 80%, 90% and 100% (V/V) ethanol 
for 15 minutes each, before being dried in a critical point drier. They were then 
mounted onto SEM stubs, and sputter coated with silver using a High Resolution 
Sputter Coater (Agar Scientific, UK). Imaging was performed on a JSM IT300 
Scanning Electron Microscope (Jeol, Japan). Subsequent analysis was performed 
using FIJI software.39 
4.2.2.3 3D cell viability 
The viability of bioprinted hMSCs was assessed using confocal fluorescence 
microscopy with the live–dead stains acetoxymethyl calcein and ethidium 
homodimer, respectively. The stains were added to the bioprinted constructs’ media 
30 minutes before imaging. Confocal imaging was used to capture Z-stacks so that 
cells could be imaged through the layers. Percentage cell viability was calculated 
from the number of live cells divided by the total number of cells, i.e. live and dead 
cells. Cells plated in 2D were used as controls. Each time point is a separate sample 
so as to avoid effects of repeated use. 
4.2.2.4 Bacterial device activity 
To qualitatively determine activity of the OpdA-expressing E. coli encapsulated 
in the bioink, a 200 μM solution of coumaphos (1% isopropanol) was added to the 
devices in a 6-well plate. A Synergy Neo 2 plate reader (BioTek) was used to read the 
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resulting fluorescence over time. The samples were excited with 355±5 nm light, with 





4.3.1 Bioprinter design 
In producing a printable, bacteria-based system for degrading OPs, there are a 
number of design constraints: the printing procedure and printed structure must 
support the cells, the final structure must be durable enough to be handled, and 
structures of centimetre scale must be printable with millimetre accuracy. 
Furthermore, a system capable of printing these devices should ideally be relatively 
low cost and simple to maintain so that they can be used in the rural communities 
where OP-exposure is most common. 
A commercially available extrusion-type 3D printer, the MendelMax 2, was 
selected as a base for the initial design, and was later upgraded to the MendelMax 3. 
The MendelMax printers are Cartesian-type printers, meaning they operate with three 
independently driven axes: X, Y, and Z. They have a glass bed that may be heated 
via a heating resistor, which enhances the adhesion of plastic prints, but conveniently 
enables the incubation of cells at 37°C while the structure is being printed. They are 
designed to print with plastic filaments such as polylactic acid and acrylonitrile 
butadiene styrene, which require melting at around 200°C to print. As bioinks are not 
compatible with the printers’ original mechanism, the printers were modified. The 
MendelMax printers, and indeed almost any extrusion printer, can print the 
components required to convert them into bioprinters; only a few additional 
components are required, such as nuts, bolts, leadscrews and motors, although 
these can be recycled from the base printer.  
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The printers were retrofitted with printed syringe drivers to enable the printing 
of hydrogels. Using syringe drivers allows the use of disposable sterile syringes. 
Dedicated bioprinting systems, such as the Allevi 1 (Allevi)40 or BioX (CellInk)41 
bioprinters, use pneumatic pressure to drive extrusion from cartridges, but these 
systems are difficult to calibrate to get accurate bioink flow, require an air 
compressor, and do not integrate well with typical 3D printing firmware. 
The first design used an open-source syringe-driven extrusion system designed 
by Richard Horne (Figure 4-1A).42 The syringe is driven by a belt that is in turn driven 
by a gears powered by a stepper motor. However, this system suffered from poor 
volume accuracy due to play in the belt driver, and was limited to a single syringe due 
to its width. An improved syringe-driver extrusion system was designed by Thomas 
Richardson, University of Bristol (Figure 4-1B). The system utilises stepper motors 
coupled to leadscrews that are in turn screwed into the ‘pushers’. As the motors turn, 
the pushers depress the syringes’ plungers. This extrusion system enabled the 
printing of two materials simultaneously, which may be two different hydrogels, a cell-
laden and cell-free hydrogel, or a permanent hydrogel and a sacrificial scaffolding 
component. Each system was mounted directly on the X-axis of the printer so that 
material could be extruded directly out of a disposable syringe. It would have also 
been possible to unmount the drivers and have the material driven through a tube to 
the to reduce the amount of mass on the actuated axis and therefore inertial effects, 
but this would introduce a large dead-volume, which would be troublesome when 




Figure 4-1 The two extrusion systems used. A) the belt-driven system designed by Richard 
Horne,42 with the position of the syringe highlighted, mounted on a MendelMax 2. B) the 
leadscrew-driven system designed by Thomas Richardson, mounted on a MendelMax 3. 
Image taken by Thomas Richardson.  
Both Horne and Richardson’s systems integrate seamlessly with generic 3D 
printing firmware and software. Most 3D printers use G-code, a type of machine-





Figure 4-2 An excerpt of G-code describing steps for the bioprinter to complete. The axes 
are described as X (left to right), Y (forward and back), Z (up and down), and E (extrusion). 
Each step begins with ‘G’ and a number, followed by a set of parameter. For example, ‘G1 
X112.0 Y150.0 Z0.771’ instructs the printer to move the printhead to the given coordinates. 
A repository of all G-code commands is available online at http://reprap.org/wiki/G-code. 
In G-code, each extrusion step is described as the length of filament that is 
pushed through the nozzle. In the syringe-driven system, this equates to the distance 
the plunger is depressed. As each motor step is a known angle, and the thread size 
of the belt or leadscrews are known, the downwards translation of the syringe 
plungers was calculated, and subsequently converted into the volume of material 
extruded. A stepper motor of step size 1.8° was used, and the 3D printer’s 
motherboard had microstepping capabilities of 1/16th. Therefore, a single microstep 
equates to 0.1125°. Using a leadscrew of pitch 2 mm, a microstep caused 0.625 μm 
of displacement, therefore 1600 microsteps were required per millimetre. The volume 
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of material extruded from a syringe was calculated as the volume of a cylinder, where 
the radius is the internal radius of the syringe, and the height is the distance the 
plunger is displaced. For a 5 mL syringe with internal diameter 13.5 mm, the extruded 
volume per microstep was theoretically 90 nl. While this is mathematically correct, 
this estimate is weak at low volumes; at larger scales, the calculation becomes more 
accurate. 
The assembled syringe-driver systems were calibrated by using G-code to 
move the syringe-plunger a given distance, measuring any errors, and adjusting the 
firmware where necessary. With the 3D printer converted into a syringe-driven 
bioprinter, the process of designing the bioink began. 
4.3.2 Bioink design 
Alginate and F127 were selected for investigation. This combination provides 
the permanency of the structure via the ionic crosslinking of alginate, with the 
stiffness required for printing through the thermal gelation of F127. No additives were 
used. 
A range of alginate:F127 ratios were tested for printability, using hollow square 
test prints (Figure 4-3). The hollow squares are a non-equilibrium shape, meaning that 
they will deform over time in the absence sufficient stiffness, and so serve a 
diagnostic function. Below 11% (W/V) F127, the gels did not stiffen enough upon 
thermogelation to support the growing structure, and below 5% (W/V) alginate, the 
gels were too thin when combined with F127. Above 6% (W/V) alginate, the solutions 
were too viscous to be printable. 12–14% (W/V) F127 yielded good structural fidelity, 
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although 12% lacked stiffness. Therefore, 6% (W/V) alginate – 13% (W/V) F127 was 
selected as the optimal composition.  
 
Figure 4-3 Images of prints with varying compositions of alginate and Pluronic F127 in the 
bioink. The photographs were taken immediately after printing, pre-crosslinking. Prints were 




With a printable bioink composition found, the alginate crosslinking conditions 
were optimised. Alginate can be crosslinked via many different divalent cations, such 
as Pb2+, Cd2+, Ba2+, Ca2+, Sr2+, Mg2+, Co2+ and Zn2+. Ca2+ has lower affinity than Pb2+, 
Cd2+ and Ba2+,20 however Ca2+ salts are safest to work with. The source of Ca2+ also 
affects alginate gelation. The solubility of calcium salts is highly variable, and can 
therefore be exploited: calcium carbonate is essentially insoluble at physiologic pH, 
but can be combined with D-glucono-δ-lactone to induce slow crosslinking,23 or a 
photoacid generator for stereolithography;43 calcium sulfate is more soluble, induces 
rapid crosslinking, and can be combined with calcium carbonate to tune gelation 
times; calcium chloride is extremely soluble and gelates alginate very rapidly.23 
Furthermore, photolabile calcium-cages can be used for stereolithography, or simply 
homogenous crosslinking.44 CaCl2 was selected as the Ca2+ source to rapidly gelate 
the constructs so as to minimise exposure of cells to osmotic stresses that may lead 
to reduced viability. 
The uptake of calcium by an uncrosslinked construct was analysed using a Ca2+ 
-selective probe (Figure 4-4). Over the course of 10 minutes, approximately 130 μmol 
of Ca2+ was bound by the construct, and another 13 μmol over the following 20 
minutes. Therefore, 90% of the crosslinking was complete within 10 minutes of 100 
mM CaCl2 bathing. Consequently, this was deemed as sufficient crosslinking time. 
Crosslinking for longer times may increase the stiffness of gels, but also increases 




Figure 4-4 Calcium sequestration by square prints in 5 mL of 100 mM calcium chloride over 
time.  
The leaching of Ca2+ from a crosslinked construct was similarly measured with 
the ion-selective probe (Figure 4-5). Approximately 6 μmol of Ca2+ (1.2 mM in a 5 mL 
solution) leached out of the construct within 4 hours, before stabilising. This 
corresponds to approximately 4% of the Ca2+ found to be chelated in the prior 
experiment. 
 
Figure 4-5 Leaching of calcium ions from a crosslinked square-print construct over time. 
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Kuo et al. suggested that the media of an alginate gel should contain millimolar 
concentrations of Ca2+ to maintain the dimensions and mechanical properties of the 
gels.45 Therefore, square prints were bathed in varying concentrations of CaCl2 to 
determine the optimal concentration for maintaining their dimensions (Figure 4-6). 
From the images, it was clear that 5 mM CaCl2 was the optimal concentration for the 
long-term exposure of the constructs to aqueous media. 
 
Figure 4-6 Photographs showing the effect of the CaCl2 concentration of the long-term 
bathing solution for the bioprinted structures over 10 days. 
From these data, the final bioink preparation was decided: a mixture of 6% (W/V) 
alginate and 13% (W/V) F127, crosslinked for 10 minutes in 100 mM CaCl2, washed, 
then bathed in 5 mM CaCl2 until further use. With this set, the bioink was 
characterised. 
4.3.3 Bioink characterisation 
The bioink was designed to have two gelation mechanisms: thermal gelation of 
the F127 to stiffen the gel while printing, and crosslinking of the alginate to maintain 
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the structure. As F127 does not have a crosslinking mechanism, it was hypothesised 
that it may leach out of the gel over time, leaving an alginate-only gel (Figure 4-7). 
 
Figure 4-7 Schematic of proposed bioink gelation mechanism and F127 expulsion. A) Pre-gel 
mixture of alginate and F127; B) Heat-induced micellarisation of F127 to form gel; C) 
Crosslinking of alginate via Ca2+ binding. Green, alginate chains; blue and red, F127; red 
circles, Ca2+ ions. Adapted from Armstrong et al.38 
To investigate, Fourier-transform infrared spectroscopy was performed on the 
bioink, pre- and post-crosslinking (A), and compared against reference spectra for 
each component (B). While the pre-crosslinking sample spectrum had features from 
each component, the post-crosslinking sample spectrum closely resembled the 
alginate-only sample. This showed that the F127 had leached out of the gel during 




Figure 4-8 Fourier-transform infrared spectra of A) uncrosslinked bioink (green) and 
crosslinked bioink (purple), and B) alginate (red) and F127 (blue) separately. As the 
crosslinked-bioink spectrum closely resembles the alginate-only spectrum, it shows that the 
F127 is expelled from the bioink during the crosslinking process. Adapted from Armstrong et 
al.38 
As F127 gelates through micellarisation, its expulsion from the crosslinked 
bioink was hypothesised to impart features in the resulting structure. To examine this 
process, scanning electron microscopy was used. The crosslinked bioink had 
approximately 8-fold larger pores than the crosslinked alginate-only gel (6.4±0.6 μm 
vs 0.76±0.01 μm, respectively; Figure 4-9A–C). When the bioink was crosslinked 
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unidirectionally by carefully applying the CaCl2 solution only to the top of the bioink, 
the pores aligned (Figure 4-9D). These pores and microchannels enhance nutrient 
flow,46 and may therefore be exploited for OP diffusion. 
 
Figure 4-9 Representative scanning electron micrographs of A) crosslinked bioink, B) 
crosslinked alginate, and C) the mean pore diameters from image analysis of each (n=50). D) 
When the bioink was crosslinked unidirectionally, the pores aligned. Adapted from Armstrong 
et al.38 
Experiments were performed to investigate the resolution limits of this bioink 
composition. Alginate was dyed with the fluorescent tag rhodamine isothiocyanate 
so that widefield microscopy could be used. This dyed alginate was then printed in a 
line through a 500 μm tip (Figure 4-10A), and a 159 μm needle (Figure 4-10B), and 
the results compared. The alginate fibres showed anisotropy when printed through 
the finer needle, showing shear alignment. Finally, a crosshatch motif was printed 
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through a 260 μm needle to demonstrate the printability of fine structures (Figure 
4-10C). 
 
Figure 4-10 Resolution tests of 6% (W/V) alginate, 13% (W/V) F127 bioink dyed with 
rhodamine and imaged with widefield microscopy. A) Line printed with a 500 μm tip. B) Line 
printed through a 159 μm needle, with a higher magnification image inset showing shear 
alignment of the alginate fibres. C) Crosshatch pattern printed through a 260 μm needle to 
demonstrate the printability of fine structures.  
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Whilst the bioink has been shown to print well, its ability to support cells must 
be investigated. In tandem research, the viability of bioprinted hMSCs within the ink 
was assessed over 7 days using live/dead fluorescent stains and confocal 
microscopy. The hMSCs retained an average of over 80% viability over the entire 
time course, with no downward trend (Figure 4-11). 
 
Figure 4-11 Cell viability of hMSCs in the bioink over 7 days. Representative confocal 
fluorescence micrographs (Z-projections) of days 0-4 and 7, A–E and F, respectively. G) Cell 
viability over time, n=5 for each.  
Whole square-prints were also stained with live/dead fluorescent stains and 
imaged with widefield microscopy over 10 days (Figure 4-12). The cells were well 
distributed throughout, with no evidence of central cell necrosis resulting from 




Figure 4-12 Square prints stained with live (top) and dead (bottom) stains and imaged with 
widefield microscopy. Each image is a composite of multiple smaller images. No data are 
presented for day 0 and day 2 dead stains as there were too few dead cells to create a 
composite image. Each square has approximate dimensions 10×10×2.4 mm, with each side 
being approximately 1.6 mm thick. 
With the acellular bioink characterisation showing high fidelity, microporous 
prints are possible, and the tandem research showing the bioink supports the growth 
of hMSCs, the bioink was investigated for its ability to support bacterial growth and 
subsequently degrading OPs.  
4.3.4 Bacterial bioprinted device 
With the success of the bioink using hMSCs, the bioink was investigated for its 
potential to support bacterial growth. As a preliminary test, an E. coli-laden gel was 
printed into the test square. Using a solution of E. coli grown to stationary phase to 
dissolve the gel components lead to thinning of the bioink and frequent blockages of 
the 500 μm print-nozzle. Therefore, a 1% (V/V) solution of this bacterial culture with 
TB media was used, which could be printed successfully. Using a 1% bacterial 
233 
 
solution, the resulting structures printed accurately, and when crosslinked were 
robust enough to be handled with tweezers (Figure 4-13). 
 
Figure 4-13 The crosslinked E. coli-laden square prints were stiff enough to handle with 
tweezers. The gel comprised 6% (W/V) alginate and 13% (W/V) F127, dissolved in a 1% (V/V) 
solution of E. coli grown to stationary phase. This was subsequently crosslinked in 100 mM 
CaCl2 for 10 minutes, washed with PBS and bathed in 5 mM CaCl2 overnight, then tested for 
robustness. 
To expand on this and demonstrate the ability to 3D print the more complex 
structures required for microreactor devices, a test-macro/microfluidic device was 
designed. A cylinder of diameter 36.8 mm and height 5 mm was used as the base. 
Then, a sine wave with circular width with a 1 mm channel was subtracted from the 
cylinder. This produced a model that requires structural fidelity to maintain the 
channel, and fits into a 6-well plate for convenience in testing. The model was printed 
and crosslinked, then fluorescein was loaded into the channel immediately before 






Figure 4-14 Mock-microfluidic device for bacterial bioink testing. A) Top-down view of the 
model; B) Side-on view of the model; C) The device being printed; D) the final construct with 
fluorescein as a contrast agent. Hue modified for clarity. 
To confirm the presence and retention of cells in the gel, printed and crosslinked 
hollow-squares were analysed with 0.002% (W/V) resazurin solution. The unwashed 
E. coli-laden gels changed from blue to red within 30 minutes, whereas the acellular 
control gels stayed blue (Figure 4-15A,B). The gels were then washed in PBS three 
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times to remove non-encapsulated cells, before application of resazurin. These gels 
exhibited a less intense colour change (Figure 4-15C,D). This indicated that some E. 
coli were bound within the gels, although many were washed away. 
 
Figure 4-15 E. coli-laden gels treated with resazurin and incubated for 30 minutes. Well 1, 
empty control; well 2, eGFP-expressing E. coli-laden gel; well 3, OpdA-expressing E. coli-
laden gel. A,C) full colour images of A) unwashed and C) washed samples. B,D) red channels 
of B) unwashed and D) washed samples. 
The bacterial bioink was then subjected to confocal fluorescence microscopy 
to show the distribution of bacteria. An eGFP-expressing E. coli-laden bioink was 
prepared for simple visualisation of bacterial colonies and compared against a 
bacteria-free bioink. The bioink was printed into hollow squares, crosslinked and 
bathed in CaCl2, and imaged immediately. The bacteria were well dispersed, and 
effectively suspended in the printed structure (Figure 4-16). E. coli is known to bind 
alginate via FLiC, a flagellin,47 therefore the cells are not expected to diffuse out of the 
gel. Furthermore, there appeared to be several clumps comprising colonies of 
bacteria. From this single time-point, it is not possible to discern whether these 




Figure 4-16 3D-projected confocal micrographs of sections of printed devices. A) GFP-
expressing E. coli laden bioink; B) bacteria-free control. Each ‘x’ mark represents 100 μm. 
 The devices were tested for activity to confirm that intracellular-OpdA still had 
OP-hydrolysing capabilities. As absorbance assays are not suitable for 3D gels due 
to light scattering, coumaphos, a fluorescent substrate was used and read from the 
top using a fluorescence spectrophotometer. Coumaphos has been used to screen 
agar plates for phosphotriesterase activity in colonies for identifying OP-hydrolysing 
bacteria,48 therefore coumaphos was used to probe the activity of the E. coli 
embedded in the bioink. One day post-printing, coumaphos was applied to the 
devices in a 6-well plate. Crucially, the OpdA-expressing bioink exhibited significant 




Figure 4-17 Activity of OpdA-expressing E. coli in bioink vs an empty control. Bioprinted 
devices were plated in a 6 well plate and assayed for activity using 200 μM coumaphos, a 
fluorescent OP. *, P<0.05; n=3 for each. 
This preliminary work shows that the bioink initially developed for printing 
hMSCs for tissue engineering can be readily adapted for printing E. coli. As OPs are 
small lipophilic molecules, which penetrate cell membranes,49 the cells are able to 
degrade OPs through intracellular OpdA expression.  
4.4 Conclusions and further work 
Here, preliminary work towards the bioprinting of bacteria-based devices with 
enzymatic activity has been presented. The selection and design of the bioprinting 
system was described. A hybrid bioink was designed and characterised. The bioink’s 
ability to support cells was first investigated with hMSCs, with subsequent 
characterisation using OpdA-expressing E. coli. Finally, OP-degrading structures 
were printed, and were assayed for cellular distribution and activity. 
The bioprinter used in this study was a 3D printer retrofitted with a syringe driver, 
with most of the components printed on the printer itself. The total cost of producing 
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the bioprinter was approximately £1200, with most of the cost being from the base 
3D printer. This simple design is also highly accessible and easy to use. An 
environmental chamber may be added to enhance temperature diffusion through the 
structures as they print, and provide humidity to prevent the printed structures drying 
out. 
The design of the bioink comprised selection of appropriate components, and 
subsequent testing of different compositions using a diagnostic hollow-square print 
to investigate the printability. A combination of 6% (W/V) alginate and 13% (W/V) 
F127 was found to be optimal, and when crosslinked and incubated with CaCl2, 
remained stable for up to 35 days. This optimal composition was then tested with 
hMSCs, before the process was adapted for use with E. coli. In each case, the bioink 
had no apparent deleterious effects on the cells, and crucially, the OpdA-expressing 
E. coli bioprinted structures were capable of hydrolysing coumaphos, an OP. 
With optimisation, the concentration of bacteria in the ink could likely be 
increased, however the rapid growth of bacteria makes high-concentration bacterial 
printing unnecessary. Alternatively, a cell-free print could be inoculated post-printing, 
but this would likely lead to poor cell distribution. 
The long-term behaviour of bacteria within the bioink should be investigated. 
Using microscopy over time would provide information on the mobility of the bacteria, 
as well as their proliferation rates. It is also important to confirm that the bacteria 
remain encapsulated in the gels, and do not simply diffuse out. The formation of a 
biofilm may aid in the entrapment of bacteria; the addition of quorum-sensing factors 
known to enhance biofilm formation,50 or the use of preconditioned media could be 
explored.51 Furthermore, it is known that some bacteria express alginate lyases 
239 
 
capable of degrading the crosslinked gel;52 while no alginate lyases have been 
discovered in E. coli, it is pertinent to ensure no similar alginate-degradation 
pathways break down the devices over time. 
Moreover, the selection of bacterial organism should be considered. The device 
described in this chapter uses OpdA-expressing E. coli that would be considered 
genetically-modified organisms by regulatory bodies. Releasing genetically modified 
organisms into the wild is heavily regulated. Therefore, if this technology were to be 
developed for real-world use, using an isolated bacterial strain with known OP-
hydrolysing activity should be investigated to incur less regulatory burden.  
Beyond OP-degradation, the scope of bioprinted bacterial devices should be 
explored. In the field of synthetic biology, gene circuits have been designed that aim 
to recreate computational circuits, however, no integrated biological circuit boards 
built up of various bacterial strains spatially-distributed in two- or three-dimensions 
have been produced. A device comprising bacterial strains expressing different 
enzymes printed in sequence along a fluidic channel could take an input and produce 
a cascade of outputs, for example. 
Bioprinting bacteria may be combined with other 3D printing techniques for 
automating assays. For example, Cronin et al. have produced a 3D printing platform 
that prints a plate in plastic and fills it with agar for testing antibiotic resistance of 
bacteria.53 
A cell-free system should also be investigated. The principal reason for not using 
stereolithography is the inherent cytotoxicity of the technique, and this can be 
mitigated by either embedding purified protein into the matrix, perhaps by 
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5 Concluding remarks 
The overarching aim of this research project was to produce novel artificial 
membrane-binding constructs for the detoxification of OPs that address the 
persistence of in vivo enzyme-based therapies, and to investigate bioprinting and 
bioink technology for the production of bacteria-laden microreactor devices for the 
ex vivo detoxification of OPs in water bodies. 
 OP poisoning is thought to affect 3 million people per year, and military use of 
OPs has recently increased in frequency. However, current treatment regimens 
primarily support the symptoms of the resulting cholinergic crises, but do not actively 
detoxify the systemic OPs, which sequester into fat tissue and may cause toxicity for 
weeks. Enzyme therapies for OP poisoning suffer from short systemic circulation, 
with half-lives of less than 1 hour. A new class of modified proteins known as artificial 
membrane-binding proteins, in which an amphiphilic surfactant corona is 
electrostatically grafted to the protein surface, may increase the half-life of enzymes 
through the surfactant corona spontaneously inserting the lipid component into the 
plasma membrane of cells, anchoring them to the surface. 
In this project, the synthesis of the first artificial membrane-binding enzyme is 
described, based on the OP-degrading enzyme, OpdA, from Agrobacterium 
tumefaciens. The modification process originally described by Armstrong et al., 
comprising cationisation of the enzyme, in which the acidic residues are covalently 
modified with a small diamine, and electrostatic engraftment of the amphiphilic 
surfactant, is shown to have no deleterious effects on the enzyme secondary, tertiary, 
and quaternary structures, increases its thermostability, and surprisingly increases 
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the hydrolytic efficiency. This system was found to be non-cytotoxic, and remained 
functional at the cell surface. MD analysis of the construct also showed dynamic 
rearrangement of the surfactant corona in H2O and acetonitrile solvents. 
Two new approaches to the production of artificial membrane-binding proteins 
were also explored: genetic supercharging of the protein, and dual-surfactant 
conjugation, each mitigating the need for the cationisation step. The genetic 
supercharging approach, with the residues chosen for modification selected by 
proteomic analysis of the chemically-cationised protein, was hampered by insolubility 
of the protein, but may still yield a functioning supercharged OpdA with further 
optimisation work. The dual-surfactant conjugated system was simpler than the 
original method, requiring only the sequential addition of cationic and anionic 
surfactants. This system also had no deleterious effects on protein structure, and 
yielded modest increases in turnover rate, however it was too cytotoxic for use. 
Optimisation of the cationic surfactant may potentially decrease the cytotoxicity. 
Finally, the bioprinting of a bacteria-laden bioink to produce microreactors for 
the detoxification of environmental OPs was investigated. A 3D printer was retrofitted 
with a syringe-driver system, and calibrated for use. Subsequently, a bioink was 
designed and characterised in tandem research with tissue engineering studies with 
hMSCs. A hybrid bioink comprising alginate and F127 was optimised for printability 
and characterised. It was shown to support cellular life over extended periods of time. 
FTIR showed that the F127 component was fugitive, and SEM imaging showed a 
microporous structure, which is beneficial for diffusion of small compounds through 
the structure. A proof-of-concept mock microfluidic device laden with OpdA-
expressing E. coli was printed with the developed bioink. The E. coli were well 
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distributed throughout the constructs, and were able to degrade coumaphos, an OP 
with a fluorescent leaving group. 
To further develop the ideas presented in this thesis, the use of different 
enzymes should be investigated, such as mutants with enhanced catalytic activity, or 
enzymes or mutants that do not hydrolyse ACh and its analogues. The constructs 
should be tested against live nerve agents, such as sarin and VX, as well as commonly 
used pesticides, such as malathion and parathion, to ensure activity beyond the 
substrates tested in this thesis. Furthermore, the artificial membrane-binding 
constructs should be investigated in vivo to test the efficacy of OP degradation in the 
body, as well as to test the safety aspects, such as immunogenicity. 
For the artificial membrane-binding constructs to be clinically useful, their 
production must be suitable for scale-up. The two novel approaches to producing 
these constructs described in this thesis are theoretically more amenable to scale-
up, requiring only the engraftment of surfactants, however each approach needs 
further development. The recombinant-supercharging approach did not yield folded 
protein, but could be modified to produce a library of mutants based on combinations 
of the modified residues, rather than including all of the high-confidence sites, and 
processed using high-throughput screening methods to find folded and active 
mutants rapidly. The dual-surfactant conjugation method was too cytotoxic for use, 
but may be enhanced by exploring the use of different cationic surfactants. 
Cytotoxicity screens of a range of cationic surfactants may yield one that is 
sufficiently non-toxic for use. 
Regarding the bacteria-laden bioprinted microreactors, there are several 
aspects that should be investigated in further work: the behaviour of bacteria 
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encapsulated within the gel, the gel composition, the design of the microreactor 
architecture, and cell and/or enzyme choice. Investigation into the behaviour of the 
encapsulated bacteria over time may be performed using fluorescence microscopy, 
either by exploiting the autofluorescence of bacteria, or by using bacteria transformed 
with a fluorescent-protein gene. If the bacteria are seen to escape from the gel, the 
composition of the bioink may have to be adjusted, either to reduce the pore size to 
limit mobility, or to introduce adhesion factors that the bacteria will bind to. 
The microreactor in this thesis was designed to challenge the printability of the 
bioink into a high surface-area model, whilst being able to fit into a 6-well plate format 
for activity screening. For real-world applications, the design would likely be 
incorporated into a pipe or guttering system to detoxify pesticide run-off from fields, 
and this will necessitate considerations into flow rates. A more realistic design would 
likely be elongated to sufficiently degrade OPs without slowing wastewater flow. 
The enzyme and cell-type used may be further optimised. OpdA expressed in 
E. coli was selected for use in this thesis due to its high-activity in vitro, post-
purification, but it may not be the most suitable for whole-cell in situ OP degradation. 
Co-expressing OpdA with an OP-transporter protein to enhance substrate diffusion 
across the membrane may yield improvements in activity. Alternatively, inserting an 
export tag into the OpdA sequence would allow OP degradation to occur outside the 
cell. Using naturally-occurring OP-degrading bacteria would mitigate the regulatory 






6.1 Protein sequences 















6.2 DNA sequences 
6.2.1 scOpdA gene 
Overlapping ends are underlined, fragment primers are highlighted yellow, the 























6.2.2 Forward fragment primer 
TAACTTTAAGAAGGAGATATACATATGCACCATCACCATCACCATAGCATGGCACGTCCGAT
TGGCACCG 




6.2.4 Forward vector primer 
CCGACCGTGCGTGCAAGCTAAGAATTCGAGCTCCCGGGTACCATG 
6.2.5 Reverse vector primer 
ATGGTGATGGTGATGGTGCATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTC 
6.3 Python scripts 
6.3.1 Uniprot scraper for supercharged proteins 












#Function to calculate the mass of a given sequence 
def getmass(seq): 
    mass=0 
    for aa in seq: 
        mass+=aas[aa] 
    return(mass) 
 
#Function to calculate the net charge of a given sequence 
def getcharge(seq): 
    pos=0 
    neg=0 
    for aa in seq: 
        if aa == 'D' or aa == 'E': 
            neg+=1 
        if aa == 'K' or aa == 'R' : 
            pos+=1 
        if aa == 'H': 
            pos+=0.5 
    return(pos-neg) 
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#Function to find any sequences with hexahistidine tags 
def getHis(seq): 
    if 'HHHHHH' in seq: 
        return(True) 
 
#Function that parses the Uniprot database line-by-line and 
pulls out the Uniprot ID, the organism the data relates to, any 
related protein databank records, any reactions the protein is 
involved with, and the sequence of the protein. It is also set 
up to display the pdb records of proteins similar to scOpdA. 
def parser(file): 
    block=[] 
    lines=(row for row in file) 
    i=0 
    pdb='' 
    lastpdb='x' 
    rx='' 
    while lines: 
        #if i % 100 == 0: 
           # print(i) 
        line=next(lines) 
        check=line.split()[0] 
        while check!='//': 
            if check=='ID': 
                idno=line.split()[1] 
            if check=='OS': 
                organism=line.split()[1:] 
            if check == 'DR' and 'PDB;' in line: 
                pdb=line.split()[2:4] 
            if check == 'RX': 
                rx=line.split()[1:] 
            if check=='SQ': 
                sq='' 
                line=next(lines) 
                while check!='//': 
                    sq+=line.strip().replace(' ','') 
                    line=next(lines) 
                    check=line.split()[0] 
            else: 
                line=next(lines) 
                check=line.split()[0] 
        else: 
            if rx and pdb and 25<getcharge(sq)<35 and 
35000<getmass(sq)<40000: 
                if pdb==lastpdb: 
                    pass 
                else: 
                    print(pdb,getcharge(sq),getmass(sq)) 
                    lastpdb=pdb 
            block.append([getmass(sq)])             
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block.append([idno,organism,sq,pdb,rx,getmass(sq),getcharge(sq
)]) 
            i+=1 
    return(block) 
 
#This downloads the Uniprot trembl database and loads it into 




_trembl.dat.gz'),'rt') as data: 
    chunk=parser(data) 
    print(chunk) 
6.3.2 Interatom distance calculator for MD 
#This imports the required plotting libraries 




#This calculates the distance between two coordinates using 
Pythagoras’ theorem 
def dist(c1,c2): 
    c1=[float(i) for i in c1] 
    c2=[float(i) for i in c2] 
    return((c1[0]-c2[0])**2+(c1[1]-c2[1])**2+(c1[2]-
c2[2])**2)**0.5 
 
#This opens the .pdb file of the simulation line-by-line, and 
records the coordinates of every surfactant coordinate by frame. 
with open('aqfinalmdfixed.pdb','r') as pdb: 
    lines=(row for row in pdb) 
    frame=0 
    frames=[] 
    coords=[] 
    while lines: 
        line=next(lines,None) 
        if line==None: 
            break 
        split=line.split() 
        if split[3]=='LIG': 
            lig=True 
            ligid=split[5] 
            while lig==True: 
                if split[5]==ligid: 
                    coords.append(split[6:9]) 
                    line=next(lines,None) 
                    if line==None: 
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                        break 
                    split=line.split() 
                    if len(split)<5: 
                        lig=False 
                        if split[0]=='END': 
                            frame+=1 
                            frames.append(coords) 
                            coords=[] 
                else: 
                    lig=False 
                     
#This is setting up the resulting figure. A histogram of all of 
the interatom distances is calculated per frame, and a plot 




for n in frames: 
    for c in n: 
        c1=n.pop(0) 
        hist.append([f,dist(c1,c)]) 
    plt.hist([x[1] for x in hist if 
x[0]==f],bins=100,color=[f/100,0,1-f/100,0.2],histtype='step') 
    f+=1 
plt.xlabel('Interatom distance / Angstroms') 
plt.xlim(0,240) 
plt.ylabel('Frequency') 
plt.savefig('ACN PR Hist.pdf') 
 
#Finally, the maximum distance between any two atoms per frame 
is reported. 
atoms=7925 
for n in range(f): 
    print(n,max(hist[n*atoms:n*atoms+atoms])[1]) 
6.3.3 Electrostatic interaction distance for MD 
#This imports the necessary plotting libraries 
import matplotlib.pyplot as plt 
import matplotlib 
 
#This calculates the distance between two coordinates using 
Pythagoras’ theorem 
def dist(c1,c2): 
    c1=[float(i) for i in c1] 
    c2=[float(i) for i in c2] 






#This opens the pdb file containing only the terimal oxygen 
atoms of the surfactants in the simulation and records their 
coordinates 
with open('CH3N LIG OXT only.pdb','r') as pdb: 
    lines=(row for row in pdb) 
    frame=0 
    frames=[] 
    coords=[] 
    while lines: 
        line=next(lines,None) 
        if line==None: 
            break 
        split=line.split() 
        if split[6:9]: 
            coords.append(split[6:9]) 
        if len(split)<5: 
            if split[0]=='END': 
                frame+=1 
                frames.append(coords) 
                coords=[] 
 
#This opens the pdb file containing only the positively-charged 
protein sidechain atoms in the simulation and records their 
coordinates 
with open('CH3N PosRes only.pdb','r') as pdb: 
    lines=(row for row in pdb) 
    frame=0 
    pframes=[] 
    coords=[] 
    while lines: 
        line=next(lines,None) 
        if line==None: 
            break 
        split=line.split() 
        if split[6:9]: 
            coords.append(split[6:9]) 
        if len(split)<5: 
            if split[0]=='END': 
                frame+=1 
                pframes.append(coords) 
                coords=[] 
            
#This is setting up the resulting figure. A histogram of all of 
the interatom distances between the surfactant terminal oxygens 
and positively charged protein sidechain atoms is calculated per 







for i,n in enumerate(frames): 
    for cs in n: 
        distance=min([dist(cs,cp) for cp in pframes[i]]) 
        hist.append([i,distance]) 
        if distance<=4: 
            bind+=1 
        else: 
            nobind+=1 
    bindhist.append(bind/(bind+nobind)) 
    bind=0 








plt.xlabel('Time / ns') 
plt.ylabel('Distance / angstroms') 
#plt.show() 
plt.savefig('CH3N coupling distance.pdf') 
6.4 TCL script for SASA calculations 
The following script selects a set of atoms and calculated the surface accessible 
surface area for each set within the overall model per frame. 
set allatoms [atomselect top all] 
echo all 
set sel [atomselect top all] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo protein 
set sel [atomselect top protein] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo hydrophobic 
set sel [atomselect top hydrophobic] 
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set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo polar 
set sel [atomselect top polar] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo lig 
set sel [atomselect top "resname LIG"] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo nonylphenyl 
set sel [atomselect top "resname LIG and name C1 C2 C3 C4 C5 C6 
C7 C8 C9 C10 C11 C12 C13 C14 C15"] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 
  echo [measure sasa 1.4 $allatoms -restrict $sel] 
} 
echo not nonylphenyl 
set sel [atomselect top "resname LIG and not name C1 C2 C3 C4 
C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15"] 
set n [molinfo top get numframes] 
for { set i 0 } { $i < $n } {incr i} { 
  $sel frame $i 
  $allatoms frame $i 




6.5 Amino acids 
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